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CHAPTER 1 
General Introduction 
Nicole van den Braak 
Chapter 1 
The Genus Enterococcus 
In 1899, Thiercelin described gram-positive coccoid bacteria isolated from the 
human intestine and introduced the name "enterocoque" [1]. However, in the 
beginning of the twentieth century the term Streptococcus was more commonly 
used. In 1937, Sherman developed a new scheme and classified the genus 
Streptococcus into four main groups: pyogenic, viridans and lactic streptococci 
and enterococci [2]. Enterococci were separated from other Streptococcus 
species as they grow between 10°C and 45°C, in 6.5% NaCI, and at pH 9.6. 
Moreover, they are able to survive for 30 min. at 60°C and hydrolyze esculine 
into esculitine. All members of the genus Enterococcus react with the Lancefield 
group D antisera [3]. Recently, DNA hybridization experiments have indicated 
that enterococci are distinct from streptococci, and subsequently, the genus 
Enterococcus was introduced in 1984 [4]. Biochemical classification divided the 
genus Enterococcus in 17 different species; Enterococcus faecium, Enterococcus 
faecafis, Enterococcus hirae, Enterococcus durans, Enterococcus gallinarum, 
Enterococcus avium/ Enterococcus mundtii, Enterococcus casse/iflavus, 
Enterococcus moledoratus, Enterococcus pseudoavium, Enterococcus so!itarus, 
Enterococcus raffinosus, Enterococcus cecorum, Enterococcus flavescens, 
Enterococcus co!umbae, Enterococcus dispar, Enterococcus sacchrolyticus [5]. 
Enterococci are part of the human and animal gut-flora, normally 105-107 CFU 
can be cultured from one gram of human feces [6], but oral and vaginal 
colonization has also been described [5]. The number of each of these species 
found in the human intestine varies with diet and several other factors [7, 8]. 
E. faeca/is and E. faecium are the species most commonly found in humans. Both 
species have also been found on plants. E. faecium is also part of the intestinal 
flora of poultry and pigs. E. durans is found in human as well as in poultry. In 
contrast, E. ga!Jinarum and E. avium appears to be host specific and are mainly 
found in poultry [5]. The yellow pigmented species E. casse/if/avus is associated 
with plants. 
Over a period of time, the distribution of organisms involved in nosocomial 
infections has shifted from Gram-negative to Gram-positive bacteria [9]. 
Enterococci have emerged as one of the most commonly isolated nosocomial 
pathogens. Two sources of infections with enterococci have been proposed: first, 
infections may be caused by enterococcal isolates present in the patient's own 
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flora; second, infections may be caused by enterococci acquired by transmission 
in the hospital environment [10]. During the last decade, enterococci have been 
recognized as one of the leading causes of nosocomial infections. The most 
prevalent infections caused by enterococci are urinary tract infections (UTI), 
bacteremia, abdominal wound infections and endocarditis [11, 12]. Most of these 
infections are caused by E. faeca/is and only a small number of infections are 
caused by E. faecium [5]. However, in recent years a progressive increase of 
infections caused by E. faecium [13] has been observed. In most cases, it 
remains difficult to ascertain whether the organism originated from the patients 
own flora or whether the organism was acquired during hospitalization of the 
patient. 
Antmicrobial Resistance in Enterococci 
Antimicrobial resistance in enterococci can be divided in two classes, intrinsic 
resistance and acquired resistance (table 1). Some bacteria are intrinsically 
resistant to antimicrobial agents because they either lack the target site for that 
drug, or the drug is unable to transfer through the organism's cell wall or 
membrane to reach its site of action. In contrast, acquired resistance is usually 
transposon or plasmid encoded [5]. From a clinical perspective, multi-resistant 
enterococci or the vancomycin-resistant enterococci present a major problem. 
Infections with resistant enterococci are difficult to treat and these organisms 
show a strong propensity to disseminate and spread from patient to patient in 
the hospital setting. 
Table 1 Antimicrobial susceptibility of enterococci 
Intrinsic resistance 
Antimicrobial agent 
Acquired resistance 
Aminoglycosides (low level) 
Aztreonam 
Cephalosporins 
Clindamycin 
Imipenem 
Antimicrobial agent 
Aminoglycosides (high~level) 
Am picHI in 
Ampicillin 
Chloramphenicol 
Erythromycin 
Penicillin Tetracyclines 
Trimethoprim-sulfamethoxazole Glycopeptides 
Adapted from W.Witte Chemotherapy 1999;45:135~145 [5} 
Resistance mechanism 
AAC (6'APH(2") enzym 
E. faeca/is : j3~1actamase 
E. faecium : PBPS 
cat-encoded enzyme 
ermB-mediated enzyme 
modification of ribosome protein 
precusor modification 
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Glycopeptides 
The emergence of resistance of Staphylococcus aureus against penicillin, 
erythromycin and tetracycline in the mid-1950s, stimulated the development of 
new antimicrobial agents. In 1954, vancomycin, which belongs to the group of 
glycopeptide antibiotics, was isolated from Amyco/aptosis orienta/is [14). Another 
glycopeptide, teicoplanin, was introduced in 1984 in several European countries 
[15). Glycopeptides are relatively large water-soluble molecules that cannot 
penetrate the lipid outer-membrane of Gram-negative bacteria. In contrast, 
almost all Gram-positive bacteria are susceptible to the activity of glycopeptides. 
Glycopeptide antibiotics interact with the terminal D-alanyi-D-alanine group of 
the pentapeptide side chains of peptidoglycan precursors. Due to this interaction, 
the cell wall synthesis is inhibited [16). 
For 20 years, vancomycin was not used in clinical medicine, because of the 
frequently observed nefro-toxicity and because of the introduction of penicillinase 
resistant ~-lactam antibiotics. However, in the mid-1980s the interest in 
vancomycin treatment greatly expanded due to the introduction of a more 
purified and less toxic formulation of vancomycin and due to a sharp increase in 
the incidence of infections caused by methicillin resistant and multi-drug 
resistant staphylococci. From that moment on, vancomycin has remained the 
treatment of choice for infections with these multi-drug resistant organisms [17) 
and these circumstances have led to a dramatic increase in the use of 
vancomycin, especially in the USA. In contrast, the rise of glycopeptide use has 
been less pronounced in Europe (Figure 1, adapted from reference [18]). In 
Europe, however, a vancomycin homologue/ avoparcin, has been widely used as 
growth promoter in animal husbandry from its introduction in the late-1970s, 
until 1997 when it was banned. Large amounts of antibiotics were used in 
animal husbandry as proved in a recent study from the Health Council of The 
Netherlands which reported that 40% of the total amount of antibiotics used in 
the Netherlands was for growth enhancement in animal husbandry in 1997. 
Approximately 47% were prescribed for prophylaxis and therapy in veterinary 
medicine, whereas only 13°/o served human medicinal purposes. 
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The fight against infections was successful from the mid 1950's. Despite these 
successes, the development of glycopeptide resistance was noted and the first 
vancomycin resistant enterococcus was isolated in 1986 in France [19]. 
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Figure 1: Intravenous vancomycin use in the USA, France and The Netherlands (NED) (kg/year 
per 100.000 inhabitants) (adapted from Kirst eta! 1998 [18]). 
Mechanisms of Glycopeptide Resistance in Enterococci 
Resistance to glycopeptides is due to the synthesis of modified cell wall 
precursors that show decreased affinity for vancomycin and teicoplanin (Figure 
2). The genetics of vancomycin resistance in enterococci has been studied in 
detail over the past decade and various molecular mechanisms have been 
elucidated [20-23]. Resistance types can either be intrinsic (low-level resistance 
to both vancomycin and teicoplanin; e.g. VanCl, VanC2 and VanC3) or acquired 
(high-level resistance to both vancomycin and teicoplanin [VanA], intermediate 
level resistance to both glycopeptides [VanD] or variable level of resistance to 
vancomycin only [VanB]) [24, 25]. A new, VanE-type resistance has recently 
been described [26]. The VanA/VanB resistances are encoded largely by 
homologous transposons named Tn1546 and Tn1547, respectively. These 
transposons are located on self-transferable plasmids and are transferred by 
conjugation. VanA mediated resistance has been most extensively studied and is 
associated with the presence of the transposon Tn1546. Tn1546 is a large 
± 11-kb transposon and harbors nine genes encoding nine different proteins 
(Figure 3). These polypeptides can be divided in four functional groups: 
transposition function (open reading frames 1 and 2 (ORF)), regulation of 
vancomycin resistance genes (VanR and VanS), resistance to glycopeptides 
(VanH, VanA and VanX), and synthesis of peptidoglycan (VanY and VanZ). These 
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two later genes encode accessory proteins that are not essential for the 
expression of glycopeptide resistance. 
Vancomycin susceptible enterococci 
o~ala D-ala 
Vancomycin resistant enterococci 
cell wall 
synthesis 
vancomycin 
~vancomycin 
Inhibition of 
cell wall 
synthesis 
Figure 2: Vancomycin susceptible enterococci make cell wall precursors (D-a!a-D-a!a) that have 
high affinity for vancomycin. After binding of vancomycin to D-afa-D-a/a, inhibition of the cell wall 
synthesis occurs. Vancomycin resistant enterococci synthesize cell wall precursors have low affinity 
to vancomycin (D-a/a-D-Iac). Consequently, there will be no irreversible interaction between 
vancomycin and these precursors and cell wall synthesis continues. 
VanA (ligation D-Lac), vanH (dehydrogenase) and VanX (removes the terminal 
D-ala residue) genes are necessary for the synthesis of the depsipeptide D-ala-
D-Iac, which substitutes for D-ala-D-ala. VanR and vanS genes regulate the 
D-ala-D-Iac production. The VanY and VanZ genes encode accessory proteins 
that prevent translocation of D-ala-D-ala precursors to the cell surface (vanY). 
The function of vanZ is presently unclear. 
ORF 1 ORF2 vanR vanS vanH vanA vanX vanY vanZ 
Transposition Regulation Glycopeptide resistance Accessory proteins 
Figure 3: Map of the Tn1546 transposon in E. faecium BM4147. 
14 
General Introduct;on 
Most of the genes of the vanB gene cluster share a large percentage of 
homology with genes of the vanA cluster. One additional gene, vanW, is uniquely 
found in the vanB cluster (Figure 4). 
ORF1 ORF2 vanR vanS vanY vanw vanH vanB vanX 
Transposition Regulation Accessory proteins Glycopeptide resistance 
Figure 4: Map of the Tn1547 transposon in E. faecafis V583. 
Vane mediated intrinsic resistance is characterized by low level resistance and 
is specific for E. gallinarum (vanCl), E. casse/iflavus (vanC2) and E. flavescens 
(vanC3). Enterococci that carry the vane gene synthesize 0-ala-0-serine, which 
replaced 0-ala-0-ala in the precursor molecules. Two newly acquired resistance 
phenotypes, vanD and vanE were found in the late nineties in E. faec;um and E. 
faecalis, respectively [25, 26]. 
Vancomycin Resistance in other Bacteria 
Microbiologists have been forecasting the spread of the Tn1546 resistance 
factor to other microbial species as was suggested by in-vitro experiments and in 
controlled trials in nude mice indicating that this possibility is a realistic one. 
Conjugative transfer of the vanA gene to Staphylococcus aureus has been 
achieved in model studies [27] and has contributed significantly to the discussion 
on what to do when ultimately vancomycin and methicillin-resistant 5. aureus 
(VRSA) is identified in the hospital environment or in a given patient [28]. As a 
prelude to VRSA, the so-called vancomycin-intermediate 5. aureus (VISA or 
GISA) has very recently been isolated from a Japanese patient and two patients 
in the USA [29, 30]. Fortunately, these strains did not contain the Tn1546 
transposon or other related genes. 
In contrast, vancomycin-intermediate and -resistant coagulase-negative 
staphylococci have been found in larger numbers [31, 32]. For many of these 
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isolates, interesting mixtures of bacterial phenotypes can be encountered in 
otherwise genetically homogeneous populations of cells. This type of vancomycin 
resistance was also not related to one of the van genes found in enterococci. In 
contrast, low-and high level resistances were reported in Streptococcus spp., 
Arconobacterium and Bacillus spp caused by vanA or vanB related genes [33]. 
Prevalence of VRE in the United States versus Europe 
Since the first American VRE was isolated in 1987 in Missouri [34], the 
prevalence of VRE increased enormously and is still on the rise. The National 
Nosocomial Infection Surveillance (NNIS) system in the USA has revealed a 
significant increase in the percentage of invasive nosocomial Enterococcus strains 
displaying high-level vancomycin resistance. The figures for the proportion of 
enterococcal infection due to these so-called vancomycin-resistant enterococci 
(VRE) have risen in intensive care unit patients from 0.4% in 1989 to 23.4% in 
1997. In non-ICU patients the percentage rose from 0.3% to 15.4%, 
representing a 50-fold increase in a limited time-span. Prevalences of VRE in 
1998 and 1999 were published recently (Figure 5) [34]. Most of the outbreaks of 
VRE in US hospitals are caused by multi-resistant enterococci but in contrast, 
human VRE colonization outside hospitals and animal derived VRE were not 
found. It has been suggested that in the USA the large amounts of glycopeptides 
administered to patients represent the prime determinant driving the 
development and spread of resistance [35, 36]. 
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Although the very first VRE was reported in France [19], the prevalence of 
VRE in European hospitals remains low. In contrast to the USA [37], the majority 
of the hospital-related VRE are genetically heterogeneous. Fortunately, vanA 
related outbreaks of VRE are caused by strains that remained susceptible to 
other antimicrobial agents. In Europe, VRE have also been detected in 
non-hospitalized persons. Of major concern is the high prevalence in animals, 
especially in countries where avoparcin and other antibiotics are commonly used 
as growth-promoters in animal husbandry. The addition of antibiotics to animal 
food has been documented as carrying an economical benefit: animals grow 
faster and attain higher weights [38, 39]. In 1993, the first VRE outside the 
health care setting was reported in Europe. From that moment VRE were isolated 
from sources as diverse as sewage in Germany and England, livestock faeces and 
uncooked-chicken in England and pig and poultry in German. The association 
between VRE from animal- and human- sources was first described by Bates et 
al. [40], who reported identical genotypes of VRE in retail poultry cadavers and 
humans. 
Knowing these facts about vancomycin resistant enterococci we became 
interested in the prevalence and molecular epidemiology of VRE in and outside 
the hospital setting in the Netherlands. 
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Outline of the thesis 
This thesis describes the detection, prevalence and molecular analysis of 
vancomycin resistant enterococci in and outside the hospital setting in The 
Netherlands. The following topics were specifically addressed in this work: 
• Assessment of the quality of commercial assays available for 
identification of glycopeptide resistance 
We tested the accuracy of nine different susceptibility test methods for the 
detection of glycopeptide resistance in enterococci (chapter 2 and 3). 
• Prevalence, risk factors and molecular analysis of vancomycin 
resistant enterococci in and outside the hospital setting in The 
Netherlands 
We determined the prevalence and determinants of VRE carriage in intensive 
care units and Hematology Oncology wards in nine Dutch hospitals and 200 
community based patients between 1995 and 1998 (chapter 4 and 5). 
• Prevalence of VRE in pet-animals 
We determined the prevalence of VRE in cats and dogs in Rotterdam, The 
Netherlands (chapter 6b). 
• Prevalence and molecular analysis of VRE in poultry products sold to 
the public in the Netherlands 
We determined the prevalence of VRE in poultry product nation wide in order 
to analyze whether the bacterial flora of consumer poultry serves as gene 
reservoir (chapter 7). 
• Prevalence of VRE in vegetarians in The Netherlands 
We described a case-control study in vegetarians versus meat eaters to 
analyze whether meat can serve a role in dissemination of VRE from animals 
too human (chapter 6a). 
• Development of molecular techniques to gain more insight in the 
spread of vancomycin resistant enterococci. 
18 
We described several molecular techniques to get more insight in to the 
spread of vancomycin resistant enterococci. The techniques we used were 
Pulsed Field Gel Electrophoresis, Random Amplification of Polymorphic DNA, 
transposon analysis using PCR and sequencing, and Amplified Fragment 
Length Polymorphism. (chapter 8, 9 and 10) 
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Chapter 2 
Abstract 
A collection of genetically unrelated vancomycin-resistant enterococci (VRE) 
including 50 vanA, 15 vanB, 50 vanCl, and 30 vanC2 VRE were used to evaluate the 
accuracy of eight currently available susceptibility test methods (agar dilution, disk 
diffusion, E-test, agar screen plate, Vitek GPS-TA and GPS-101, and MicroScan 
overnight and rapid panels). VanA VRE were detected by all methods. vanB-VRE 
were often not detected by Vitek GPS-TA and MicroScan rapid (sensitivity 47% and 
53%, resp.), though the new Vitek GPS-101 was found to be a significant 
improvement. E-test and the agar screen were the only two methods detecting all 
VRE, including the vanC1/C2 VRE. 
22 
VRE and Detection 
Introduction 
The rapid increase in the incidence of infections with vancomycin-resistant 
enterococci (VRE) in the Western Hemisphere is reason for great concern [1]. The 
Hospital Infection Control Practices Advisory Committee (HICPAC) recently published 
recommendations for preventing the spread of vancomycin resistance [2]. An 
important role is sought for the microbiology laboratories as they, through accurate 
and timely detection of resistance, are the first line of defense. To date, several 
studies have been done assessing the accuracy of various antimicrobial susceptibility 
methods in detecting vancomycin resistance in enterococci [3-9]. Since the 
occurrence of VRE is increasing in the US [10] and is likely to increase in Europe as 
well, it is crucial to optimize the laboratory's ability to detect vancomycin resistance. 
Three different genotypes (vanA, vanB and vanD) have been described that encode 
for either high-, intermediate-, or low-level acquired glycopeptide resistance, mainly 
in Enterococcus faecium and Enterococcus faecalis [11]. In addition, a fourth 
genotype (vanC) has been found in Enterococcus gallinarum and Enterococcus 
casse/if/avus. This genotype encodes intrinsic, low-level resistance to vancomycin 
but not to teicoplanin. Antimicrobial susceptibility tests may have problems 
detecting the low-level glycopeptide resistance phenotype (Vans orVanC). To date, 
some reports have shown failure of several automated susceptibility test methods to 
detect vancomycin resistance [8, 9]. In response, the manufacturers of the Vitek 
system (BioMerieux, Marcy I'Etoile, France) developed a new gram-positive 
susceptibility card (GPS-101) and updated the software to overcome this problem. 
Thus, the objective of this study was to evaluate the accuracy of seven currently 
available 
commercial methods, including the Vitek GPS-101 card, to detect VRE compared to 
a reference agar dilution method [12]. 
Materials and Methods 
A collection of fully characterized VRE strains, representing all the above 
mentioned genotypes and phenotypes, was used in this study. One hundred and 
ninety-five enterococci, including 50 vanA, 15 vanB, 50 vanCl VRE (E.gallinarum), 
and 30 vanC2 VRE (E. casse/iflavus) were isolated from patients or poultry products 
in Europe; the remaining SO strains lacked these resistance markers and were fully 
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susceptible to vancomycin. Identification of Enterococcus spp. was made on the 
basis of colonial morphology, pigment production, Gram stain, catalase, pyrrolidonyl 
arylamidase, and Lancefield group D antigen and by API 32 rapid system. 
E. Gallinarum was identified upon digestion of DNA with Smai and pulsed-field gel 
electrophoresis (PFGE) showing all fragments <200kb, and by the presence of the 
vanCl gene [13, 14]. The test strains were carefully selected in order to maximize 
the variety of resistance genotypes and phenotypes [8]. Identical strains were 
excluded. All had unique PFGE patterns and were, therefore, genetically unrelated 
(data not shown). PCR assays for vanA, vanS, vanCl and vanC2 genes were 
performed as described earlier by Dutka-Malen et al. [15]. 
Agar dilution and disk diffusion were performed in accordance with the NCCLS 
guidelines [12, 16] on cation-adjusted Mueller-Hinton (MH) agar (Difco laboratories, 
Detroit, Mich). E-test (AB Biodisk, Solna, Sweden) was done on MH (Difco) in 
accordance with the instructions of the manufacturer. The results were read after 
24h incubation at 37°C. An agar screen containing 6 ~g of vancomycin (BBL 
Microbiology Systems, Cockeysville, Md) per ml was used as described by Ten over et 
al. [8] with an inoculum of 10~L (approximately 106 CFU) of a 0.5 McFarland 
standard suspension. The 30-well Vitek GPS-TA, the 45-well Vitek GPS-101 with the 
updated GUI-software, MicroScan conventional overnight Pas Combo Type 6 panels 
and MicroScan Rapid Pas Combo Type 1 panels with V.20.30 software (Dade 
International, West Sacramento, Calif.) were used as recommended by their 
respective manufacturers. E. faecatis ATCC 29212 and S.aureus ATCC 29213 were 
used as quality control strains. The NCCLS breakpoints were used for interpretation 
of the result [8]. A very major error was defined as an isolate that was resistant by 
the reference agar dilution method but susceptible with the test method. A major 
error was defined as an isolate that was susceptible by the reference agar dilution 
method but resistant with the test method. Thus, lack of sensitivity of a given test 
was deemed to be more serious clinically than lack of specificity. A minor error was 
defined as a discrepancy between the results of the reference agar dilution method 
and the test method that differed only by one interpretation category. However, for 
the E. gallinarum and E. casseliflavus strains with MIC 8 to16 ~g/ml, both 
intermediate and resistant results were considered correct, since both interpretation 
categories correctly distinguish these vanCl- or vanC2-harboring enterococci from 
fully susceptible strains (MIC,; 4 ~g/ml). Similarly, the sensitivity was defined as the 
ability of the test method to correctly distinguish the vanA, vanB, vanCl or vanC2-
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harboring resistant enterococci from susceptible strains not harboring these genes. 
Therefore, for strains with intermediate results with the reference agar dilution (MIC, 
8 to 16 ~g/ml), both intermediate- and resistant-phenotype test results were 
considered correct. 
Results 
The M!Cs of vancomycin with the reference agardilution method are shown by 
genotype in Table 1. Table 2 presents the percentages of very major, major and 
minor errors of the different test compared with the reference agar dilution method. 
The comparative sensitivities of seven methods for the detection of vanA,. vanB,. 
vanC1/C2 VRE are shown in Table 3. All methods were 100% sensitive for the 
detection of vanA-mediated vancomycin resistance. However, it is important to note 
that for all of the 50 vanA VRE M!Cs of vancomycin was 256 ~g/ml, and these 
strains were therefore detected easily. For vanB VRE, the sensitivity dropped to 47, 
53 and 93% with Vitek GPS-TA, MicroScan rapid and disk diffusion, respectively. In 
contrast, Vitek GPS-101, MicroScan conventional, the agar screen and E-test were 
100% sensitive for detecting vanB VRE. For vanC1/C2-VRE, E-test and the agar 
screen were the only methods that correctly identified all resistant strains as such. 
High error rates were produced by disk diffusion and by all automated methods 
(Table 2). The MicroScan conventional panel detected only 7% of the vanC2 E. 
casseliflavus. The sensitivities of the other automated methods varied from 67 to 
90% (Table 3). The specificities of the different methods were 96 to 100%. 
Table 1: MH agar determination of MICs for 145 VRE and 50 VSEl by genotype 
No. of isolates for which MIC (IJQ/ml) was: 
Organism 
(n) 0.25 0.5 1 2 4 8 16 32 64 128 ;::256 
VRE 
van A (SO) so 
vanB (15) 1 1 3 1 5 4 
vanC1 (50) 30 19 1 
vanC2 (30) 25 4 1 
VSE (50) 1 6 32 9 2 
a VSE, vancomycin susceptible enterococci 
25 
Chapter 2 
TABLE 2: Error rates of seven methods for the detection of vancomycin resistance in enterococci 
Error rate (%)" 
Very major Major Minor 
Method vanA vanB vanCl vanC2 vanA vanB vanC1 vanC2 
( n~so )( n ~ 15) ( n~so) (n ~30) (n~so) ( n ~so)( n ~ 15)( n~so) ( n~30) 
E-test 0 0 0 0 0 0 13 2 
Disk diffusion 0 0 0 0 2 0 27 so 
Agar screen 0 0 0 0 4 
Microscan 
Conventional 0 0 0 3 0 0 0 24 
Rapid 0 33 0 0 0 0 27 14 
Vitek 
GPS-TA 0 40 0 0 4 0 13 28 
GPS-101 0 0 0 0 4 2 7 12 
" Relative to the NCCLS reference agar dilution assay. Error types are defined in the text, 
TABLE 3: Sensitivities of seven methods for the detection of vanA, vanB, and vanCl/C2-
enterococci' 
sensitivity(%) for VRE 
VanA vans vanCl vanC2 
method (n~SO) (n~1S) (n~SO) (n~30) 
E-test 100 100 100 100 
Disk diffusion 100 93 52 63 
Agar screen 100 100 100 100 
Microscan 
Conventional 100 100 76 7 
Rapid 100 53 86 90 
Vitek 
GPS-TA 100 47 72 67 
GPS-101 100 100 88 73 
"For vanB, vanCl and vanC2 strains with MICs of 8 tol6 IJQ/ml, both intermediate-
and resistant-phenotypes were considered correct. 
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Discussion 
Earlier studies have reported on the performance of commercial and reference 
methods for the detection of vancomycin resistance in enterococci [3-10], 
Surprisingly, none of these studies were performed in Europe. Some of the studies 
report on the difficulties of automated methods in detecting low-level or 
intermediate-level vancomycin-resistance [8, 9]. In the study by Tenover et al., the 
performance of the MicroScan rapid panel and the Vitek GPS-TA card were 
problematic, with very major error rate of 20.7 and 10.3%, respectively. Many 
errors occurred with E. casseliflavus, E. gallinarum and vanB VRE. We confirm the 
failure of these two methods. The MicroScan rapid and Vitek GPS-TA produced 33 
and 40% very major errors with van8-strains, respectively (Table 2). However, no 
very major errors occurred with MicroScan conventional or with Vitek GPS-101. No 
susceptible (vancomycin MIC,; 4 ~g/1) E. gallinarum or E. casseliflavus was found, 
possibly due to the fact that the strains were initially isolated with the use of a 
selective broth medium containing 6 ~g of vancomycin per liter. Since for 78 of the 
80 E. galiinarum and E. casseliflavus had vancomycin M!Cs were in the intermediate 
category (MIC 8 to16 ~g/ml), most errors in these species were, by definition, minor 
errors. For one vanCl E. ga/iinarum and one vanC2 E. casseliflavus, the MIC of 
vancomycin was 32 ~g/ml. The latter was incorrectly reported as susceptible by 
MicroScan conventional panel, and this result was scored as very major error (Table 
2). The MicroScan conventional panel and MicroScan rapid had 24 and 14% minor 
errors, respectively, with vanC1 E. gal/inarum but 90 and 10°/o, respectively, with 
vanC2 E. casselif/avus. Vitek GPS-TA and Vitek GPS-101 produced 28 and 12% 
minor errors, respectively, with vanC1 E. ga/linarum and 37 and 30%, respectively, 
with vanC2 E. casseliflavus. The minor error rates of the disk diffusion in E. 
gal/inarum and E. casselif/avus were 50 and 37%, respectively. Swenson et al. 
reported minor error rates of 14,5% of total values. However, their collection of 100 
VRE included only 10 E. gal/inarum or E. casse/iflavus isolates, and the most 
significant errors in detection were in fact made mainly with these strains [5]. E-test 
and the agar screen were the only methods that correctly detected all VRE in our 
study. Light growth was observed on the agar screen with two vancomycin-
susceptible strains with (MIC, 4 ~g/ml}. This high sensitivity is in concordance with 
recent data reported by Willey et al. [9]. They found the agar screen plate (using 
the same vancomycin concentration as used in our study) to be 100% sensitive and 
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specific. In another study, which included only a small number of strains with MICs 
in the 8-16 ~g/ml range, E-test proved to be a reliable method compared to agar 
dilution [4]. The prevalence and the clinical relevance of E. casseliflavus and E. 
ga!linarum remain to be elucidated. These VRE are often misidentified by 
commercial identification systems (data not shown [3], and their intermediate level 
of resistance may not be detected. It is likely that these two species are being 
underreported in the literature [10, 17]. 
In conclusion, vanA VRE are detected by all methods. VanB VRE are often not 
detected by Vitek GPS-TA and MicroScan rapid panel, though the new Vitek GPS-101 
appears to be a significant improvement. All methods except E-test and the agar 
screen continue to show problems in the detection of vanC1/C2 VRE. The agar 
screen appears to be the most reliable and easy to perform method for routine 
screening, if detection of vanA-, vanB-, and vanC1/C2-mediated resistance in 
enterococci is required, The new 45-well Vitek GPS-101 shows improved sensitivity, 
compared to the Vitek GPS-TA without significant loss of specificity. 
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Abstract 
We evaluated the accuracy of the VITEK®2 fully automated system to detect 
and to identify glycopeptide-resistant enterococci (GRE) compared to a reference 
agar dilution method. The sensitivity of vancomycin susceptibility testing with 
VITEK®2 for the detection of vanA-, vanB and vanC1-strains was 100%. The 
sensitivity of vancomycin susceptibility testing of VanC2 strains was 77%. The 
sensitivity of teicoplanin susceptibility testing of vanA strains was 90%. Of 80 
Vane enterococci, 78 (98%) were correctly identified by VITEK®2 as 
Enterococcus gallinarum/Enterococcus casselifiavus. Since the identification and 
susceptibility data are produced within 3 h and 8 h, respectively, VITEK®2 
appears a fast and reliable method for detection of GRE in microbiology 
laboratories. 
32 
VRE detection by Vitek2 
Introduction 
The prevalence of glycopeptide resistance among clinical isolates of 
Enterococcus spp., first described in 1986 [1], is ever increasing, thereby limiting 
the treatment options for infections caused by glycopeptide-resistant enterococci 
(GRE). Molecular epidemiology has elucidated several determinants of 
glycopeptide resistance as well as gene reservoirs and has increased our 
awareness of the spread of GRE in hospitals and in the community [2-4]. 
However, although the microbiology laboratories have been delineated as the 
first line of defense to control the spread of GRE within our hospitals [5], many 
technical problems concerning the laboratory detection of GRE still exist. 
Previous studies have reported on problems with the detection of vans-, vanCl-
and vanC2-type strains, in particular [6-8]. Both convential and automated 
methods have problems in detecting these particular genotypes. The 
manufacturers of commercial susceptibility testing methods have joined in their 
efforts to contain the problem of increasing resistance, by developing new and 
rapid susceptibility test methods. Our main objective in this study was to 
evaluate the ability of VITEK®2 to determine vancomycin and teicoplanin 
resistance in strains containing vanA~ vanB, vanC1 or vanC2 genes. The 
performance of VITEK GPI and VITEK®2 for the identification of E. faeca/is and 
E. faecium has been evaluated by others [9, 10]. Therefore, our second objective 
was to evaluate the performance of VITEK®2 for the identification of vane 
enterococci up to the species level, as most automated methods have problems 
with the identification of Enterococcus gallinarum and Enterococcus casseliflavus 
[6-8]. 
Materials and Methods 
Bacterial strains 
A collection of genetically distinct GRE and glycopeptide susceptible 
enterococci (GSE) from diverse sources was used in this study. This collection 
was assembled and characterized by molecular methods in a previous study [6]. 
A total of 195 enterococci, including vanA (n=50), vanS (n=15) vanCl (n=50), 
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vanC2 (n=30) and GSE (n=SO), were isolated from patients, pets or poultry 
products in The Netherlands. 
Identification 
All enterococci were identified to the species level on the basis of colony 
morphology, Gram stain, pyrase and catalase testing, pigment production, the 
presence of the Lancefield Group D antigen and Rapid ID32 Strep (bioMerieux, 
's Hertogenbosch, the Netherlands). PCR assays for vanA, vanB, vanCl and 
vanC2 genes [11] were used to assess the presence of the various glycopeptide 
resistance genes. Strains carrying the vanCl or vanC2 genes were identified as 
E. gallinarum and E. casseliflavus, respectively. The identification of 
E. gallinarum was confirmed by pulsed-field gel electrophoresis (PFGE) after 
digestion with Smal, which led to the display of macrorestriction fragments of 
less then 200 kb only [3]. All strains were genetically characterized by PFGE, and 
only unique strains were included in the study. 
Susceptibility testing 
Susceptibility results for vancomycin and teicoplanin obtained by agar 
dilution performed according to the guidelines of the NCCLS [12] were used as a 
reference method. The VITEK®2 system was used according to the instructions of 
the manufacturer (bioMerieux, Marcy I' Etoile, France); ID-Gram Positive Cocci 
(GPC) cards were used for identification. The Antimicrobial Susceptibility Testing 
(ASP) P516 card was used for susceptibility testing. Enterococcus faecalis ATCC 
29212 and Staphylococcus aureus ATCC 29213 were used as quality control 
strains. MICs were interpreted as indicating susceptible, intermediate or resistant 
categories according to the breakpoints recommended by the NCCLS. A very 
major error was defined as occurring when an isolate that was resistant by the 
agar dilution method appeared to be susceptible by the test method. A major 
error was defined as occurring when an isolate that was susceptible by the 
reference agar dilution method was scored resistant by the test method. Thus, 
lack of sensitivity of a given test was considered to be a more serious handicap 
than lack of specificity. A minor error was defined as a discrepancy between the 
results of the reference agar dilution method and the test method that differed 
only by one interpretation category. The sensitivity was defined as the ability of 
the test method to correctly distinguish the vanA, vanB, vanCl or vanC2-
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harbouring resistant enterococci from susceptible strains not harboring these 
genes. However, for enterococcal strains with vancomycin M!Cs of 8-16 ~g/ml 
both intermediate and resistant results were considered correct, since both 
interpretation categories correctly distinguish these enterococci from fully 
susceptible strains (vancomycin MIC ;,;; 4 ~g/ml; teicoplanin MIC ;,;; 8 ~g/ml). For 
reporting the accuracy of VITEK®2 compared to the reference method, overall 
agreement was defined as lOOX (number of strains with the reference MIC ± 1 
dilution/total number of strains tested). 
Results 
Table 1 shows the susceptibility results for the 195 enterococci obtained by 
VITEK®2 and the reference agar dilution method for vancomycin and teicoplanin. 
The sensitivity of vancomycin susceptibility testing with VITEK®2 for the 
detecting of vanA-, vanB and vanC1-strains was 100°/o. However, it is important 
to note that vancomycin M!Cs for all vanA strains in this study were >256 ~g/ml. 
The sensitivity of the system for detecting vanC2 strains was 77%. Several minor 
errors were found in the vanB, vanC1, vanC2 enterococci as well as in GSE 
group: 1% (2 of 195), 5.6% (11 of 195), 4.1% (8 of 195) and 0.5% (1 of 195), 
respectively. No major- or very major errors were encountered in the GRE or 
GSE group. 
In contrast, 3 minor errors in 50 samples (6°/o) and 5 very major errors in 50 
samples (10%) occurred when the teicoplanin susceptibility test results were 
analyzed for detecting vanA strains. These 5 very major errors were confirmed 
several times, both by bioMerieux researchers and in our laboratory. However, 
the teicoplanin M!Cs of these 5 strains as determined by re-testing with VITEK®2 
ranged from 4 to >32 mg/L on different testing days. Neither the isolation media 
used nor the inocula can explain these major errors (data not shown). All vanB, 
vanCl and vanC2 enterococci susceptible for teicoplanin were classified correct 
with the VITEK®2 system. 
The overall agreement of vancomycin susceptibility testing with the VITEK®2 
system compared with the reference agar dilution method was 94% (184 of 195) 
(Table 2); the overall agreement of teicoplanin testing results between the two 
methods was 97% (189 of 195). 
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Table 1: Determination using VITEJ<®2 automated system versus standard agar dilution of 
vancomycin and teicoplanin MICs of 145 GRE and SO GSE by genotype 
No. of isolates with the following MIC (mg/L) 
vancomycin teicoplanin 
<=1 2 4 8 16 >= 32 <=1 2 4 8 16 >::= 32 
Organism (no.) 
vanA-GRE (50) V2 50 5 3 42 
AD 50 50 
vanB-GRE (15) V2 15 14 1 
AD 1 1 13 15 
vanCt-GRE (50) V2 21 19 10 50 
AD 30 19 1 50 
vanC2-GRE (30) V2 1 6 23 30 
AD 25 4 1 30 
GSE (50) V2 42 6 1 1 49 1 
AD 39 9 2 50 
Table 2: Comparison of vancomycin MICs determined by VITEKE'2 with MICS determined by the 
reference agar dilution method for 195 isolates of Enterococcus spp. 
No. of Vitek2 MICs of vancomycin within indicated log of reference MIC 
Organism (no.) >-2 -2 -1 0 +1 +2 >+2 Agreement (%> )* 
vanA-GRE (SO) 50 100 
vans- GRE (15) 13 1 1 93 
vanCl-GRE (50) 8 22 14 6 88 
vanC2-GRE (30) 2 10 18 93 
GSE (SO) 6 40 4 100 
Total 2 2 24 143 19 7 95 
"' agreement% - number of strains with reference MIC ± one dilution divided by the total number of strains x 
100% 
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Of 80 vane enterococci, 78 (98%) were classified by VITEK®2 as 
E. gallinarum/E. casseliflavus and 2 were classified as unidentified by VITEK®2. 
This is a significant improvement over other non-automated methods. Although 
VITEK®2 separates the vanC1/vanC2 enterococci from the other enterococci it 
can not differentiate between E. gal/inarum and E. casseliflavus. However, the 
clinical significance of separating these two species is doubtful. 
The mean time for obtaining antimicrobial susceptibility results for the 
enterococci tested in this study was 8 h and 6 min (range, Sh 25 min to 14 h 30 
min). All identification data were obtained within 3 h after starting the 
identification procedure, as guaranteed by the manufacturer. 
Discussion 
Several studies have reported the accuracy of automated methods to detect 
GRE. Most of these studies identified major problems in detection of enterococci 
harboring the vanB, vanCl and vanC2 genes [6-8]. We previously reported very 
major errors, which occurred with the Vitek GPS-TA card. However, most strains 
were correctly classified with the new VITEK GPS-101 card. The VITEK GPS-101 
card had a sensitivity of 100% detecting VanB phenotypes [6]. In this study no 
problems were found to detect vanB strains. Minor errors (n=22) occur with the 
VITEK®2 system in detecting GRE. However, the 2 minor errors in the vanB 
group and 10 minor errors in vanC1 enterococci were intermediate strains 
reported as resistant. VITEK®2 is the first automated susceptibility method that 
tests vancomycin as well as teicoplanin for antimicrobial susceptibility, which is 
important for the description of the resistance phenotype. 
For identification and susceptibility testing, most conventional methods 
require a full 24 h of incubation, VITEK®2 reports susceptibility results in 
approximately 8 h. Barenfanger et al. [13] have demonstrated that rapid 
reporting of identification and susceptibility results may have important benefits 
in terms of patient outcome and cost effectiveness. Moreover, Doern et al., 
reported that rapid identification and susceptibility tests results even reduced 
morbidity and mortality [14]. VITEK®2 provides enterococcal susceptibility data 
in approximately 8 h. Although this is significant faster than overnight convential 
methods, it implies that results can still not be obtained in one working shift. To 
maximize the impact of rapid testing, further improvement of the speed without 
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compromising the accuracy of the test method is desired. In the mean time, we 
have experienced that prolonging the opening hours of the microbiology 
laboratory and adapting the workflow in order to proceed to earlier reports is an 
achievable goal. 
In conclusion, The VITEK®2 appears to be an improvement over convential 
methods for the detection of vancomycin resistance in enterococci. However, 
detection of teicoplanin resistance in enterococci containing the VanA gene needs 
to be reassessed. Although the detection time was reduced to 8 h, further 
improvement of the algorithm and further reduction of the detection time may 
considerably increase the impact of rapid testing on patient care [1,3]. 
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Abstract 
In order to determine the prevalence of vancomycin-resistant enterococci 
(VRE) in The Netherlands, 624 hospitalized patients from ICU or hemato-
oncology wards in nine hospitals and 200 community-based patients were 
screened for VRE colonization. In 49% of the hospitalized patients and in 80% of 
the community-based patients, enterococci were found. Of these strains 43% 
and 32%, respectively, were Enterococcus faecium. VRE were isolated in 12/624 
(2%) and 4/200 (2%), respectively. PCR analysis of these 16 strains and 11 
additional clinical VRE isolates from one of the participating hospitals revealed 24 
VanA-, 1 VanB-, and 2 VanCl-gene containing strains. All strains were cross 
resistant to avoparcin, but sensitive to the novel glycopeptide antibiotic 
LY333328. Genotyping of the strains with arbitrarily primed PCR and pulsed-field 
gel electrophoresis revealed a high degree of genetic heterogeneity. This 
underscores a lack of hospital-driven endemicity of VRE-clones. It is suggested 
that the VRE in hospitalized patients have originated from presently unknown 
sources in the community and may be linked to the extensive use of the 
glycopeptide avoparcin as growth promoting agent in animals. 
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Introduction 
Enterococcus spp. have recently emerged as important nosocomial pathogens 
[1]. According to the data from the National Nosocomial Infections Surveillance 
System, enterococci are the fourth leading cause of nosocomial infections in the 
United States [2]. Enterococcal infections that have frequently been reported 
include urinary tract infections, bacteremia, endocarditis, intra-abdominal 
infections and surgical wound infections [3]. E. faecalis is commonly isolated 
from the human gastro-intestinal tract, whereas E. faecium is less frequent [4]. 
This latter species, however, is noted for its antimicrobial resistance. 
Vancomycin-resistant E. faecium (VREF) have emerged in a setting of increasing 
high-level resistance of enterococci against penicillins and aminoglycosides [5]. 
During the last years, nosocomial outbreaks due to VREF have been described 
[6,7]. The emergence of VREF has raised serious concerns [5] and in response, 
the Hospital Infections Control Practices Advisory Committee (HICPAC) in 
collaboration with the Centers for Disease Control and Prevention (CDC) has 
developed recommendations to prevent the spread of vancomycin-resistant 
enterococci (VRE) [8]. Given the concern that vancomycin-resistance genes may 
transfer from enterococci to Staphylococcus aureus, a phenomenon that has 
been observed in vitro [4], control measures have already been proposed, should 
vancomycin-resistant 5. aureus eventually arise [9]. 
The microbiology laboratory has an important role in the detection, reporting 
and control of VRE. The HICPAC document emphasizes the need for routine 
susceptibility testing of all enterococci isolated from clinical specimens. 
Furthermore, in hospitals where VRE have not yet been detected, periodic culture 
surveys of stools or rectal swabs of patients at high risk for VRE infection or 
colonization is indicated [8]. In The Netherlands, no systematic study has been 
done to evaluate the prevalence of VRE infection or colonization in hospital- or in 
community-based patients. 
Therefore, the present study was started to determine the prevalence of fecal 
carriage of VRE in hospitalized patients with an increased risk for VRE infection or 
colonization, and in community-based patients. We determined the susceptibility 
of VRE for vancomycin, teicoplanin, avoparcin, a glycopeptide available 
throughout Europe as additive in animal feed [10], and LY333328, a new 
glycopeptide antibiotic [11]. In order to determine the genetic basis of the 
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glycopeptide resistance phenotype, PCR assays aiming at the various resistance 
genes were performed. Moreover, the VRE were typed using pulsed-field gel 
electrophoresis (PFGE), arbitrarily primed PCR (AP-PCR) and ribotyping to 
determine genetic relatedness of this group of resistant microorganisms. 
Materials and Methods 
Prevalence study 
Five Dutch university hospitals in Rotterdam, Utrecht, Nijmegen and 
Amsterdam and 4 regional teaching hospitals in Breda and Tilburg participated in 
the study. Six hundred twenty-four patients that were hospitalized in the 
following wards were screened for gastro-intestinal carriage of VRE: medical and 
surgical ICU; thoracic surgical ICU; neurological/neurosurgical ICU; pediatric ICU 
(surgical, neonatal or general pediatric); and hemato-oncology wards. The 
prevalence study was carried out in November 1995 and in February 1996. In 
addition, 200 outpatients attending general practitioners for diarrhea were 
screened. 
Bacterial strains 
Sixteen VRE isolated during the prevalence study were analyzed. Four of these 
16 strains were isolated at Rotterdam University Hospital (Hospital A). In 
addition, 11 clinical VRE strains that were isolated in 1995 in Hospital A before 
the start of the survey were studied. 
Culture and identification 
Stool specimens or rectal swabs from all patients were cultured in a selective, 
aesculin-containing enrichment broth [12,13], supplemented with 50 mg(L 
cephalexin and 75 mg/L aztreonam (Bristol-Myers Squib, Princeton, NJ). All 
aesculin-positive broth cultures were subcultured on a new elective agar 
designed for isolation of E. faecium [14], with and without 6 mg/L vancomycin, 
and on Columbia bloodagar. In a pilot study this procedure proved very 
convenient and easy since all broth cultures containing enterococci did turn 
black; all other broth cultures could be disregarded without further processing. 
All enterococcus-like, arabinose-fermenting as well as arabinose-non-fermenting 
colonies were sub-cultured. A presumptive identification of Enterococcus was 
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made on the basis of colonial morphology, Gram stain, catalase, PYRase (Difco 
laboratories, Detroit, Mich.) and Lancefield group D antigen [15]. Definitive 
identification was done by API 32 rapid system (BioMerieux, Marcy !'Etoile, 
France). E. gallinarum was identified by digestion of DNA with Smai and 
pulsed-field gel electrophoresis. Strains with all DNA-fragments of <200kb were 
identified as E. gallinarum [16]. 
Susceptibility testing 
Resistance to vancomycin was detected by E-test (AB biodisk, Solna, Sweden) 
[17]. An inoculum of 0.5 McFarland and Mueller-Hinton agar (Difco) were used. 
Plates were read after incubation at 37'C for 24h. and the E-test MICs were 
rounded to the nearest higher doubling dilution. All vancomycin-resistant (MIC>4 
mg/L) enterococci were subjected to further susceptibility tests using standard 
agar dilution and broth dilution methods according to NCCLS guidelines [18]. 
E. faecalis ATCC 29212 and 5. aureus ATCC 29213 were used as reference 
strains. The following glycopeptide agents were tested: vancomycin (Eli Lilly, 
Indianapolis, Ind.), teicoplanin (MMDRI-Lepetit Research Center, Gerenzano, 
Italy), avoparcin (Roche, Basel, Switzerland) and LY333328 (Eli Lilly). 
DNA isolation 
DNA was isolated according to Boom et al [19]. The strains were grown 
overnight at 37°C on Brucella bloodagar plates. Colonies were suspended in TEG 
buffer (25 mM Tris-HCI, pH 8.0; 10 mM EDTA and 50 mM glucose). A lysozyme 
solution (10 mg/L) was added and this mixture was incubated for one hour at 
3JCC. Guanidine-hydrothiocyanate was added for cell lysis and Celite (Janssen 
Pharmaceuticals, Beerse, Belgium) was used for DNA binding. DNA was eluted 
with 10 mM Tris-HCI (pH 8.0). DNA concentration was estimated by 
electrophoresis on a 1% agarose gel (Hispanagar; Sphaero Q, Leiden, The 
Netherlands) containing ethidium-bromide in the presence of known quantities of 
lambda DNA. 
PCR assay for VanA, VanB and Vane genes 
The PCR assays were performed as described earlier by Dutka-Malen et al. 
[20]. Approximately 10-100 ng (10 ~I) of DNA was added to a PCR mixture (90 
~I) containing 10 mM Tris-HCI (pH 9.0), 50 mM KCI, 2.5 mM MgCI2, 0.01 % 
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gelatine, 0.1% Triton X-100, 0.2 mM of the 4 deoxyribonucleotide triphosphates, 
1.2 units of Taq DNA polymerase (Sphaero Q, Leiden, The Netherlands). Four 
different primer couples (vanA, vanB, vanC1 and vanC2 [20]) were used in the 
assay (SO pmol of each primer per reaction). Amplification of DNA was performed 
in a Biomed model 60 thermocycler (Biomed, The res, Germany), using 
predenaturation at 94° C for 2 minutes, followed by 30 cycles of 1 minute at 
94° C, 1 minute at S4° C and 1 minute at 72° C. Amplicons were analyzed by 
electrophoresis on a 1% agarose gel (Gibco BRL, Brussel, Belgium) containing 
ethidium-bromide in the presence of a 100 bp ladder. 
Ribotyping 
Restriction digestion of 20 ~I (5 ~g) samples of DNA was done by overnight 
incubation at 37° C with EcoRI (Boehringer GmbH, Mannheim, Germany). DNA 
fragments were separated by electrophoresis on a 1% agarose gel for 16 hours 
(30 V, 200 mA). Southern transfers of the gel with EcoRI digested DNA were 
made by capillary blotting to a nylon membrane (Hybond N+, Amersham, UK). 
The blots were hybridized with a 165 rRNA riboprobe. The probe was synthesized 
by PCR-mediated amplification of the ribosomal genes of E. coli. The amplicon 
was purified by Qiaquick procedures (Westburg, Leusden, The Netherlands) and 
labeled ECL-kits (Amersham). Further processing (hybridization, washing, and 
development) was done according to the ECL guidelines. 
AP-PCR 
AP-PCR was performed as described before [21]. Approximately 5-50 ng (10 
~I) of DNA was added to a PCR mixture ( 40 ~I) containing 10 mM Tris-HCI (pH 
9.0), SO mM KCI, 2.S mM MgC12 , 0.01 % gelatine, 0.1% Triton X-100, 0.2 mM of 
the deoxyribonucleotide triphosphates, 1.2 units of Taq DNA polymerase. Four 
different primers were used in separate assays (50 pmol of primer per reaction; 
ERIC-1R, 5'-ATG TAA GCT CCT GGG GAT TCA C-3'; ER!C-2, 5'-AAG TAA GTG ACT 
GGG GTG AGC G-3'; AP-1, 5'-GGT TGG GTG AGA ATT GCA CG-3'; AP-7, 5'-GTG 
GAT GCG A-3'. Amplification of DNA was performed in a Biomed model 60 
thermocycler (Biomed, Theres, Germany), using predenaturation at 94° C for 4 
minutes, followed by 40 cycles of 1 minute at 94° C, 1 minute at 2S° C and two 
minutes at 74° C. Banding patterns were visualized after electrophoresis on a 
1% agarose gel, containing ethidium-bromide in the presence of a 100 bp ladder. 
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Banding patterns were interpreted upon visual inspection. Different types were 
identified on the basis of even a single differentiating DNA fragment. Differences 
in ethidium bromide staining intensity were ignored. 
Pulsed Field Gel Electrophoresis 
Ten colonies of an overnight culture, grown on bloodagar1 were suspended in 
100 ~I EET buffer (100 mM Na2EDTA, 10 mM EGTA, 10 mM Tris-HCI [pH 8.0]). 
This suspension was mixed with 100 ~I of 1% agarose (lncert agarose; FMC Co., 
Bioproducts, Rockland, Maine) and transferred into sample plug molds (final 
agarose concentration, 0.5%). The plugs were incubated for four hours at 37°C 
in 1 ml EET buffer containing 10 mg of lysozyme (Sigma Chemicals Co., St. 
Louis, and Mo). This lysis solution was replaced for a 1 ml EET buffer solution 
containing 1 mg proteinase K and 1% SDS for a further overnight incubation at 
37° C. The plugs were washed six times (30 minutes each at room temperature) 
in TE solution (10 mM Tris-HCI [pH 8.0], 1mM EDTA). To digest the DNA, a 5 mm 
slice of the sample plug was placed in a TE solution (10 mM Tris-HCI [pH 8.0], 
0.1mM EDTA) with 40 U of Smal (Boehringer GmbH) and incubated overnight at 
25° c. The plugs were loaded on 1% agarose gel (SeaKem GTG agarose; FMC) in 
0.5x TBE [22]. Electrophoresis was performed using a CHEF DR II apparatus 
(Bio-Rad, Richmond, Calif.), programmed in the auto-algorithm mode; block 1: 
runtime 8 hours, switch time: 0.5-15 seconds and block 2: runtime 10 hours, 
switch time 15-30 seconds. The gels were stained with ethidium-bromide for 15 
minutes and destained in distilled water for 1 hour before photography. All gels 
were inspected visually by two different investigators. Profiles were designated 
by a different capital letter any time a distinct (4 or more bands difference) 
pattern was obtained. Isolates with identical profiles were assigned the same 
letter. Isolates that differed by 1-3 bands, consistent with a single genetic event, 
were assigned a subtype [23]. 
Statistical analysis 
Fisher's two-tailed test was used to assess differences between frequencies of 
isolation of enterococci in the two different patient populations. 
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Results 
Three hundred six (49%) of the 624 hospitalized patients and 161 (80%) of 
200 community-based patients carried enterococci in the gastro-intestinal tract 
(p<0.01). Of the 306 enterococci isolated from hospitalized patients, 132 (43%) 
were identified as E. faecium. Out of 161 enterococci from patients outside the 
hospital, 52 (32%) were identified as E. faecium (p< 0.05). Thus, E. faecium was 
isolated from 132/624 (21 %) of the hospitalized patients and from 52/200 
(26%) of the community-based patients (p> 0.05). VRE were isolated from 12 
(2%) of the 624 hospitalized patients and from 4 (2%) of the 200 community-
based patients. Fifteen VRE were identified as E. faecium; one was identified as 
E. faeca/is. Fifteen (8%) of 184 E. faecium strains isolated in the prevalence 
study were vancomycin-resistant. In addition, 11 strains of VRE were isolated in 
Hospital A at times separate from the prevalence study period. Nine were 
identified as E. faecium, two as E. gaflinarum. Thus, 27 VRE were available for 
further studies. 
Table 1: In-vitro activity of four glycopeptide agents against 27 VRe 
strain MIC (mg/L)0 Van genotype 
number species Vac Tei Avo LY333328 
clinical 10-a E. faecium >256 >256 >256 1 
Isolates" 10-b E. faecium >256 >256 >256 0.5 
10-c E. faecium >256 >256 >256 0.25 
10-d E. faecium >256 >256 >256 0.5 
10-e E faecium >256 128 >256 0.5 
10-f E. faeclum >256 >256 >256 0.5 
10-g E. faectum >256 >255 >256 0.25 
10-h E. faecium >256 >256 >256 0.5 
10-i E. ga/finarum 8 0.5 8 0.25 
10-j E. faecium 8 0.5 8 0.25 
10-k E. ga!linarum 8 0.5 8 0.25 
survey 11-1° E. faecium >256 >256 >256 0.25 
isolates 12-mc E. faecium >256 >256 >256 0.125 
12-n° E. faecafis >256 >256 >256 0.25 
12-o" E. faecium >256 >256 >256 0.125 
21-p E. faecium >256 >256 >256 0.125 
22-q E. faecium >256 >256 >256 1 
22-r E. faecium >256 >256 >256 0.25 
22-s E. faedum >256 128 >256 0.25 
31-t E. faecium >256 >256 >256 0.25 
32-u E. faecium >256 >256 >256 0.125 
42-v E. faecium >256 >256 >256 0.125 
52-W E. faecium >256 >256 >256 0.125 
62-x E. faecfum >256 >256 >256 0.125 
62-y E. faecium >256 >256 >256 0.25 
62-z E. faecium >256 >256 >256 0.25 
62-o. E. faecium >256 >256 >256 0.5 
"using a standard NCCLS broth dilution method; bVan, vancomycin; Tel, teicoplanin; Avo, Avoparcin 
c strains isolated in Hospital A 
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Susceptibilities of the 27 VRE for vancomycin, teicoplanin, avoparcin and 
LY333328 and the resistance genotype are presented in Table 1. Complete cross-
resistance was found between vancomycin and avopardn. LY333328, however, 
was 250-> 1000 -fold more active against VanA VRE compared to vancomycin. 
Major discrepancies were observed between the MICs of LY333328 that were 
found using agar dilution compared to broth dilution: on agar, the MIC,o of 
LY333328 against VanA VRE was 4 mg/L (range 0.25-4 mg/L) compared to 0.5 
mg/L (range 0.125-1 mg/L) in broth. We did not observe such differences with 
the other glycopeptide agents. Twenty-four of the 27 VRE, including all VRE from 
the prevalence study, had the VanA genotype; one had the VanB, and two had 
the VanCl genotype. All VanA E. faecium had MICs of vancomycin > 256 mg/L 
and teicoplanin > 64 mg/l. The VanB and VanC1 strains had a vancomycin MIC 
of 8 mg/L and a teicoplanin MIC of 0.5 mg/l. 
Table 2: Overview of PFGE, AP-PCR and Ribotyping of 27 VRE 
clinical 
isolatesb 
survey 
isolates 
strain 
number 
10-a 
10-b 
10-c 
10-d 
10-e 
10-f 
10-g 
10-h 
10-i 
10-j 
10-k 
11-1° 
12-mb 
12-n° 
12-o0 
21-p 
22-q 
22-r 
22-s 
31-t 
32-u 
42-v 
52-w 
62-x 
62-y 
62-z 
62-a: 
Ribotype PFGE 
A A 
B B 
A c 
A 0 
A E 
B F 
c G 
A H 
0 I 
A J 
0 K 
E L 
A M 
F N 
c 0 
A M' 
c p 
A Q 
A M' 
A R 
A M' 
c s 
A T 
A u 
G v 
A w 
A M' 
• based on AP-1 and ERIC-2 primers 
b strains isolated in Hospital A 
AP-PCR~ 
A 
B 
c 
0 
E 
B 
F 
G 
H 
I 
H 
J 
K 
L 
M 
M 
K 
K 
M 
N 
M 
0 
N 
M 
p 
Q 
K 
49 
Chapter4 
location 
Screening 
Strain 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2 23 3 45 55 6 5 
000000000001222122212222222 
ABCDE FGH lJ KLMNOPQRSTUV'\/VXYZcx 
Figure 1: Restriction endonuclease pattern obtained by PFGE with Smal for 27 strains of VRE isolated from 
hospital- and community-based patients in The Netherlands. From teft to right, the strains appear in the lanes 
in the same order in which they are listed in Tables 1 and 2. Each strain has a two digital/one letter code 
corresponding to the location (1, Rotterdam; 2, Amsterdam; 3, Breda; 4, Utrecht; 5, Nijmegen; 6, community), 
the screening (0, routine isolates from hospital A; 1, prevalence study November 1996; 2, prevalence study 
February 1997), and a strain letter code corresponding to the order of the strains fisted in Tables 1 and 2. A 
50 Kb ladder (bio-Rad, Veenendaal, The Netherlands fs shown in the lane on the right as molecular size 
standard 
The restriction endonuclease patterns obtained by PFGE with Smai for 27 VRE 
are shown in Figure 1. An overview of all typing results is given in Table 2. The 
discriminatory power of AP-PCR with primers AP-7 and ERIC-1 was low compared 
to primers AP -1 and ERIC-2. Therefore, only the results of AP-PCR with AP-1 
and ERIC-2 are presented in Table 2. Analysis of all 27 VRE revealed 23 different 
patterns by PFGE, 17 by AP-PCR analysis with primers AP-1 and ERIC-2 and only 
7 by ribotyping. Some strains that were indistinguishable by AP-PCR were 
unrelated by PFGE (e.g. strain 21-p and 12-o). Vice versa, AP-PCR was able to 
distinguish strains that appeared highly related by PFGE (e.g. strain 32-u and 
62-<X). 
PFGE of 15 strains from Hospital A yielded 15 different patterns. PFGE of 16 
VRE from the prevalence study (including 4 strains from Hospital A) yielded 12 
different patterns. Five strains isolated from patients hospitalized in three 
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different hospitals appeared closely related (Table 2). These 5 strains could be 
divided into 2 different subtypes by AP-PCR. Therefore, the combination of PFGE 
and AP-PCR demonstrated genetic unrelatedness in 13/16 VRE from the survey. 
Discussion 
The rapid emergence of resistance in enterococci and the increasing incidence 
of colonization and infection with VRE have become a health care issue that has 
caused serious concern to physicians and health authorities alike [8]. This study 
documents the prevalence of intestinal colonization of selected patients from 
ICUs and hemato-oncology wards as well as of general practice patients in The 
Netherlands. Enterococci were found in 49% of the inpatients and in 80% of the 
outpatients. This proportion of hospitalized patients who carry enterococci is 
lower than found in previous studies, where 75-90% of the patients carried these 
microorganisms [4, 24]. These latter studies screened unselected hospitalized 
patients. One can speculate as to whether greater use of penicillins like 
amoxicillin or amoxicillin/clavulanic acid combination, may have occurred in our 
selected group of patients and, thus, may have influenced the prevalence of 
enterococci isolated from the gastrointestinal tract. We isolated E. faecium in 
21% of the inpatients and 26% of the outpatients, which is in agreement with 
previous findings of E. faecium in 20-40% of stool cultures [4, 25]. VRE were 
isolated in 2% of the community-based patients. Several European studies have 
reported similar frequencies in the community [26,27]. However, a much higher 
frequency has been reported in a Belgian study [28]. In the latter study, 11 
(28%) of 40 healthy community-based volunteers who were not health care 
workers and had not received antibiotics for at least 1 year, were colonized with 
VRE. The results of North-American studies performed in the Houston 
metropolitan area, however, contrast with the European data since VRE appear 
to be absent in healthy persons in this geographic area [29]. The presence of 
VRE in the community in Europe parallels the colonization of animals with these 
resistant organisms [6]. Several studies have now reported the absence of VRE 
in animals and in the community in the United States, in contrast with the high 
frequencies in hospitals [30-32]. Some authors, however, have cautioned against 
comparing the results of the above mentioned studies, since differences in 
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methodology could, at least in part, explain the observed differences in isolation 
rates [29]. 
Since ICU patients and patients in oncology wards were found to be at 
increased risk for VRE infection or colonization [8], we decided to select these 
patients for our inpatient survey. The isolation rate in these hospitalized patients 
was 2°/o and, therefore, similar to the isolation rate in outpatients. This is roughly 
in agreement with a recent Belgian study where it was shown that 3.5% of 
hospitalized patients were VRE carrier [32]. In Finland, Suppola et a! [24] 
investigated hospitalized patients with hematological malignancies and reported 
a VRE prevalence of 2%. 
We analyzed the genetic relatedness of the 27 VRE strains by PFGE and 
AP-PCR. In previous studies PFGE has been shown to be the most discriminating 
typing technique for VRE and this technique is now considered the gold standard 
[7, 33]. Recently, however, AP-PCR has proven a powerful typing tool as well. 
Results of PFGE and AP-PCR are often in concordance [34]. In our study, 
however, PFGE was more discriminatory compared to AP-PCR. Combining the 
data generated by the two methods, we demonstrated genetic unrelatedness of 
13/16 VRE strains isolated during the survey and of all 15 strains that were 
isolated in hospital A. No evidence exists for major inter- or intra-hospital spread 
of VRE in The Netherlands. This observation is remarkable since no special 
infection-control measures to prevent VRE transmission were in vigor in the 
participating hospitals at the time of the survey. Together with the observed 
isolation rate of 2% in the community-based patients, it is suggested that VRE in 
hospitalized patients may have originated from presently unknown sources in the 
community. The gastro-intestinal tract is probably the major reservoir in men, 
from which subsequent infection can eventually develop. This is in agreement 
with a recent report from New York [22]. Food has been proposed as a source 
[5, 35]. Others have put forward pets and other domestic animals [36, 37]. 
Furthermore, the use of antibiotics as feed additives for growth enhancement in 
animals may be associated with the emergence of VRE [27]. An example of such 
a growth-promoting agent is avoparcin, a drug that has been used in The 
Netherlands for a long time. The pig, poultry and calf production is an area of 
important economic activity in The Netherlands. To date, this country is one of 
the leading exporters of consumer poultry products in the world, after the US 
and France [38]. Although official figures are not available, it is clear that 
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avoparcin has been used in this country on a very large scale. Preliminary results 
of a nationwide VRE prevalence study in poultry suggest that approx. 80% of the 
consumer poultry at retail level is colonized with VRE, possibly as a result of 
unrestricted use of avoparcin in the poultry industry [39]. Thus, the use of oral 
glycopeptide antibiotics in the bio-industry should be strongly discouraged. 
Recently, the European Community committed itself to a cautious approach and 
banned all use of avoparcin as feed additive in animals by 1 April 1997 [Directive 
97 /6/EC of January 30th 1997]. The emergence of VRE has resulted in an 
increase in the incidence of infections caused by these organisms that can not be 
treated with currently available antimicrobial agents [40]. LY333328 is a new 
semisynthetic glycopeptide that has been reported to increase activity against 
vancomycin-resistant Gram-positive microorganism's [ 41]. In our study, 
LY333328 was found to posses greatly enhanced activity against VRE. In general, 
the MICs were 25 - 1000 -fold lower against VRE compared to vancomycin. 
These data are in agreement with an earlier report [11]. Surprisingly, the MICs 
of LY333328 obtained with an agar dilution method were 4-8 fold higher than 
with a broth dilution method, for which we do not have an explanation. This 
phenomenon has recently been reported by others [42]. The results, however, 
indicate that LY333328 is a promising new drug that deserves further evaluation. 
In conclusion, we have shown in a multicenter study that VRE can be isolated in 
hospitalized and in community-based patients in The Netherlands, at a frequency 
of 2°/o. Second, these strains appear unrelated and, therefore, no evidence exists 
for major inter- or intra-hospital spread of VRE strains in our country. Third, our 
data suggest that VRE be acquired outside the hospital environment. Further 
studies are warranted to elucidate the origin and the epidemiology of vancomycin 
resistance. In countries with a large animal livestock, including The Netherlands, 
where large quantities of feed additives are used, it seems wise to strongly 
discourage the use of oral glycopeptides not only in man, but in the bio-industry 
as well. 
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Abstract 
We determined the prevalence and determinants of vancomycin resistant 
enterococci (VRE) fecal carriage in Intensive-Care Unit (ICU)-, Hematology-
Oncology (HO)- and hemodialysis patients in The Netherlands with a descriptive, 
multi-center study, with yearly one-week point-prevalence assessment between 
1995-1998. All patients hospitalized on the testing days in ICUs and HOwards in 
nine hospitals in The Netherlands were included. Rectal swabs obtained from 
1112 patients were screened for enterococci in a selective broth and subcultured 
on selective media with and without 6 mg/L vancomycin. Resistance genotypes 
were determined by PCR. Further characterization of VRE strains was done by 
pulsed field gel electrophoresis (PFGE). We studied possible determinants of VRE 
colonization with a logistic regression analysis model. Determinants analyzed 
included sex, age and log-transformed length of prior hospital stay. The results 
showed that 614/1112 (55%) patients were colonized with vancomycin sensitive 
enterococci (VSE) and 15/1112 (1.4%) carried VRE. From 1995-1998, no 
increase in VRE colonization was observed. Eleven strains were identified as 
Enterococcus faecium and four as Enterococcus faecalis. All E. faecium and one 
E. faeca/is carried the vanA gene; the other E. faeca/is strains harbored the vanB 
gene. PFGE revealed that 3 vanB VRE isolated from patients hospitalized in one 
single ICU, were related, suggesting nosocomial transmission. Though higher age 
seemed associated with VRE colonization, exclusion of patients with the 
nosocomial strain from the regression analyses decreased this relation to 
non-significant. Duration of hospital stay was not associated with VRE 
colonization. VRE colonization in Dutch hospitals is an infrequent phenomenon. 
Though, nosocomial spread occurs, most observed cases were unrelated, which 
suggest the possibility of VRE acquisition from outside the hospital. Prolonged 
hospital stay, age and sex proved unrelated to VRE colonization. 
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Introduction 
Colonization and infection caused by vancomycin-resistant enterococci (VRE) has 
been reported in hospitalized patients, particularly in the United States, but also in 
European countries. VRE has emerged as an important cause of nosocomial 
infections. The prevalence of patients colonized with VRE is still rising in the United 
States. The Center for Disease Control (CDC) reported an increase of VRE isolated 
from nosocomial infections in intensive-care units (ICU's) in the United States from 
0.4% to 23.2% [1]. The prevalence of VRE in European hospitals over the last ten 
years remains low [2, 3]. Nosocomial transmission of VRE plays an important role 
in the United States and hospital outbreaks with clonally related VRE have been 
described on various occasions [4-6]. In contrast to the observed clonality in the 
United States, a high degree of heterogeneity is observed among VRE strains 
isolated in Europe [7, 8] , suggesting that, in the absence of intrahospital spread, 
VRE are acquired outside the hospital [9-11]. It is important to analyze and to 
understand the difference in epidemiology of VRE in the USA and Europe [12]. The 
issue is complex and the cause of the spread of VRE is likely to be multifactorial. 
However, further accumulation of epidemiological data may be instrumental to the 
development of guidelines to prevent the further spread of VRE. Therefore, the aim 
of this study was to survey the prevalence of fecal carriage of VRE in high risk 
hospitalized patients in The Netherlands and to describe and analyze several 
demographic data and patient characteristics of VRE colonization. 
Materials and Methods 
Prevalence study 
Five Dutch university hospitals in Rotterdam, Utrecht, Amsterdam (n=2) and 
Nijmegen and four regional hospitals in Tilburg and Breda participated in this 
study. The prevalence surveys were carried out in November 1995, February 
1996, February 1997 and June 1998. Preliminary results from the surveys in 
1995 and 1996 were reported by Endtz et al [10]. Eleven hundred and twelve 
patients were screened for gastro-intestinal carriage of VRE. All patients 
hospitalized on the study days in medical, surgical neurosurgical, neurological, 
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pediatric and neonatal intensive care units (ICU), hematology and oncology 
(HO), and hemodialysis wards were included. 
Isolation an identification 
Isolation and identification was done as described by Endtz et al [10]. In brief, 
stool specimens or rectum swabs from all hospitalized patients on the testing 
days were screened for enterococci in a selective, esculine enrichment broth. All 
esculin-positive broth cultures were subcultured on a selective agar, designed for 
isolation of E. faecium [13], with and without 6 mg vancomycin per liter and on a 
Columbia blood agar plate (Becton and Dickenson, Meylan Cedex, France). A 
presumptive identification of the Enterococcus spp. was made on the basis of 
colony morphology, Gram stain, catalase and pyrase (Dryslide Pyrkit, Difco 
Laboratories, Detroit, USA). Definitive identification was done by the RAPID !032 
STREP assay (BioMerieux, 's Hertogenbosch, The Netherlands). 
Antimicrobial susceptibility tests 
All enterococcal strains were tested for vancomycin susceptibility on 
Mueller-Hinton agar (DIFCO Laboratories, Detroit, USA) with E-test strips (AB 
BIODISK, Solna, Sweden) following the instructions of the manufacturer. All 
plates were incubated at 37'C and read after 24 h. 
DNA isolation 
Enterococcal DNA was isolated according to Boom et al. [14]. In brief, VRE 
strains were grown overnight at 37°C on Brucella blood agar plates. Ten colonies 
of each isolate were mixed and suspended in 75 ~I TEG buffer (25 mM Tris-HCI, 
pH 8.0; 10 mM EDTA and 50 mM glucose). A lysozyme solution (75 ~I of 10 
mgjml) was added and this mixture was incubated for one hour at 37°C. 
Guanidine-hydrothiocyanate was added for cell lysis and Celite (Janssen 
Pharmaceuticals, Beerse, Belgium) was used for DNA binding. DNA was washed 
and finally eluted from Celite with 10 mM Tris-HCI (pH 8.0) by incubation at 56°C 
for 10 minutes. The DNA concentration was estimated by electrophoresis on 1% 
agarose gels (Hispanagar; Sphaero Q, Leiden, The Netherlands) containing 
ethidium-bromide in the presence of known quantities of lambda DNA as 
references. 
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VanA, vanB, vanCl and vanC2 PCR 
Diagnostic PCR assays targeting the various resistance genes were performed 
as described by Dutka Malen et al. [15]. Four different primer couples (vanA; 
vanB; vanCl and vanC2) were used in combination with 50 ng enterococcal DNA. 
Amplification of DNA was performed in a Biomed thermocycler (Model 60, 
Theres, Germany), using predenaturation at 94° C for 2 minutes, followed by 30 
cycles of 1 minute at 94° C, 1 minute at 54° C and 1 minute at 72° C. Am pi icons 
were analyzed by electrophoresis on 1% agarose gels (Hispanagar; Sphaero Q, 
Leiden, the Netherlands) containing ethidium-bromide in the presence of a 100 
basepair DNA ladder (Gibco/BRL Life Technologies, Breda, The Netherlands). 
Pulsed field gel electrophoresis 
PFGE was performed as described previously [16]. In brief, colonies of an 
overnight culture, grown on a blood agar plate, were mixed and suspended in 
EET buffer (100 mM Na2EDTA , 10 mM EGTA, 10 mM Tris-HCI; pH 8.0). This 
suspension was mixed with 1% agarose (Incert Agarose: FMC, Rockland, USA). 
Cells in the plugs were lysed, washed, stabilized and restricted with Smal. 
Electrophoresis was performed and the gel was stained with ethidium-bromide 
before photography under UV irradiation. The gels were inspected visually by two 
different investigators. The PFGE patterns were interpreted according to Tenover 
eta/ [17]. Since the interpretative guidelines brought forward by Tenover eta/ 
are mainly for outbreak investigations, the following additional comparison was 
performed. Data obtained for all VRE were studied in more detail using 
Gelcompar software (Applied Maths, Gent, Belgium). The PFGE patterns were 
scanned and Dice analysis of peak positions was executed. UPGMA was applied 
and the bandwidth tolerance was set critically at 1.2%. 
Statistical analysis 
On the wards with sporadic cases we studied possible determinants of VRE 
carriage with multiple regression analysis, including an analysis in which hospital 
stay was log-transformed, to normalize distribution. Demographic data for the 
analysis were obtained from anonymous patient records. 
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Results 
Six hundred and fourteen (55%) of the 1112 hospitalized patients carried 
vancomycin-sensitive enterococci (VSE) in their gastro-intestinal tract. VRE was 
found in 15/1112 patients (1.4%). The overall prevalence ranged from 0.8% 
(2/230) in 1998 to 2.7% (7/256) in 1996. Table 1 gives a summary of all VRE 
isolated during the study. In 1998, for example, VRE were found only in one 
hospital which represents a local prevalence of 4.4% (2/45). Eleven strains were 
identified as E. faecium, the remaining four strains were E. faecalis. 
Table 1: Vancomycin-resistant enterococci (vancomycin MIC > 256 mg/L) isofated during yearly point-
prevalence surveys, The Netherlands, 1995 to 1998 
Location Screening VRE/Patients Species Strain Teico van PFGE 
Year (%) code MIC (mg/L) genotype 
Rotterdam 1995 1/88 (1.1%) E. faecium VRE 1 >256 A A 
1996 2/72 (2.8%) E. faecium VRE 2 >256 A 8 
E. faeca!is VRE 3 >256 A c 
Amsterdam {I) 1997 3/55 (5.4%) E. faecalis VRE 4 1 B D 
E. faecalis VRE 5 1 B D 
E. faecafis VRE 6 1 8 D 
1998 2/45 (4.4%) E. faedum VRE 7 >256 A E 
E. faecium VRE 8 >256 A E" 
Amsterdam {II) 1995 1/68 {1.5%) E. faecium VRE 9 >256 A s· 
1996 2/66 (3.0%) E. faecium VRE 10 >256 A F 
E. faecium VRE 11 128 A s· 
Breda 1995 1/36 {2.7%) E. faecium VRE 12 >256 A G 
1996 1/32 {3.1%) E. faecium VRE 13 >256 A 8" 
Nijmegen 1996 1/47 {2.1%) E. faecium VRE 14 >256 A H 
Utrecht 1996 1/46 {2.1%) E. faecium VRE 1 >256 A 
Abbreviation : MIC, minimum inhibitory concentration; PFGE pulsed f1eld gel electrophoresis; 
VRE, Vancomycin Resistant Enterococci 
• differs 3 bands from PFGE type E,+ differs 1 band from PFGE type B 
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All VRE were highly resistant to vancomycin (> 256 mg/L). Of the 15 VRE, 11 
E. faecium and 1 E. faeca/is were resistant to teicoplanin (VanA phenotype) and 
three E. faeca/is were susceptible (VanS phenotype). 
VRE isolates found in this study were analyzed by PFGE (figure 1). Most of the 
PFGE banding patterns comprised 15 to 20 DNA fragments. Analysis of banding 
patterns showed that three out of four E. faeca/is (Figure 1; VRE 4, 5, 6) were 
genetically identical and two clusters of E. faecium (cluster I; VRE 2, 9, 11, 13 
and cluster II; VRE 7, 8) were genetically related. The 3 identical E. faeca/is 
strains were isolated in an intensive care unit in one hospital in 1997 and thus 
represent an epidemic strain. The E. fae6um strains in cluster II were also 
isolated in 1997 in this hospital. Therefore, it would seem that these isolates 
might also have resulted from nosocomial transmission. In contrast, the 
genetically related E. faecium strains in cluster I were isolated in 1995 (n=1) and 
1996(n=3) in 3 different hospitals. 
Correlation: Bands, Dice (Max. tol. "!.2%, Mln. surf. 0.0%) 
Zones: {1-400] 
Clustering: UPGMA 
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Figure : Oendogram of vancomycin 
resitant enterococci isolated from 
hospitalized patients in one week 
point-prevalence studies between 
1995-1998 in The Netherlands. The 
origin of VRE 1-15 are listed in Table 1 
Abbreviation: UPGMA unweighted 
pair group method using arimethic 
averages 
We identified factors including sex, age and length of hospital stay associated 
with sporadic VRE colonization (Table2) and studied these determinants with 
multiple logistic regression analysis. We also ran an analysis in which hospital 
stay was log-transformed, to normalize distribution. Patients, who were admitted 
in the ward during the epidemic, were excluded from all regression analyses. 
Neither duration of hospitalization nor sex correlated with VRE carriage, whether 
or not the 137 patients under 5 years of age (who had long relatively stay but no 
VRE) were included in the analysis. There appeared to be a trend of more VRE 
with higher age (p=0.07). This may however have been based entirely on the 
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relatively large number of under-fives without VRE, because the relationship 
disappeared when this group was excluded from analysis. We further 
investigated the "outbreak" of vanB VRE in 1997 at the ICU in one of the 
University hospitals. At time of sampling 6/6 patients were colonized with 
enterococci. Three patients were colonized with VRE (mean age = 70 yrs, median 
67 yrs) and 3 were VSE carriers (mean age 58 yrs, median 52 yrs). Here again, 
no significant difference was found in length of hospital stay between vanB VRE 
and VSE carriers (47 days versus 53 days; p >0.5). 
Table 2: Characterizations of hospitalized patients screened for VRE in yearly point-prevalence 
surveys, The Netherlands, 1995 to 1998 
VRE VSE 
Patients, Male 9 353 
Female 6 246 
Total 15 599 
Age (years), Mean 61 43 
Range [29 .. 83] [0 .. 92] 
Median 60 51 
Lenght of stay (days), Mean 24 27 
Range [7..40] [0 .. 219] 
Median 15 18 
Abbreviation : VRE, vancomycin resisistant enterococci; VSE, vancomycin sensitive enterococci 
Discussion 
This study was undertaken to determine the prevalence, and the genetic 
background of VRE in Dutch hospitalized patients and to find determinants 
associated with VRE carriership in a selected category of hospitalized patients 
(ICU and hematology wards) in The Netherlands. Fifty-five percent of these 
patients had enterococcal colonization in the gastro-intestinal tract. Trabusli et 
al. [18] reported a similar prevalence of enterococci in a group of high-risk 
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pediatric patients. In contrast, in several studies unselected hospitalized patients 
were screened for VRE and higher frequencies (75-90%) of patients colonized 
with enterococci were reported [19, 20]. 
We isolated VRE from 1.4% of the high-risk patients included in the study. 
This is somewhat lower than found in other VRE studies in European hospitals. In 
Belgium 3.5% of the patients in a university hospital carried VRE [7]. In a study 
in France 4.9% of hospitalized patients were colonized with VRE [8]. However, 
more recent studies in other European countries report comparable percentages 
of VRE carriage. In a surveillance study in Germany [2] the VRE carriage rate 
was 1.5%. In contrast, in seven Norwegian hospitals [3] no vanA VRE were found 
in hospital patients. The authors hypothesized that this was related to the limited 
use of glycopeptide antibiotics in Norway. The prevalence of VRE in hospitals in 
The Netherlands as well as in the rest of Europe appears to be rather low and 
stable over the last ten years. However, prevalence of VRE in the community and 
in the environment is high. In a previous nation-wide study we showed a high 
prevalence of 80% VRE in Dutch consumer poultry products [16] and 
hypothesized that the use of feed additives such as avoparcine may have 
contributed to the high prevalence of VRE in meat. The European Union banned 
all use of avoparcine as feed additive in April 1997 and in December 1998; 
avilamycin, bacitracin, tylosin and virginiamycin were banned [20]. However, 
controversy still exists over the impact of these measures on the VRE prevalence 
in humans [21, 22]. 
PFGE analysis showed that all vanB E. faecalis strains were identical; these 
strains were isolated in one ICU. After the end of the study period two additional 
patients from the same ICU were reported to be colonized with this VRE clone. 
This is the first nosocomial clonal outbreak of colonization caused by VRE in the 
Netherlands. In contrast, when analyzing E. faecium we found 4/11 genetically 
related strain but no geographical relationship. Outbreaks of VRE in Europe occur 
infrequently. VRE isolated from hospitalized patients as well as from other 
sources are mostly heterogeneous strains. Interestingly, Willems et al [23] 
suggested that horizontal transmission of Tn1546 transposon might be an 
alternative determinant factor driving the spread of vancomycin resistance. Further 
studies should also take Tn1546 diversity into account; analyses of Tn1546 were 
not part of the present study. 
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Several factors can be involved to explain the dissemination of VRE. Goossens 
[12] suggested that antimicrobial pressure is one of the most important factors 
for the spread of VRE in the United States. Several risk factors for VRE 
colonization and infection have been described. Rao et al [24] identified preceding 
therapy with vancomycin or cephalosporins and prolonged hospital stay as 
important risk factors. Other studies confirmed that prolonged hospital stay is 
significantly related to VRE colonization or infection [25-28]. In contrast, we 
reported that VRE carriage is not associated with prolonged hospital stay in The 
Netherlands. One may, therefore, assume that, while vancomycin use is possibly 
the driving force leading to the observed high prevalence in US hospitals, 
glycopeptide use in animal husbandry in Europe is more likely to be responsible for 
the occurrence of VRE in Europe. In the absence of any data to refute this 
hypothesis, it appears that a different approach to intervention is needed. 
However, it is important to stress that the number of riskfactors analysis in our 
study was limited, and did not include, for example, analysis of factors such as 
previous antimicrobial therapy or proximity to known patients with VRE. Therefore, 
more studies are needed to further clarify the epidemiology of VRE and detect the 
design of future interventions. 
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Chapter 6a 
The human gastro-intestinal flora is affected by probiotics such as lactobacilli, 
the use of antibiotics and, last but not least, dietary habits [1]. It appears 
obvious that intestinal metabolism and mucosal immunity change with type of 
food intake, which is also correlated with changes in the ratio in which different 
microorganisms occur [2] . Antibiotics, like food, greatly effect the composition of 
the gastro-intestinal flora and may select for resistant strains. This does not only 
happen for patients, but it may also occur when antibiotics are used as growth 
promoters in modern food-animal production [3]. Meat products have been 
shown to be colonized with resistant microorganisms [4]. This raises the question 
whether meat serves as a vector during zoonotic transmission. The question 
whether antibiotic resistant micro-organisms present in food may persistently 
colonize the human gastro-intestinal tract can be answered by designing studies 
that compare the faecal flora of vegetarians and that of non-vegetarians, meat 
eating controls. 
We performed a large study on the presence of vancomycin-resistant 
microorganisms in the faecal flora of vegetarians in 1997. We obtained rectal 
swabs from 318 vegetarians (mean age 55±18 years, mean number of meat free 
years 30±2) and 276 non-vegetarian control individuals (mean age 53±17 
years). The swabs were inoculated in Enterococcosel medium (BBL, Cockeysville, 
USA) in order to select for vancomycin-resistant enterococci (VRE). The results 
documented a statistically significant difference in the occurrence of low-level 
VRE such as Enterococcus casse!iflavus and Enterococcus gallinarum in 
vegetarians versus controls [5]. Briefly, 31 vegetarians carried VRE, a number of 
20 E. casselif/avus (vanC2) and 10 E. gallinarum (vanC1) was found. Two of these 
31 persons were colonized with E. gal/inarum (vanC1) as well as E. casseliflavus 
(VanC2). Among 'meat-eating' persons we found that 13 persons were colonized 
with VRE, 1 with E. faecium (VanA), 7 with E. gallinarum (vanC1) and 5 with 
E. casseliflavus (vanC2). One person carried two VRE (E. gallinarum and 
E. casseliflavus). In conclusion, we found no hig.h level vancomycin resistant VRE in 
the vegetarian group. In contrast, one VRE (VanA) was isolated in the non-
vegetarian group (0.4%). Interesting is the difference in colonization by low-level 
VRE, especially E. casseliflavus, in vegetarian versus non-vegetarian persons. 
Overall, 31/318 {9,7%) and 12/276 (4.3%) {p<0.05) VRE were harboring the 
vane gene. We suggest that vegetarian people have a significantly higher carriage 
rate of VRE possessing the Vane gene. Fortunately, this kind of VRE is nowadays 
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not associated with clinical infections in human. No association was found between 
meat consumption and carriage of high level VRE, as opposed to previous 
analyses by another Dutch group [6]. However, both studies indicated an 
apparent difference in the colonization rate of antibiotic-resistant microorganisms 
as a consequence of dietary habits. This emphasizes the need for further 
investigations. It was suggested that the high rate of low-level VRE carriage in 
vegetarians could be due to the fact that especially E. casseliflavus was found to 
be associated with plants. 
In the same group of vegetarians and controls1 lactose-positive 
Gram-negative (LPGN) rods were cultured from the faecal specimens on 
MacConkey agar. Escherichia coli strains (n=117), identified with the Vitek 
system, were randomly selected from the LPGN rods isolated from faecal 
samples of 318 vegetarians. As a control group, 101 additional E. coli strains 
were cultured from the rectal swabs obtained from the 276 non-vegetarians. 
Susceptibility for various antimicrobial agents was assessed (see table) using the 
disk diffusion method according to the NCCLS [7]. The antimicrobial agents 
investigated comprised drugs registrated for use in humans as well as agents 
used as growth promoter in animal husbandry. In absence of accurate NCCLS 
guidelines for tylosine1 zone diameters were defined as following manufacturers 
criteria: ~26 mm 1 susceptible; 23-25 mm, intermediate; :::: 22 mm, resistant. The 
enterococci were also screened for high-level gentamicin and streptomycin 
resistance (MIC >500 mg/L) with E-tests (Oxoid, Hampshire, England). 
The table displays the results of the susceptibility tests performed for all 
low-level VRE. When the resistance ratios in vegetarians were compared with 
controls (Fisher's exact tests) there appeared to be significantly more bacitracin 
intermediate strains in the control group only (p = 0.0067). The table also 
provides an inventory of the antimicrobial susceptibility of the E. coli strains. 
None of the comparisons appear to be significant. However, we do observe a 
trend towards decreased susceptibility to nitrofurantoin in the control group 
(p = 0.06). Overall, no clear differences seem to exist when the resistance to 
various antibiotics is assessed in E. coli or enterococci from the two groups. 
However, when the prevalence of resistant E. coli in community-based 
vegetarians and volunteers are compared to resistance figures in E. coli from 
hospitalized patients (Table 1, column on the right) the nosocomial strains are 
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Table 1 Antimicrobial resistance as defined by disk diffusion testing of Vane enterococci and E. coli strains isolated from vegetarians and controls. 
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Vane enterococci Esc/Jerlchia coli 
Antibiotic Control strains Vegetarian isolates Control strains Vegetarian isolates Hospital strains 
(n~13) (n~30) (n~101) (n~117) (n~2447) 
R I s R I s R I s R I s R I s 
--------------------------------------------------------------------------------------------------------------------------------------------------------------
Norfloxacin 15 46 38 3 43 53 0 0 100 0 0 100 5 0 95 
Nitrofurantoin 15 23 62 3 17 80 0 20 80 0 10 90 6 0 94 
Trlmethoprim 15 0 85 27 10 63 6 0 94 10 0 90 
Cefuroxim 100 0 0 100 0 0 0 0 100 0 0 100 4 14 82 
Cotrlmoxazol 8 0 92 3 0 97 5 1 94 8 0 92 28 0 72 
Piperactllln 0 0 100 7 7 87 17 1 83 16 1 83 35 5 60 
Amoxicillln 0 0 100 3 0 97 19 0 81 24 2 74 43 1 57 
Tylosin 8 0 92 3 0 97 100 0 0 100 0 0 
Bacitracin 0 69 31 0 23 77 100 0 0 100 0 0 
Gentamicin • 0 0 100 0 0 100 2 0 98 1 0 99 4 0 96 
Streptomycin • 8 0 92 3 0 97 29 28 44 22 37 41 
Tetracyclln 31 0 69 20 0 80 24 0 76 21 0 79 
Splramycin 15 0 85 17 0 83 100 0 0 100 0 0 
-------------------------------------------------------------------------------------------------------------------------------------------------------------------
The table states percentages of strains resistant (R), intermediately susceptible (I) or fully susceptible {S) towards the antibiotics used. The control 
collection consisted of 5, 7 and 1 strains of E. casseliflavus, E. gal/inarum and E. faecium, respectively. The Isolates from the vegetarians were 20 E. 
casse/iffavus and 10 E. gal/inarum. ·values as determined byE tests for the enterococci. The E. coli hospital strains were collected In 1999, Included 
are single Isolates per patients selected for the most resistant isolate available in the files(-: data not available). Datasets that differ (nearly) 
significantly are highlighted by bold lettering. 
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Vegetarians and antibiotic resistant microorganisms 
markedly more resistant to nearly all of the antibiotics. Apparently, the impact of 
hospitalization on the prevalence of antibiotic resistant bacteria is more 
important than dietary habits. 
Our data suggest that the gastro-intestinal flora and the prevalence of 
drug-resistant bacteria vary with dietary habits. This is particularly clear from the 
enterococcal colonization of the vegetarian gut: with vane enterococci [5]. 
Interestingly, vane enterococci from vegetarians are also significantly less 
susceptible to the antibiotic bacitracin, which has been used in food production 
animals. We are, however, not aware, of the use of this drug in agriculture. Apart 
from a trend towards a decreased susceptibility to nitrofurantoin in E. coli from 
vegetarians, strains did not differ in susceptibility from controls. Our data are not 
in agreement with unexplained and contradictory figures published in The 
Netherlands three decades ago [8]. The latter study showed higher prevalences 
of antibiotic resistant E. coli strains in vegetarians and babies than in mixed-diet 
adults. To conclude, although the scope of our study was limited, it is reassuring 
to note that we failed to detect significant associations between the consumption 
of meat and antibiotic resistance determinants in the gastro-intestinal flora. 
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Chapter 6b 
In The Netherlands approximately 1,4x106 dogs and 2,0x106 cats are being kept 
as pets. Altogether these animals produce a quantity of at least 100-200 tons of 
faeces daily. Most of this is being shed in an environment which is crowded with 
people and as such might pose a microbiological threat as was recently demon-
strated for bacteria occurring in cats and belonging to the species Salmonella [1]. 
The fact that cats use indoor litter trays for defecation can be considered an 
additional risk factor. In the present era of zoonotic concern, with the recent bovine 
spongiform encephalitis (BSE) epidemic as the notorious highlight [2], an increased 
concern is voiced with the hardly controllable administration of antibiotics as food 
additives in bio-industry [3]. The use of growth promoting antibiotics results in an 
ecological pressure of multiresistant microorganisms that may reach the large 
numbers of potential animal reservoirs being kept in the household environment. 
We, therefore, wished to study the prevalence of vancomycin-resistant enterococci 
(VRE) in the population of cats and dogs in The Netherlands. 
During the last week of July (1996) 24 cats and 23 dogs attending an urban 
general veterinary practice (Rotterdam, The Netherlands) were sampled in the 
rectum. Rectal swabs were inoculated into a selective culture medium 
(Enterococcosel, containing vancomycin and aztreonam), which turns black in the 
presence of VRE. 
Surprisingly, 11/23 (48%) of the dogs and 4/24 (16%) of the cats were 
colonized with VRE. Six of the dogs (26%) were colonized with Enterococcus 
faecium, which were highly resistant to vancomycin and teicoplanin: all strains 
harbored the vanA gene as was confirmed by PCR. The other five dogs were 
colonized with Enterococcus gallinarum harboring the vanCl gene, which confers 
low level resistance to glycopeptides. For two cats, respectively, vanA and vanCl 
genotypes were detected by PCR. Taking cats and dogs together, 17% harbored 
VRE of the VanA genotype and 15% carried VRE containing the VanC1 gene. Pulsed 
field gel electrophoresis (PFGE) yielded two pairs of strains containing the vanA 
gene that were genetically identical. Interestingly, in both pairs one was derived 
from a dog, whereas the other was cultured from a cat. This indicates a Jack of host 
specificity among strains of VRE and suggests cross-colonization from one pet 
species to another. 
This incidence of VRE in pets which exceeds that encountered among the people 
living in the same geographic locale (2-3%). Although our data are representative 
of a single region only, it is obvious that domestic pets may be a significant 
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reservoir for VRE, the relevance of which has to be determined by follow-up 
analyses including studies looking into the source of these VRE. Colonization of pets 
may be a consequence of eating raw meat contaminated with VRE. In clinical 
settings the spread of VRE should be limited as much as possible [4]. By using 
simple questionnaires it can easily be established whether patients possessing a cat 
or dog are at an increased likelihood of being colonized by VRE. One of the VRE 
genotypes shared among dogs and cats was recently found in a human carrier as 
well (unpublished data). This raises the question which dog poses a greater risk to 
the average postman: the one that barks or the one that wags its tail? 
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Abstract 
Vancomycin-resistant enterococci (VRE) pose an emerging health risk but little is 
known on the precise epidemiology of the genes coding for vancomycin resistance. 
To determine whether the bacterial flora of consumer poultry serves as gene 
reservoir, the level of contamination of poultry products with VRE was determined. 
VRE were genotyped with pulsed-field gel electrophoresis (PFGE) and transposon 
structure mapping was done by PCR. The vanX-vanY intergenic regions of several 
strains were further analyzed by sequencing. 242/305 (79%) poultry products were 
found to be contaminated by VRE. Of these, 142 (59%) were high level 
vancomycin-resistant Enterococcus faecium (VREF). PFGE revealed extensive VREF 
heterogeneity. Two genotypes were found nationwide on multiple occasions (type 
A, 22/142 [15%]; type B, 14/142 [10%]). No PFGE-deduced genetic overlap was 
found, when VREF from humans were compared with the VREF poultry strains. Two 
vanA transposon types were identified among poultry strains. In 59/142 (42%) of 
the poultry VREF, the size of the intergenic region between vanX and vanY was 
± 1300 bp. This transposon type was not found in human VREF. In contrast, all 
human strains and 83/142 (58%) of the poultry VREF contained an intergenic 
region with the size of 543 bp. Comparative sequencing this 543 bp intergenic 
vanX-vanY region demonstrated full sequence conservation. Though preliminary, 
these data suggest that dissemination of the resistance genes encoded on 
transposable elements may be of greater importance than clonal dissemination of 
resistant strains. This observation is important for developing strategies to control 
the spread of glycopeptide resistance. 
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Introduction 
Colonization and infection by vancomycin-resistant enterococci (VRE) have been 
reported in hospitalized patients and in the community in various European 
countries including France [1,2], the United Kingdom [3,4], Belgium [5] and The 
Netherlands [6]. VRE pose a health risk, especially in patients with severe 
underlying disease or immunosuppression. In the United States, the prevalence of 
VRE in hospitalized patients is rising and hospital outbreaks with clonally related 
VRE have been described [7-10]. In contrast, the prevalence of VRE in hospitals in 
Europe remains low and a high degree of heterogeneity is observed among the VRE 
strains. Bates et a/ [11] suggested that European VRE might be more widely 
disseminated than originally supposed. Furthermore, there are cases on record of 
the isolation of VRE from animals and from environmental sources in many 
European countries [11-14]. Paradoxically, VRE have not yet been recovered from 
animal and environmental sources in the United States [15,16]. The spread of 
vancomycin-resistance is of considerable concern. Noble eta/ [17] reported in vitro 
conjugative transfer of high-level vancomycin resistance from Enterococcus faecalis 
to Staphylococcus aureus. In response, the Hospital Infectious Control Practices 
Advisory Committee (HICPAC) in collaboration with the Centers for Disease Control 
and Prevention (CDC) has developed recommendations to prevent the spread of 
VRE [18]. Others have proposed control measures in case vancomycin-resistant 
S. aureus should eventually arise [19]. Recently, scientists from Japan and the 
United States have reported S. aureus intermediately resistant to vancomycin 
isolated from patients [20,21], although this resistance has been shown not to be 
mediated by vanA, vanB or vane genes [22]. 
The increasing use of antimicrobial agents in human medicine and as animal 
growth promoters has been related to the emergence of VRE [9]. In Europe, 
antimicrobial agents are widely used as feed additives for growth promotion in 
animal husbandry [23]. Avoparcin is a glycopeptide antibiotic used for this purpose 
in poultry and it appears to be associated with the emergence of resistance to 
glycopeptides in general [11,24,25]. Enterococci belong to the natural intestinal 
ftora of poultry. It is, thus, not unlikely that transmission of VRE occurs through 
human contact with poultry meat contaminated with resistant bacteria. However, 
such a transmission route of VRE from poultry to humans has not been 
unequivocally documented so far. We determined the level of contamination of 
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poultry products with VRE. The VRE isolated from poultry products were compared 
with a collection of VRE isolated from humans [6] with regard to their overall 
genome structure and eventual polymorphism in Tn1546, the transposon encoding 
high-level glycopeptide resistance. 
Materials and Methods 
Poultry products 
A total of 305 poultry products (whole chicken, legs of chicken, chicken breasts 
or other parts) from either butchers, supermarkets, poulterers or market poulterers 
were collected by Dutch Food Inspection Services in the following cities: Den Haag, 
Maastricht, Alkmaar, Amsterdam, Nijmegen, Rotterdam, Leeuwarden, Den Bosch, 
Goes, Zutphen and Groningen. The sampling period was from June until September 
1996. 
Isolation of VRE 
Approximately 250 g of each poultry product was rinsed in 250 ml Buffered 
Pepton Water (BPW, Oxoid, Hampshire, England). After overnight incubation of the 
BPW at 37°C, 1 ml was used to inoculate 9 ml Enterococcosel (BBL, Becton and 
Dickinson Microbiology Systems, Cockeysville, USA ) supplemented with 6 mg/1 
vancomycin and incubated at 37° C for 24-48 hours [25]. All aesculin positive 
broth cultures were subcultured on a Kanamycin Aesculin Azide agar (Oxoid, 
Hampshire, England) [26]. A presumptive identification of the Enterococcus spp. 
was made on the basis of colony morphology, Gram stain, catalase and pyrase 
(Dryslide Pyrkit, Difco Laboratories, Detroit, USA). Definitive identification was done 
by Accuprobe (GenProbe, San Diego, USA) and RAPID 1032 STREP (bioMerieux, 
's Hertogenbosch, The Netherlands). The identification strips were read after 5 and 
24 hours of incubation at 37° C. All strains containing the vanCl gene were 
identified as Enterococcus gaffinarum [27]. Strains were stored at -SO'C in media 
containing 15% glycerol. 
Additional enterococca/ strains 
Nineteen vancomycin-resistant Enterococcus faecium (VREF) and one VR E. 
faecafis from hospitalized patients and 4 VREF from non-hospitalized patients [21] 
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were also included in the study. All strains were highly resistant to both 
vancomycin and teicoplanin and possessed the vanA gene (see below). E. faecium 
BM4147 (vanA), E. faeca!is V583 (vanS), E. faecalis ATCC 19433, E. faecaiis ATCC 
29212, E. gai/inarum BM4147 (vanCl), Enterococcus casseiif/avus CCUG 18657 
(vanC2), Streptococcus bovis ATCC 33317 and 5. aureus ATCC 29213 were used 
as reference strains. 
Antimicrobial susceptibility tests 
All enterococcal strains described above were tested for vancomycin and 
teicoplanin resistance on a Mueller-Hinton agar (DIFCO Laboratories, Detroit, USA) 
with E-test strips (AB BIODISK, Solna, Sweden) following the instructions of the 
manufacturer. All plates were incubated at 37' C and read after 24 h. 
DNA isolation 
DNA was isolated according to Boom et al. [28]. In brief, all VRE strains were 
grown overnight at 37° C on Brucella bloodagar plates. Ten colonies were mixed 
and suspended in 75 ~I TEG buffer (25 mM Tris-HCI, pH 8.0; 10 mM EDTA and 50 
mM glucose). A lysozyme solution (75 ~I of 10 mg/ml) was added and this mixture 
was incubated for one hour at 37° C. Guanidine-hydrothiocyanate was added for 
cell lysis and Celite (Janssen Pharmaceuticals, Beerse, Belgium) was used for DNA 
binding. DNA was washed and finally eluted from Celite with 10 mM Tris-HCI (pH 
8.0) by incubation at 56° C for 10 minutes. The DNA concentration was estimated 
by electrophoresis on 1% agarose gels (Hispanagar; Sphaero Q, Leiden, The 
Netherlands) containing ethidium-bromide in the presence of known quantities of 
lambda DNA as references. 
VanA, vanS, vanCl and vanC2 PCR 
Diagnostic PCR assays targeting the various resistance genes were performed as 
described by Dutka-Malen eta/ [29]. Approximately 10-100 ng (10 ~I) of DNA was 
added to a PCR mixture (90 ~I) containing 10 mM Tris-HCI (pH 9.0), SO mM KCI, 
2.5 mM MgCI2, 0.01% gelatine, 0.1% Triton X-100, 0.2 mM deoxyribonucleotide, 
1.2 units of Taq DNA polymerase (Sphaero Q, Leiden, the Netherlands). Four 
different primer couples (vanA; vanB; vanCl and vanC2, see Table 1 for DNA 
sequences) were used in the assay (50 pmol of each individual primer per 
reaction). Amplification of DNA was performed in a Biomed thermocycler (Model 
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60, Theres, Germany), using predenaturation at 94° C for 2 minutes, followed by 
30 cycles of 1 minute at 94° C, 1 minute at 54° c and 1 minute at 72° C. 
Amplicons were analyzed by electrophoresis on 1% agarose gels (Hispanagar; 
Sphaero Q, Leiden, The Netherlands) containing ethidium-bromide in the presence 
of a 100 basepair DNA ladder (Gibco/BRL Life Technologies, Breda, The Nether-
lands). 
Transposon mapping by PCR 
To study heterogeneity of the vanA encoding transposon Tn1546, potentially 
length variable regions within the 10.801 bp genetic element were studied by PCR 
(Table 1 for primer sequences) [30,31]. Trial experiments were performed for 
E. faecium and E. faeca/is only, and selection of a limited number of strains derived 
from either humans or poultry was at random. PCR was performed as described 
above. Whenever differences were detected in amplicon size, all additional 
E. faecalis and E. faecium strains harboring the vanA gene were investigated. 
Pulsed field gel electrophoresis 
Ten colonies of an overnight culture, grown on a bloodagar plate, were mixed 
and suspended in 100 ~I EET buffer (100 mM Na2EDTA , 10 mM EGTA, 10 mM 
Tris-HCI; pH 8.0). This suspension was mixed with 100 ~I of 1% agarose (Incert 
Agarose: FMC, Rockland, USA) and pi petted into small plug molds. The cells 
suspended in the agarose plugs were lysed by incubation for four hours at 37° C in 
1 ml EET buffer containing 10 mg of lysozyme (Sigma, Instruchemie, Hilversum, 
the Netherlands). Next, the lysis solution was replaced by a 1 ml EET buffer 
solution containing 1 mg proteinase K (dissolved in 10 mM NaCI, 10 mM Tris-HCI; 
pH 8.0, 1% SDS) and were further incubated at 37° C for 16 hours. The plugs were 
then washed six times (30 minutes each time at room temperature) with T10E1 
solution (10 mM Tris-HCI; pH 8.0, 1mM EDTA). Plugs were then stabilized twice for 
30 minutes in 120 ~I of 1x restriction buffer solution, and approximately 40 U of 
the restriction enzyme Smal (Boehringer Mannheim, Mannheim, Germany) was 
added (incubation 16 hr, 25° C). Electrophoresis (1% SeaKem agarose in 0.5x 
TBE) was performed using a BioRad CHEF mapper, programmed in the auto-
algorithm mode (block 1: runtime 8 hours; switchtime: 0.5-15 seconds and block 
2: runtime 10 hours; switchtime 15-30 seconds). The gel was stained with 
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ethidium-bromide for 15 minutes and then destained in distilled water for 1 hour 
before photography under UV irradiation. 
Table 1: Nucleotide sequences of PCR primers 
Primer pair Nucleotide sequences Size of PCR product (bp) Reference 
DIAGNOSTIC PCR 
A1 5'-GGGAAAACGACAATTGC-3' 732 [29] 
A2 5'-GTACAATGCGGCCGTTA-3' 
81 5'-ATGGGAAGCCGATAGTC-3' 635 [29] 
B2 5'-GATITCGTTCCTCGACC-3' 
C1 5'-GGTATCAAGGAAACCTC-3' 822 [29] 
C2 5'-CTTCCGCCATCATAGCT-3' 
D1 5'-CTCCTACGATTCTCTTG-3' 439 [29] 
D2 5'-CGAGCAAGACCTITAAG-3' 
TRANSPOSON MAPPING / STRUCTURAL GENES 
VanR 5'-AGCGATAAAATACTTATTGTGGA-3' 645 [31] 
VanRl 5'-CGGATTATCAATGGTGTCGTI-3' 
VanS 5'-AACGACTATTCCAAACTAGAAC-3 ' 1094 [31] 
VanS! 5'-GCTGGAAGCTCTACCCTAAA-3' 
VanH 5'-ATCGGCATTACTGTTTATGGAT-3' 943 [31] 
VanHl 5'-TCCTTTCAAAATCCAAACAGTTT-3' 
VanA 5'-ATGAATAGAATAAAAGTTGCAATAC-3' 1029 [31] 
VanAl 5'-CCCCTTTAACGCTAATACGAT-3' 
VanY 5'-ACTTAGGTTATGACTACGTTAAT-3' 866 [31] 
VanY1 5'-CCTCClTGAATIAGTATGTGTI-3' 
OtilA 5'-AGGGCGACATATGGTGTAACA-3' 844 [31] 
Oti1A1 5'-GGGCGACGGTACAACATClT-3' 
Oti1B 5'-TGGTGGCTCCTTTTCCCAGTIC-3' 1007 [31] 
Oti1B1 5'-CGTCCTGCCGACTATGATIATTT-3' 
OtilC 5'-ACCGmGCAGTAAGTCTAAAT-3' 1066 [31] 
Oti1Cl 5'-AAACGGGATITAGAAATAGTTAAT-3' 
Ort2D 5'-CCATTTCTGTATTTTCAATTTATIA-3' 925 [31] 
Orf2Dl 5'-CATAGTTATCACCCTTTCACATA-3' 
Ort2E 5'-TTGCGGAAAATCGGTTATATTC-3' 540 [31] 
Orf2E1 5'-AGCCCTAGATACATTAGTAATT-3' 
TRANSPOSON MAPPING / INTERGENIC REGIONS 
VanXYl 5'-AATAGCTATTTTGATITCCCCGTTA-3' 543 [30] 
VanXY2 5'-TCCTGAGAAAACAGTGCTTCA TTAA-3' 
VanSH1 5'-TAGGGTAGAGCTTCCAGCGATTGC-3' 311 [30] 
VanSH2 5'-CTCATCCTGCTCACATCCATAAACA-3' 
VanYZ1 5'-GTTTCCCGGATCAACACATACTA-3' 336 [30] 
VanY22 5'-CCCAGTAGCAGTAAATGGAGTCA-3' 
NOTES:* Primers Dl and 02 are specific for the vanC2 gene. 
"' Orfl "' transposase I Orf2 "' resolvase 
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The gels were inspected visually by two different investigators. The PFGE patterns 
were interpreted according to Tenover et a/ [32]. Isolates that differed by 1-3 
bands, consistent with a single differentiating genetic event, were assigned a 
numbered subtype. Four or more band-differences between two strains defined a 
different genotype. Genotypes determined for all VREF isolated from chicken were 
compared with the PFGE characteristics determined for VREF isolated from humans 
[6]. Since the interpretative guidelines brought forward by Tenover eta! [32] are 
for outbreak investigations mainly, additional comparisons were performed. Data 
obtained from a randomly selected group of 48 human- and poultry-derived VRE 
were studied in more detail using Gelcompar software (Applied Maths, Gent, 
Belgium). The PFGE patterns were scanned and Dice analysis of peak positions was 
executed. UPGMA was applied and the bandwidth tolerance was set critically at 
1.2%. 
Cloning and sequencing 
For several strains the amplicon derived from the vanX-vanY intergenic region 
was cloned into the plasmid pCR1 (Invitrogen, Leek, the Netherlands) according to 
the manufacturers instructions. Clones containing a correctly sized insert were 
sequenced using cycle sequencing technology and an ABI 373 sequencing machine 
(ABI, Warrington, Great Britain). Raw sequence data were edited using 373 
software (ABI, Warrington, Great Britain). 
Results 
VRE screening and antimicrobial susceptibility testing 
Table 2 summarizes all data gathered for the chicken specimens. Apparently, 
242/305 (79%) of the poultry samples studied contained VRE. Out of these, 
142/242 (59%) were identified as VREF, which were found nationwide in all of the 
participating centers. Thirty-six VRE (36/242 (15%)) were identified as 
Enterococcus durans, 34/242 (14%) as Enterococcus hirae and 27/242 (11%) as 
E. gallinarum. E. faeca/is was found only three times (3/242(1 %)). All VREF and 
VR E. faecalis had vancomycin MIC's of <: 256 ~g/ml and teicoplanin MIC's of 
16 - <: 256 ~g/ml, which is indicative of the VanA phenotype. VR E. ga!iinarum had 
vancomycin MIC's of 8 - 16 ~g/ml and teicoplanin MIC's of 1 - 3 ~g/ml, the Vane 
phenotype. The 70 strains classified as E. hirae or E. durans had MIC's that ranged 
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TABLE 2 Number and percentages of VRE isolated from 305 poultry products by 11 Health Inspectorates in The Netherlands In the 
period from June to September 1996. 
Region 
of the Food 
Inspection No.(%) of poultry products with VRE of type: 
Department No. of poultry No. of poultry 
in The products products with 
Netherlands VRE E. faeclum E. durans E.lllrae E. galllnarum E.faecalis 
Den Haag 34 18 15 (44) 3 (9) 
('.1aastricht 40 33 16 (40) 4 (10) 6 (15) 7 (18) 
Alkmaar 22 17 11 (50) 2 (9) 4 (18) 
Amsterdam 47 35 19 (40) 4 (9) 5 (11) 5 (11) 2 (4) 
Nljmegen 25 21 6 (24) 5 (20) 3 (12) 6 (24) 1(4) 
Rotterdam 17 12 5 (29) 4 (24) 3 (18) 
Leeuwarden 32 20 13 (41) 2 (6) 4 (13) 1 (3) 
Den Bosch 16 16 10 (63) 3 (19) 3 (19) 
Goes 25 25 15 (60) 5 (20) 1 (4) 4 (16) 
Zutphen 23 21 15 (65) 1 (4) 1 (4) 4 (17) 
Groningen 24 24 17 (71) 3 (13) 4 (17) 
Total(%)* 305 242 (79) 142 (47) 36 (12) 34 {11) 27 (9) 3 {1) 
* Percentage of all 305 poultry products 
"' " 
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from 16 to ;e 256 ~g/ml for vancomycin and from 2 to <: 256 ~g/ml for teicoplanin. 
All those VRE, except the VR E. gallinarum, harbored the vanA gene. Strains 
containing the vanB or vanC2 gene were not found. 
Pulsed Field Gel Electrophoresis 
One hundred and forty two E. faecium and 3 E. faecalis isolates were analyzed 
by PFGE. Most of the PFGE banding patterns comprised 15 to 20 differently sized 
DNA fragments. The data revealed that two out of three E. faecalis strains were 
genetically identical. Both strains originated from the same geographical region. 
One hundred different genotypes were identified in the group of VREF poultry 
strains (for some examples of PFGE banding patterns, see Fig. 1). However, two 
genotypes of E. faecium, (respectively 22/142 and 14/142 (A and 8; Fig. 2)), were 
more frequently found by ten out of eleven of the Food Inspection Services. These 
two genotypes could represent Dutch epidemic VREF (EVREF). When the poultry 
VREF strains were compared with VREF strains isolated from patients, however, no 
overlap in visually defined genotypes was identified by PFGE on the basis of the 
Tenover criteria [32]. This was essentially corroborated by Gelcompar analysis of 
the PFGE data of 48 strains (see Fig 3). The figure shows that the highest 
homology value between VRE from chicken and human is 60% (Goes 175 and 
Goes 178 versus lOa). Strains from the different origins present in a clustered 
fashion. The epidemic PFGE type A clusters at a high homology value (90% for Den 
Bosch 155 to Goes 84). The type that was encountered among humans relatively 
frequent (PFGE type M from reference [6]) clusters as well. Finally, the figure 
shows that chicken strains mingle with respect to the geographic origin. A total of 
27 E. gallinarum strains could be identified on the basis of the characteristic PFGE 
patterns displaying DNA fragments being smaller than 200 kb only [33]. 
Transposon mapping by PCR and sequencing 
All PCR tests for transposon mapping (Table 1) were done on a random selection 
of 5 human and 5 poultry strains. PCR products derived from structural Tn1546 
genes for all human and poultry strains displayed identity in size after 
electrophoresis. The same conclusion was reached when the intergenic vanS-vanH 
and vanY-vanZ regions were amplified. 
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-7 300 Kb 
-7 200 Kb 
-7 100 Kb 
Figure 1: PFGE patterns for 15 VREF isolated from poultry products collected by the Dutch Food 
Inspection Services in Zutphen, The Netherlands. Molecular lengths of markers are indicated on the 
right 
-7 300 Kb 
-7 200 Kb 
-7 100 Kb 
Figure 2: PFGE patterns of two epidemic genotypes of VREF. Lanes 1 to 4, genotypeA; lanes 5 to 8 
genotype 8. These genotypes were frequently found by most of the Food Inspection Services. 
Molecular lengths of the markers are indicated on the right 
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Figure 3: Phylogentic tree constructed on the basis of several PFGE types of VREF derived from 
poultry products (originating from Den Bosch, Goes and N!jmegen, The Netherlands) and humans [6). 
The arrow indicates the highest level of homo/gy between VREF from poultry and humans {Goes 175 
and Goes 178 versus lOa). Type A is the epidemic PFGE type among poultry clusters, and strains have 
a high homology cluster (Den Bosch 155 to Goes 84). Type m is the type that was encountered among 
humans relatively frequent [6] 
However, the vanX-vanY intergenic region of two poultry strains was ± 1300 bp in 
size, whereas in the other three poultry strains and the 5 human isolates the size of 
the PCR product was approximately 540 bp. Subsequently, all VREF (142 poultry 
strains and nineteen human stains) and all VR £. faecalis (3 poultry strains and one 
human strain) were analyzed with the vanX-vanY primer set. Both transposon 
types were found in all participating centers, indicating equal spread of both of 
these transposon types. All human strains and 83/142 (58%) of all isolated poultry 
VRE contained an intergenic region between vanX and vanY of approximately 
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540 bp. The 1300 bp fragment was not found in human strains, but in 59/142 
(42%) of the poultry strains. Sequencing of the 543 bp vanX-vanY intergenic 
regions of several VREF strains from poultry as well as human origin demonstrated 
full sequence conservation. In case of the larger vanX-vanY fragment sequencing 
revealed the presence of IS1216V [34]. This element was identified before in the 
same location (Genbank accession number L40841 and reference [35]). 
Discussion 
To the best of our knowledge this is the first systematic study from continental 
Europe reporting a high prevalence of VRE in consumer poultry at the retail level. 
Glycopeptide resistance in enterococci isolated from living poultry has been 
associated with the use of oral glycopeptide antibiotics in animal feed [24]. 
High-level resistance to glycopeptides has been shown to be mediated by 
transferable plasmids that may harbor resistance determinants to other drugs as 
well [36]. Therefore, other antimicrobial agents used as feed additive in veterinary 
medicine may also select for vancomycin resistance. Definition of causal 
relationships requires detailed studies on the development and spread of antibiotic 
resistance in poultry farms. Comparison of resistant microorganisms derived from 
poultry with those derived from humans may shed light on the role of poultry as a 
possible reservoir of VRE. 
We found that 70% of the poultry products at the retail level were contaminated 
with VRE containing the vanA gene. The majority of these VRE were E. faecium. A 
study from the UK documented that 22 out of 52 farm animals were colonized with 
VREF [5]. In five uncooked chicken specimens VREF was also identified. All strains 
possessed the vanA gene, which confers high-level resistance to vancomycin. A 
study from Manchester, United Kingdom, revealed that 90% of all uncooked 
chicken specimens contained VRE that were genetically distinguishable [37]. The 
strains differed from clinical isolates but were capable of transferring the resistance 
trait by conjugation experiments. Others showed that vancomycin and avoparcin 
resistant E. faecium could be detected in 5 out of 8 conventional Danish poultry 
farms [14]. On the other hand, among isolates from 6 ecology farms no 
glycopeptide resistance was observed. In Belgium, about 7% of the animals 
investigated for VRE carriage (horses, dogs, pigs and chicken) were colonized with 
VREF [13]. Interestingly, VRE have so far not been recovered from animal sources 
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in the United States, possibly related to the fact that glycopeptides are not licensed 
for use as feed additive in animal husbandry [15,16]. 
Twenty-seven of the poultry specimens contained E. gallinarum, a subspecies 
which is rarely found in humans neither as part of gut flora nor as clinical isolates. 
However, we have observed an increase in the number of E. gal!inarum strains 
isolated from clinical material in our hospital since the introduction of a screen agar 
containing 6 mg/L vancomycin (data not shown). These observations suggest that 
additional research into the relevance of E. gallinarum as a potential pathogen in 
humans is needed. As enterococci are not routinely identified up to species level in 
many microbiology laboratories, E. gal/inarum may well be underreported. 
Two main routes of dissemination of vancomycin resistance genes can be 
envisaged. Firstly, resistant strains may spread in a clonal fashion from one host to 
the other. Secondly, the resistance determinant could be passed on to other 
bacterial strains through conjugation [38,39]. Two major PFGE types of VRE have 
been identified among poultry-derived strains. Since these types were identified in 
all Food Inspection Services, we are dealing with epidemic strains and not a local 
outbreak. Neither of these two types nor any of the other unique genotypes of 
VREF were found in faecal flora of patients screened for VREF carriage in The 
Netherlands [6]. On the basis of these results, one could reject the hypothesis that 
direct horizontal transmission of VRE from poultry to humans via the food chain, is 
a major transmission route. This is corroborated by more extensive phylogenetic 
analysis of the data (see figure 3). Therefore, the answer to the question on the 
origin of human VRE still remains obscure. Several studies suggest that high-level 
resistance to glycopeptides in enterococci isolated in Europe and North America be 
mediated by transposons similar to Tn1546 [ 40]. Mapping of the transposon as 
present in the poultry VRE by PCR revealed the presence of two distinct vanA 
types. Length variability was found in the vanX-vanY regions. Among VREF from 
poultry, many strains including EVREF carried an intergenic region between vanX 
and vanY of approximately 1300 bp, not encountered in the human strains. The 
other poultry strains and all human strains shared an identical vanX-vanY 
intergenic region. This observation suggests that, for as yet unknown reasons, 
some sort of species barrier may exist for the larger transposon type or it may be 
limited with respect to conjugative transfer. More Dutch VRE from human should be 
investigated to confirm the data presented here. In contrast, another transposon 
type that is prevalent in many poultry strains and in all human strains may have 
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spread from poultry to humans via the food chain. As we studied only a limited 
number of structural genes and intergenic regions, further detailed analysis the 
vanA gene cluster is in progress to confirm that these transposons are related. 
Relationship between the VanA cluster of VRE isolated from humans and poultry 
was also determined by means of restriction fragment length polymorphism (RFLP) 
analysis of the Tn1546-like element. For this, several human and poultry isolates 
were analyzed in detail. All human isolates showed the same RFLP type as well as 
some poultry isolates. The other isolates from poultry contained a RFLP type, which 
was nearly distinct from the human RFLP type. (Work still in progress in 
collaboration with the National Institute of Health and Environmental Protection 
(RIVM, Bilthoven, The Netherlands [33]). 
In conclusion, we report an extremely high prevalence of VRE in consumer 
poultry in The Netherlands. A high prevalence of a deviating transposon type is 
found in poultry VRE especially. Transmission of the resistance genes, rather than 
clonal dissemination of resistant microorganisms1 may be the factor driving the 
spread of vancomycin resistance from poultry to humans. If this suggestion can be 
substantiated by additional research this may have major implications for the 
development of strategies to control the spread of glycopeptide resistance among 
bacterial species pathogenic to man. More information is needed to further clarify 
and quantify the antibiotic resistance gene transfer from bacterial isolates derived 
from animals or humans. 
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Abstract 
Genetic typing of vancomycin resistant enterococci (VRE) can be performed 
using a variety of methods, but comparative analyses of the quality of these 
methods are still relatively scarce. We here compare random amplification of 
polymorphic DNA (RAPD) analysis with pulsed field gel electrophoresis (PFGE) of 
DNA macrorestriction fragments as examples of two of the recent and 
well-accepted molecular typing methods. For the latter method, empirical 
guidelines for the interpretation of the DNA fingerprints have been proposed in 
the international literature. Based on our experimental analyses, we define 
similar criteria for RAPD fingerprinting. A collection of 100 strains of VRE, 
comprising Enterococcus faecium, E. faecalis, E. avium, E. gaflinarum and 
E. casselif/avus, was assembled. Fifty isolates were Dutch; another fifty were 
isolated in the United Kingdom. Strains were selected on the basis of previously 
determined putative identity, close relatedness or uniqueness. The strains were 
analyzed using well-standardized RAPD and PFGE protocols. Resulting 
fingerprints were interpreted with computerized methods involving band 
positioning and we show that typing of VRE by PFGE and RAPD generates highly 
congruent DNA fingerprint clustering. When the proposed international criteria 
for interpretation of PFGE fingerprints were applied in our case, 86% PFGE 
homology as discriminating value between close relatedness and uniqueness, a 
75% homology cut-off for the comparison of the RAPD-generated DNA 
fingerprints revealed essentially identical strain clusters. As a spin-off it is 
revealed that strains from the different species can be efficiently discriminated, 
that strains from the United Kingdom and The Netherlands form separate 
clusters and that strains from veterinary origin can be identified separately as 
well. 
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Introduction 
The need for adequate molecular typing schemes is especially relevant in 
cases of pathogens that either increase in clinical prevalence or gain specific 
features increasing their disease-causing capacity. Both facts became apparent 
for enterococci upon the rise in number of infections caused by these bacteria in 
immune-incompetent patients and the appearance of antibiotic resistant types in 
the late eighties and the early nineties [1]. Several approaches for the 
identification below the species level were developed, among others pulsed field 
gel electrophoresis (PFGE) of DNA macrorestriction fragments [2]. The first study 
involving enterococci demonstrated the usefulness of the procedure for typing 
strains of Enterococcus faeca!is [3]. Also, for Enterococcus faecium it was 
demonstrated that PFGE provided an efficient procedure for mapping genomic 
polymorphism in an epidemiologically concordant fashion [4]. 
More recently, PCR mediated procedures capable of identifying enterococcal 
subtypes within the different species have become available. Upon amplification 
of the so-called ribosomal intergenic spacer (ITS PCR) species characteristic 
banding patterns are generated [5]. However, the major application of PCR 
technology in the field of enterococcal studies is the random amplification of 
polymorphic DNA under relaxed hybridization conditions during the annealing 
phase of the PCR (RAPD analysis) [6]. This procedure generates complex 
mixtures of amplicons that can be translated into DNA fingerprints by simple 
electrophoresis in agarose gels. Comparisons with respect to the resolving power 
and epidemiological concordance for RAPD versus PFGE have been made and the 
overlap in the data suggested that RAPD analysis is well suited for 
epidemiological typing of enterococci [7]. 
Suggestions for the adequate interpretation of data provided by PFGE have 
been published in recent literature [8]. Although these suggestions provide an 
adequate framework for determining genetic relatedness in case of a local 
outbreak situation, little is known on the molecular basis of the changes that can 
be observed in the banding patterns. In addition, the two multicenter studies 
performed to date on Staphylococcus aureus strains show a disappointing degree 
of reproducibility between centers (see [9] and references therein). Because of 
these inconsistencies, we became interested in the establishment of inter-strain 
relatedness of vancomycin resistant enterococci (VRE) by multiple DNA mediated 
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technologies in order to verify the guidelines brought forward for PFGE [8] while 
at the same time trying to establish similar frameworks for RAPD typing data 
[10]. Hundred VRE strains from the United Kingdom and The Netherlands were 
combined in a single collection and for all strains both RAPD and PFGE was 
performed. Subsequently, the banding patterns were interpreted and maximizing 
the overlap in types obtained by both techniques helped in the formulation of 
guidelines for the interpretation of banding patterns and inferring reliable 
inter-strain relatedness. 
Materials and Methods 
Bacterial strains 
A collection of 100 VRE strains was analyzed in the present study. Fifty VRE 
strains isolated in The Netherlands and fifty VRE strains isolated in the United 
Kingdom were included. This collection of VRE included the species E. faecium, 
E. faecafis~ Enterococcus aviumf Enterococcus gal/inarum and Enterococcus 
casseliflavus isolated from diverse sources (Table 1). All enterococci were 
identified to the species level on the basis of colony morphology, Gram stain, 
pyrase and catalase testing, pigment production, the presence of the Lancefield 
Group D antigen and Rapid ID32 Strep (bioMerieux, 's Hertogenbosch, The 
Netherlands) or API 20STREP system (bioMerieux, Basingstoke, UK). English 
strains were selected on the basis of earlier RAPD analyses as performed in the 
St. Thomas' Hospital, London, United Kingdom [12]. Dutch strains were chosen 
on the basis of former PFGE-determined genotypes as performed at the EMCR, 
Rotterdam, The Netherlands (e.g. [11]). Twenty-four out of fifty Dutch VRE 
(48%) were isolated from poultry products and 26/50 (52%) were gathered from 
humans. Each collection contained presumptively unique, related and identical 
genotypes. 
Pulsed field gel electrophoresis 
PFGE was used as "gold" standard and performed for all strains at the EMCR, 
Rotterdam, The Netherlands. Samples of genomic DNA extracted from the strains 
were digested with Smal (Boehringer Mannheim, Mannheim, Germany) and 
compared by PFGE as described previously [11]. 
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Table 1: Dutch and UK VRE strains used and their origin 
Species 
E. faecium 
E. faecafis 
E. avium 
E. ga/linarum 
E. casseliflavus 
Strain Source of Isolation 
d2, d3,d5, dll, d12,d14,d19,d20,d21, d24,d25 
d26, d28, d31, d36, d38, d39, d40, d42, d43, d45, 
d46 
d23, e3, es, e6, e9, e7, e8, e12, e17, e18, e21, 
e23, e24, e25, e26, e29, e38, e42, e43, e46, e48, eSO 
dl, d9, dlO, dl7, d27, d29, d30, d32, d35, d37, d41 
d49, dSO 
e16,e22, e33,e35, e47 
d4, e37 
dl3 
d22, e36 
d47 
e4 
e27 
d6 
dl5,d33 
elO, e13 
ell 
el9 
e20, e28 
e32, e40 
e34 
e44 
e45 
el4 
elS, e41 
e30 
d7, dl6, dl8, d48 
el, e2, e49 
d8, d34, d44 
e31 
e39 
poultry 
urine 
rectum 
stool 
wound 
ascites 
blood 
bile 
wound-line 
central line tip 
ascites 
poultry 
stool 
tip catheter 
central line tip 
throat swab 
urine 
vascath tip 
exit site 
unknown 
CAPO 
blood 
unknown 
rectum 
blood 
rectum 
blood 
unknown 
NB The source of the isolates is indicated with respect to anatomical or veterinary niche. Dutch 
strains share a prefixed d in the code, the UK strain codes start with e. The£. gal/inarum and£. 
casseliflavus strains derived from a surveillance study performed in cohorts of volunteers and 
vegetarians. Additional data on the Dutch strains can be derived from references [11, 20, 21], 
details concerning the UK isolates can be derived from [12]. CAPO: chronic ambulatory peritoneal 
dialysis. 
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Electrophoresis (1% SeaKem agarose in 0.5x TBE) was performed using a 
BioRad CHEF mapper, programmed in the auto-algorithm mode (block 1: 
runtime 8 hours; switchtime: 0.5-15 seconds and block 2: runtime 10 hours; 
switchtime 15-30 seconds). The gel was stained with ethidium-bromide for 15 
minutes and then destained in distilled water for 1 hour before photography 
under UV irradiation. The PFGE patterns were interpreted according to Ten over et 
a! [8]. Isolates were considered identical and representative of a single strain if 
they showed identical PFGE patterns. Isolates that differed by 1-3 bands, 
consistent with a single differentiating genetic event, were assigned a numbered 
subtype. Four or more band-differences between two strains defined different 
genotypes. Data obtained for all VRE were studied in more detail using 
Gelcompar software (Applied Maths, Gent, Belgium). The PFGE patterns were 
scanned and Dice analysis of peak positions was executed. The Unweighted Pair 
Group Method with Arithmetic Averages (UPGMA) was applied and the bandwidth 
tolerance was set critically at 1.2%. 
DNA extraction and random amplified polymorphic DNA (RAPD) analysis 
DNA extraction and RAPD were performed for all strains in England (St. 
Thomas' Hospital, London). DNA was isolated as described previously [12]. 
RAPD was performed in volumes of 50 ul containing 1x DNaZyme DNA 
polymerase buffer (Fiowgen, Leicestershire, United Kingdom), 200 uM of each 
deoxyribonucleotide triphosphate, 5 ul of template DNA (equaling approximately 
50 ng), and 1 U DNaZyme polymerase. Two different primers were used in 
separate assays at a concentration of 1 uM. The sequences were TGCTCTGCCC 
(AB106) and GTAGACCCGT (AB111). The reaction was overlaid with 50 ul of 
paraffin oil. Amplification of DNA was performed in a Techne PHC-3 model 
thermal cycler (Techne Ltd, Duxford, Cambridge, United Kingdom) using 35 
cycles of 30 sec at 95° C, 30s at 34° C and 1 min at 72° C. Banding patterns 
were visualized under UV light, after electrophoresis on a 2% agarose gel and 
ethidium bromide staining. Two independent researchers categorized banding 
patterns, and (sub) types were assigned on the basis of band differences. Data 
obtained for all VRE were studied in more detail using Gelcompar software. Dice 
analysis of peak positions was executed, UPGMA was applied and the bandwidth 
tolerance was set critically at 1.2%. 
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Results 
PFGE analysis 
Most of the PFGE patterns comprised of 15 to 20 differently sized DNA 
fragments ranging from approximately 50 Kb to 450 Kb in size (Figure 1). 
Overall, 11 clusters were identified, a cluster being a set of strains (n 2: 2) 
showing more than 86% homology. Among VRE isolated in The Netherlands, 31 
different genotypes were obtained by PFGE analysis, including three clonally 
related clusters of strains (cluster I - III (n=22 strains)), according to the 
Gelcompar analysis based on a homology of >86%. Strains of cluster I were 
completely identical. Cluster II and III contained isolates that showed identical or 
almost identical (up to three-band difference) PFGE-derived patterns. PFGE data 
of the English VRE revealed that 19 different genotypes were identified according 
to the same interpretation guidelines. Strain e16, e20 and e22 were untypable, 
probably due to endogenous endonuclease activity. Eight clusters containing 
multiple isolates (cluster IV- XI (n=35)) were identified in addition, whereas 11 
isolates had unique PFGE-derived patterns. Ten out of 15 strains of cluster IV 
were PFGE identical and the other five strains differed in 1-3 bands and were 
classified as closely related isolates. There was no apparent overlap between 
English and Dutch VRE PFGE genotypes examined in this study. The maximum 
level of homology between these clusters was 80 % (English VRE strains in 
cluster X (e1, e2 and e49) and Dutch VRE strain 6). 
Multiple Enterococcus species were included in this study. Characteristic PFGE 
patterns with all fragments smaller than 200 Kb was found for 6/7 E. gaffinarum 
strains (Figure 1). PFGE analysis of E. faecafis strains revealed some specific 
fragments of more than 400 Kb in size. Nine out of thirteen E. faecafis strains 
were in cluster V, VI and XI and the other four strains were unique genotypes 
that scattered throughout the dendrogram. Most of the species E. gaffinarium, 
E. avium and E. cassefifiavus were found in one single branch with a homology 
between 52% and 60%. The Dutch VRE group contained 24 poultry isolates, 12 
of them had unique genotypes and the other 12 were placed in clusters II and 
III. No close homology was found between VRE isolated from humans and 
poultry. 
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Figure 1: Dendrogram showing the clustering of VRE strains !so fated in The Netherfands ( d prefixed to the 
Identification number) or in the United Kingdom (e prefix), The strains were anafyzed with PFGE and clustering 
took place on the basis of a homology of 86% (vertical line, the homology percentage bar is presented on top). 
Clusters are identified by Roman numbering. All strains are described in Table 1. Different species are marked 
in the dendrogram. Most strains are E. faecium; the fol!owing characters are used to Identify strains belonging 
to other species: 
0: VRE from poultry origin; 0 : E. cassefiffavus; 8 : E. gaf!inarum; 
D : E. faecalis. 
RAPD analysis 
:E. avium; 
Banding patterns obtained from RAPD analysis comprised of 8 to 14 differently 
sized DNA fragments (Figure 2). Overall, 18 clusters were identified. The Dutch 
VRE showed 7 clusters (cluster A-G (n=34)) and 12 strains had unique RAPD 
patterns, based on a homology of < 75% upon Gelcompar analysis. Fourteen 
different genotypes were analyzed among the English VRE RAPD-derived banding 
patterns. Among these genotypes 10 types were found on multiple occasions 
(cluster J-Q (n=26)) and 8 strains had unique RAPD patterns. Interestingly, 
clusters Rand I consisted of both Dutch and English VRE strains 
Analyzing the different species, we found that 11/13 E. faecalis strains were 
clustered, the other two strains displaying unique genotypes found in the same 
branch as the other E. faecaiis strains (homology 55%). Most of the species 
E. gallinarium, E. avium and E. casselif/avus were found in two branches with a 
homology of 40% and 45%. Twenty-four isolates of Dutch poultry-derived VRE 
were included. Seven of these strains had unique genotypes, whereas the other 
17 isolates clustered. Both clusters included strains from human origin as well. 
RAPD versus PFGE 
The comparison between PFGE and RAPD data gathered for Dutch and UK 
VRE can be deduced from Figures 1 and 2. Overall, PFGE typing resulted in 11 
clusters (cluster I-XI) containing genetically related or identical strains versus 18 
clusters (cluster A-R) using the RAPD typing method. Some of these clusters are 
identical (I = A; V = J; VI = J; VII = K; Vlll = L; X = N). This concerns 25 
strains. Several strains (n = 40) are identified as unique genotypes by both 
techniques. For clusters II and III, relatively small numbers of strains do not 
seem to belong to these clusters on the basis of RAPD. In case of cluster IV, 3/15 
strains are deemed unique by RAPD analysis. 
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Figure 2: Dendrogram showing the clustering of VRE strains isolated in The Netherlands (d prefixed to the 
identification number) or in the United Kingdom (e prefix). The strains were analyzed with random amplification 
of polymorphic DNA analysis and clustering took pface on the basis of a homology of 75% (vertical line, the 
homology percentage bar is presented on top). Clusters are identffied by capita/letter codes, All strains are 
described in Tabfe 1, identification symbols are as described in the legend to Figure 1. 
Based on this general survey, 89 of 100 strains are categorized in an identical 
fashion both by PFGE and RAPD. RAPD group B, for instance, contained 8/10 
strains of PFGE group II and 2 PFGE-unique strains. The other strains of PFGE 
group II were assorted in RAPD group C and H, clustering with some unique 
PFGE genotypes. RAPD group D, E, F, and G comprised two VRE strains identified 
as unique genotypes applying the PFGE method. More clustering of PFGE-unique 
genotypes was found in RAPD group G and N. We also noticed that some PFGE 
clusters were resolved by RAPD typing. VRE of PFGE cluster Ill and 1/3 strains of 
cluster VIII gave rise to multiple unique RAPD types. Comparison of PFGE and 
RAPD data supports the conclusion that PFGE deduced relatedness among strains 
is corroborated by RAPD and vice versa. If published interpretation guidelines for 
PFGE are implemented [8]; a homology setting of 75% for interpretation of the 
RAPD data gives optimal overlap between the data sets. Lowering or increasing 
this percentage leads to diminished concordance between data sets (results not 
shown). 
Discussion 
Molecular typing studies need to be performed using a standard protocol in 
order to increase inter-laboratory reproducibility. For PFGE this level of 
laboratory standardization has not yet been achieved [9]. However, it has been 
evident for some years that PFGE is a reliable technique for helping solve 
epidemiological problems. Lack of intercenter reproducibility of RAPD assays has 
also been identified before, but in a single institution this methodology can be 
standardized to a satisfactory level [13]. This gives us the confidence that both 
the RAPD and the PFGE tests performed during the present study give an 
appropriate index of genetic diversity among the strains tested. 
Recently, the use of repetitive sequence-based PCR and PFGE were compared 
for typing of Enterococcus faeca/is at the sub-species level. This study concluded 
that PFGE is the more reliable technique as the interpretation of the data and the 
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assay reproducibility is clearly superior to those of repeat PCR [14]. In the 
present study we analyzed two geographically diverse VRE collections (n;100) 
performing both PFGE ("gold standard") and RAPD genotyping methods. Using 
the PFGE method, 11 clusters could be identified among the Dutch and English 
VRE strains. In comparison, RAPD analysis revealed 18 VRE clusters. 
PFGE-unique VRE types that clustered when RAPD analysis was performed 
produced most of the discrepancies. RAPD analysis of these VRE strains showed 
no relationship with VRE strains that clustered with PFGE. These phenomena 
have been described before for VRE and other organisms [7, 10, 15]. 
The PFGE interpretation guidelines we used in this study were recommended 
by Tenover eta/ [8]. These guidelines are comparable to a Gel com par setting of 
a homology of >86% in PFGE banding patterns comparison. However, data 
obtained for two strains (d7 and d16) were not in concordance with these 
interpretation guidelines. Strain d7 and d16 revealed a 3-bands difference and 
showed a homology of 85% only. In contrast, strain e23 and e27 showed a 
common homology of 85% as well, while differing in 4 bands upon PFGE typing. 
These marginal findings of two different interpretations of Gelcompar analysis 
can be explained on the basis of relatively small numbers of bands revealed after 
PFGE analysis. Fingerprints for strain d7 and d16 comprised 10 to 12 bands, 
whereas the average VRE PFGE patterns showed 15-20 bands. 
The collection of VRE isolated in The Netherlands contained strains from 
different clinical and environmental sources. PFGE did not reveal overlap between 
human strains isolated in The Netherlands and England versus VRE from poultry 
origin. These findings are in concordance with a former study we performed in 
The Netherlands [11]. However, several studies in Europe showed some 
indistinguishable VRE strains isolated from humans and animals [16, 17]. In 
contrast, the RAPD analysis presented here revealed 17 poultry strains that 
showed homology with VRE isolated in humans. This phenomenon can be related 
to a presumptively lower discriminatory power of RAPD analysis. A possible 
explanation of our results would be that transmission of resistant strains is not 
the exclusive way by which resistance is spread. Interestingly, various studies 
suggested that horizontal transmission of Tn1546 transposon might be an 
alternative determinant factor driving the spread of vancomycin resistance [18]. It 
remains surprising to see that intermingling hardly takes place, since several 
studies in the United States showed strain dissemination of enterococci between 
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geographically distinct hospitals (e.g. [19]). Further studies should also take 
Tn1546 diversity into account. 
In conclusion, PFGE and RAPD performed on diverse strains of VRE are largely 
concordant in outcome. Although exceptions occur, clustering leads to 
homologous identifications. This indicates that both methods can be used for 
adequate molecular typing and that data interpretation guidelines for RAPD can 
be set at a homology value of approximately of 75% which is lower than the 
suggested value for PFGE. However, in case of clonal outbreaks we suggest to 
confirm strain relatedness with PFGE. The current analysis revealed that UK 
strains, even the epidemic ones, appear to be generally distinct from Dutch 
strains. Future studies should include larger numbers of strains and should be 
focussed on developing a robust, multicenter reproducible typing protocol for 
PFGE. 
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Abstract 
We report on a detailed study on the molecular diversity and evolutionary 
relationships of Tn1546-like elements in vancomycin-resistant enterococci (VRE) 
from humans and animals. Restriction fragment length polymorphism (RFLP) 
analysis of the VanA transposon of 97 VRE revealed seven different Tn1546 
types. Subsequent sequencing of the complete VanA transposons of 13 VRE 
isolates representing the seven RFLP types followed by sequencing of the 
identified polymorphic regions in 84 other VanA transposons resulted in the 
identification of 22 different Tn1546 derivatives. Differences between the Tn1546 
types included point mutations in orfl, vanS1 vanA, vanX, and vanY. Moreover, 
insertions of an I51216V-I53-Iike element in orfl, of IS1251 in the vanS-vanH 
intergenic region, and of IS1216V in the vanX-vanY intergenic region were found. 
The presence of insertion sequence elements was often associated with deletions 
in Tn1546. Identical Tn1546 types were found among isolates from humans and 
farm animals in The Netherlands, suggesting the sharing of a common 
vancomycin resistance gene pool. Application of the genetic analysis of Tn1546 
to VRE isolates causing infections in hospitals in Oxford, United Kingdom, and 
Chicago, Ill., suggested the possibility of the horizontal transmission of the 
vancomycin resistance transposon. The genetic diversity in Tn1546 combined 
with epidemiological data suggests that the DNA polymorphism among Tn1546 
variants can successfully be exploited for the tracing of the routes of 
transmission of vancomycin resistance genes. 
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Introduction 
In recent years, the nosocomial prevalence of infections caused by 
vancomycin-resistant enterococci (VRE) has in-creased significantly in the United 
States [1, 2], while virtually no VRE have been found in the gut flora of healthy 
people [3]. The epidemiology of VRE in Europe differs from that in the United 
States. The prevalence of VRE in Europe is low among strains causing 
hospital-associated infections [ 4-6], while VanA-positive enterococci can easily 
be detected outside the hospital in several European countries [4, 7-12]. A 
possible source of VRE is the food chain since VRE have been isolated from farm 
animals and animal products in several European countries [10, 11, 13-20]. It 
has been suggested that the use of the antibiotic avoparcin as a feed additive in 
animal husbandry in numerous European countries has resulted in the selection 
of vancomycin resistance in strains from farm animals [14, 21, 22]. This is 
consistent with the lack of non-hospital-associated VRE in the United States, 
where the use of avoparcin has not been permitted [3]. 
Although resistance to glycopeptides has spread primarily in enterococci, 
vanA- and vanB-related genes were recently isolated from various other gram-
positive bacteria like Arcanobacterium, haemolyticum [23], Oerskovia turbata 
[23], Streptococcus bovis [24], and Bacillus circulans [25]. Vancomycin 
resistance may disseminate to other pathogens, such as methicillin-resistant 
Staphylococcus aureus strains, which would result in a highly dangerous 
pathogen that could cause an infection that would be difficult to treat with 
currently available antibiotics. Indeed, conjugative transfer of glycopeptide 
resistance from Enterococcus faeca!is to 5. aureus has been reported under 
laboratory conditions [26]. The possibility that such a transfer will eventually 
occur in nature stresses the need to limit the spread of VRE and to gain insight 
into the factors that contribute to the selection of VRE and the routes of 
dissemination. 
The genes encoding the VanA and VanB types of vancomycin resistance are 
located on mobile DNA elements. Therefore, the horizontal transfer of resistance 
genes among enterococci may have a more significant impact on the 
dissemination of vancomycin resistance than the clonal spread of resistant 
enterococci. The isolation of genetically unrelated VREs during well-documented 
nosocomial outbreaks suggests such a mechanism [27-31]. Thus, direct 
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comparison of the vancomycin resistance determinants may provide additional 
insight into the epidemiology of vancomycin resistance. The vanA gene is the 
most frequently encountered gene among isolates causing VRE infections in 
humans [4, 5, 32-34]. This gene is part of the transposable element Tn1546, 
which was first characterized in 1993 by Arthur et al. [35]. Genetic heterogeneity 
in Tn1546-related elements has been documented previously [10, 19, 35-43]. 
The polymorphisms described so far have included insertion of the insertion 
sequence (IS) elements 151216V, 151251, 151476, and 151542 and deletions at 
both the left (orf1 side) and right (vanZ side) ends of the transposon that 
includes the orf1 and vanZ genes. Recently, a point mutation in the vanX gene 
has been described [10, 39]. 
The aim of the present study was to perform a detailed molecular 
characterization of the DNA polymorphisms in the vanA gene cluster originating 
from human and animal sources. By means of restriction fragment length 
polymorphism (RFLP) analysis and DNA sequencing, 22 different VanA 
transposon types among 97 VRE strains were identified. Differences included 
point mutations in the orfl, vanA, vanX, and vanY genes, the presence of the IS 
elements 151251 and I51216V, and deletions associated with IS insertions. 
Indistinguishable Tn1546-like elements were found among enterococci isolated 
from human and animal sources, suggesting the existence of a common 
vancomycin resistance gene pool. 
Materials and Methods 
Bacterial strains 
The VRE used in this study are listed in Table 1. Stool samples from 
nonhospitalized individuals were collected and cultured in kanamycin-esculin-
azide enrichment broth (Oxoid Ltd., Basingstoke, United Kingdom) supplemented 
with 6 mg of vancomycin per mi. Bacteria from tubes whose contents turned 
black after 1 or 2 days of incubation at 37° C were subcultured onto Slanetz and 
Bartley agar (Oxoid Ltd.) supplemented with 6 mg of vancomycin per mi. VRE 
were identified to the species level and were tested for the presence of the vanA 
gene by means of a PCR described by Dutka-Malen et al. [44]. Fecal samples 
from veal calves were examined as described above. Dutch clinical isolates 
(isolates 11 to 21), pig isolates (isolates 27 to 37), and chicken isolates (isolates 
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38 to 45) have been described previously [11, 19, 33], as have the isolates from 
The United Kingdom (isolates 46 to 87) [15, 34] and the United States (isolates 
88 to 97) [45, 46]. 
Susceptibility testing 
MICs were determined by the agar dilution method on Mueller-Hinton II agar 
plates (BBL, Becton Dickinson, Cockeysville, Md.). Inocula (approximately 10 8 
CFU/ml) were prepared from overnight cultures on Columbia agar plates 
supplemented with defribrinated horse blood (Oxoid Ltd.). The antimicrobial 
agents tested were vancomycin (Eli Lilly, Indianapolis, Ind.), teicoplanin (Hoechst 
Marion Roussel Inc., Frankfurt, Germany), and avoparcin (Roche 
Pharmaceuticals, Basel, Switzerland). 
Pulsed Field Gel Electrophoresis 
Pulsed-field gel electrophoresis (PFGE) analysis was performed as described 
previously [19]. The banding patterns were interpreted as described by 
Tenover et al. [47], and the different types were identified by capital-letter 
codes. 
RFLP analysis 
Genomic DNAs from all VRE were isolated by a modification of the initial steps 
of the method described by Ausubel et al. [48]. The bacterial pellets were 
suspended in 557 ~I of 10 mM Tris-1 mM EDTA, and 10 ~I of a 50-mg/ml 
solution of egg white lysozyme (Boehringer Mannheim, Mannheim, Germany) 
was added. After incubation for 15 min at 37° C, the bacteria were lysed by the 
addition of 30 ~I of 10% sodium dodecyl sulfate and 3 ~I of a 20 mg/ml 
proteinase K (Merck, Darmstadt, Germany) solution. Subsequently, the protocol 
described by Ausubel et al. [46] was used. Chromosomal DNA preparations were 
digested with Haem and Xbal (Boehringer Mannheim), respectively, separated 
by agarose gel electrophoresis (1.5% agarose gels), transferred onto a Hybond N 
1 nylon membrane (Nycomed Amersham pic, Buckinghamshire, United Kingdom) 
with a vacuum blotting system (Millipore, Bedford, Mass.), and subsequently 
hybridized with internal Tn1546 PCR fragments (probes 1, 2, 3, and 4 generated 
with primers 22.F-1913.R, 3514.F-5374.R, 5235.F-7035.R, and 8544.F-10716.R, 
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Table 1: Enterococcaf isolates used in this study 
Strain Strain Enterococcal Source Country Tn1546 Reference 
No. species -types 
1 9600188 E. faecium Human stool NL A2 This study 
2 9600205 E. faecafis Human stool NL Al This study 
3 9600220 E. faecium Human stool NL Alb This study 
4 9600224 E. faecium Human stool NL A2 This study 
5 9600253 E. faecium Human stool NL A2 This study 
6 9600266 E. faecfum Human stool NL A2 This study 
7 9600276 E. faecfum Human stool NL Al This study 
8 9600291 E. faecium Human stool NL Al This study 
9 9700196 E. faecium Human stool NL Al This study 
10 9700228 E. faecfum Human stool NL A2 This study 
11 22-R E. faecium Human stool NL A2 4 
12 10-A E. faecium Human wound NL Al 4 
13 10-B E. faecium Human ascites NL A2 4 
14 10-C E. faecium Human blood NL A2 4 
15 10-D E. fae6um Human urine NL A2 4 
16 10-G E. faedum Human bile NL A2 4 
17 10-H E. faedum Human blood NL A2 b 4 
18 10-J E. faecafis Human ascites NL Al 4 
19 1245964 E. faecium Human urine NL A2 This study 
20 2074639 E. faecium Human ascites NL A2 This study 
21 4252948 E. faecium Human ascites NL E6 This study 
22 1-A2 E. gaflinarum Veal calf NL Alb This study 
23 1-A6 E. flavescens Veal calf NL A3 b This study 
24 l-AS E. faeca/is Veal calf NL Bl b This study 
25 1-AlO E. avium Veal calf NL Al This study 
26 1-All E. faecium Veal calf NL A4b This study 
27 A2 E. faecium Pig NL A2 11 
28 A4 E. faecium Pig NL A2 11 
29 A16 E. faedum Pig NL A2 11 
30 B9 E. faecium Pig NL A2 11 
31 837 E. faecium Pig NL A2 11 
32 M4 E. faecium Pig NL A2 11 
33 M7 E. faecium Pig NL A2 11 
34 M11 E. faecium Pig NL A2 11 
35 012 E. faecium Pig NL A2 11 
36 0118 E. faecium Pig NL A2 11 
37 0122 E. faecium Pig NL A2 11 
38 chicken 2 E. faedum Chicken NL E3 19 
39 chicken 3 E. faecium Chicken NL Al 19 
40 chicken 43 E. faecium Chicken NL A2 19 
41 chicken 48 E. faecium Chicken NL B2 19 
42 chicken 57 E. faecium Chicken NL E2 b 19 
43 chicken 59 E. faecium Chicken NL Al 19 
44 chicken 69 E. faecium Chicken NL E5 19 
45 chicken 72 E. faecium Chicken NL Al 19 
46 58538 {GP) E. faecium Human stool UK E2 34 
47 61741 (GP3) E. faecium Human stool UK Al 15 
48 55859 (pat. 12) E. faedum Human stool UK 01 b 34 
49 59479 E. faedum Human stool UK 01 34 
50 60761 E. faedum Human stool UK Dl 34 
51 63910 E. faedum Human stool UK Cb 34 
52 67668 E. faecium Human stool UK Al 34 
53 53864 (pat. 3) E. faecium Human stool UK Dl 34 
54 77364 (pat. 10) E. faecium Human stool UK Dl 34 
55 58155 {pat. 9) E. faecium Human urine UK Dl 34 
56 62899 {pat. 11) E. faecium Human urine UK 02 34 
57 68521 (pat. 15) E. faecium Human urine UK Dl 34 
58 72801 (pat. 12) E. faedum Human wound UK Dl 34 
59 80103 (BC20) E. faecium Human blood UK Dl 15 
60 89407 (U22) E. faecium Human urine UK 01 15 
61 26712 {pat. 1) E. faecium Human urine UK 01 34 
52 38658 (pat. 2) E. faecium Human blood UK 01 34 
53 42757 {pat. 3) E. fae6um Human urine UK 01 34 
Continued on following page 
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Table l-Continued 
Strain Strain Enterococcal Source Country Tn1546 Reference 
No. species -types 
64 43088 (pat, 4) E. faecium Human urine UK 01 34 
65 68140 (pat. 10) E. faedum Human urine UK 01 34 
66 66925 (pat. 13) E. faecium Human urine UK 01 34 
67 74198 (pat. 14) E. faecium Human pus UK 04 34 
68 70040 (pat. 16) E. faecium Human urine UK 04 34 
69 75436 (pat. 18) E. faecium Human pus UK 01 34 
70 51 (C2) E. faecium Sewage inlet A UK E1 b 15 
71 55 (L#3) E. faecium Sewage inlet B UK 03 15 
72 S10 (C1) E. faedum Sewage inlet A UK E7 15 
73 S17 (M7) E. faecium Sewage inlet B UK E3 15 
74 S25 (M2) E. faecium Sewage inlet C UK Gb 15 
75 526 (M3) E. faeclum Sewage inlet C UK A2 15 
76 527 (Mix, 0.1#1) E. faeclum Sewage inlet A UK A1 15 
77 A1 (VF1) E. faeclum Pig UK A2 15 
78 A6 (Pig 22) E. faeclum Pig UK A2 15 
79 A10 (Pig 2,19) E. faecium Pig UK A2 b 15 
80 C2 (Sim Chick) E. faeclum Uncooked chick. UK 83 15 
81 C3 (T2) E. faeclum Uncooked chick, UK A1 15 
82 C4 (Chicken 1) E. faeclum Uncooked chick. UK 81 15 
83 C5 (Grade A) E. faecium Uncooked chick. UK E4 15 
84 Cl2 (VF4) E. faecium Turkey UK A1 15 
85 C13 (VF7 alfa) E. faecium Duck UK A1 15 
86 C14 (VFS) E. faecium Chicken UK A1 15 
87 C15 (VF9) E. faeclum Pony UK A1 15 
88 V51 E. faecium Human USA F2 b 45 
89 VS2 E. faecium Human USA F2 45 
90 VS3 E. faecium Human USA F2 4S 
91 VS4 E. faecium Human USA F1 45 
92 VSS E. faecium Human USA F2 45 
93 VS6 E. faecium Human USA F2 45 
94 VS7 E. faeclum Human USA F2 45 
95 VS8 E. faedum Human USA F2 45 
96 VS9 E. faedum Human USA F2 45 
97 VS10 E. faedum Human USA F2 45 
pat. patient 
a NL, The Netherlands; UK, United Kingdom; USA, United States. 
b Tn1546 types which were sequenced entirely. 
respectively; see Table 2 and Fig. 1). Labeling of the PCR fragments and 
detection of hybrids were performed as described in the instructions for the ECL 
direct nucleic acid labeling and detection kit (Nycomed Amersham pic.). 
DNA sequence analysis 
The PCR products described below were purified with a Qiagen PCR purification 
kit (Qiagen Inc., Hilden, Germany) according to the manufacturer's instructions. 
Subsequently, the purified PCR products were sequenced directly with the ABI 
PRISM Big Dye cycle sequencing ready reaction kit (Perkin-Elmer, Applied 
Biosystems, Foster City, Calif.) on an ABI PRISM 377 DNA Sequencer (Perkin 
Elmer). All VRE isolates were analyzed for the point mutation in the orfl, vanS, 
and vanX genes. To determine the DNA sequence of the left end of the truncated 
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VanA transposon derivatives, type A2, B3, C, Dl to D4, El to E7, Fl, F2, and G 
DNA fragments were amplified with Tn1546 primer 184.R, 1009.R, 1292.R, or 
4511R in combination with 151216 primer IS1216V.B. 
Table 2: PCR and sequence primers used in this study 
Primer a 
Tn1546 primers 
22.F 
184.R 
934.F 
1009.R 
1292.R 
1723.F 
1890.F 
1913.R 
1924.R 
2768.F 
2880.R 
3514.F 
3560.R 
3940.R 
3992.F 
4426.F 
4511.R 
5235.F 
5374.R 
5747.F 
6039.F 
6113.R 
6964.F 
7035.R 
7486.R 
7875.F 
7986.R 
8544.F 
8691.R 
8969.R 
9519.F 
9580.R 
9970.R 
10716.R 
10778.F 
151216V primers 
IS1216V.A 
IS1216V.B 
IS1216V.C 
IS1216V.D 
IS1216V.E 
IS1216V.F 
Sequence 
5'-GGATTTACAACGCTAAGCC 
5'-ACCATATGTCGCCCTIAG 
5'-TGTGGATTTGCATCTGC 
5'-ACGGTACAACATCTTCGTC 
5'-TTACTCATGGATGTGGCC 
5'-ACAGGTGAGTCATCAGGC 
5'-TAAATAATCATAGTCGGCAGG 
5'-CGTCCTGCCGACTATG 
5'-TAGGAACTIGCACGTCCT 
5'-AGGATGGACTAACACCAATC 
5'-TGCTGTTCAATTAGCTGTTC 
5'-ACTGTAATGGCTGGTGTTAAC 
5'-TATCCGAATAAGATCTCGCT 
5'-ATTTATCAGATTATAGGGCCG 
5'-TTATTGTGGATGATGAACATG 
5'-AACGAGAAGCAGTTATCCC 
5'-TCGGAGCTAACCACATTC 
5'-ATATCACGTTGGACAAAGC 
5'-TTCATCGGTCATCTGCAC 
5'-ACGTTTAGGGTAGAGCTTCC 
5'-GTTTATGGATGTGAGCAGG 
5'-TATCGTTGCCATAACGC 
5'-AAAGGAGACAGGAGCATG 
5'-TTACGTCATGCTCCTCTGAG 
5'-CAAAAACAGGATAGGTAAACG 
5'-CCGCATTGTACTGAACG 
5'-CAAGCGGTCAATCAGTTC 
5'-GCATATAGCCTCGAATGG 
5'-TTACATACGTCGGGTTTCC 
5'-GATTGTGCCGITTT'GC 
5'-ACCAGCAGGTTATAGTGAGC 
5'-TCGTCAAGCITGATCCTAC 
5'-GCCATCCTTACCTCCTTG 
5'-TTTTCCCCTCACTTCACAC 
5'-TTTAGTGCTGAGGAATIGG 
5'-GGAAAGCAATTTCAGCAG 
5'-TCGATGCAGATGGTTTAAC 
5'-CACTTGTAATAGAGGGGGC 
5'-TGGGATICCCAATAATACC 
5'-AGCTTAAATCATAGATACCGTAAGG 
5'-TICATCGTCATICCTCCTCCTG 
Positions b 
22-40 
184-167 
934-950 
1009-991 
1292-1275 
1723-1740 
1890-1910 
1913-1898 
1924-1908 
2768-2787 
2880-2861 
3514-3534 
3560-3542 
3940-3920 
3992-4012 
4426-4444 
4511-4494 
5235-5253 
5374-5357 
5747-5766 
6039-6057 
6113-6097 
6964-6981 
7035-7017 
7486-7466 
7875-7891 
7986-7969 
8544-8561 
8691-8673 
8969-8954 
9519-9538 
9580-9562 
9970-9953 
10716-10698 
10778-19796 
254-271 
516-534 
659-641 
895-913 
913-935 
243-225 
a The names of the Tn1546 primers indicate the position of the first nucleotide and the orientation of the primer 
(F, forward; R, reverse). b The positions of the Tn1546 primers are based on the sequence of Tn1546 (GenBank 
and EMBL accession no. M97297). The positions of the IS1216Vprimers are based on the sequence of IS1216V 
(GenBank and EMBL accession no. L40841). 
The exact integration site and orientation of IS1216V in the vanX-vanY intergenic 
region were determined by amplifying a DNA fragment with primers 7875.F and 
10716.R, and the sequence was determined with the IS1216V primers IS1216.E 
and 151216.F. Finally, all VRE isolates carrying Tn1546 types Fl and F2 were 
118 
Molecular diversity of Tn1546 elements 
analyzed for the mutation in the vanA and vanY genes, as determined with 
isolate VSl, by sequencing the corresponding region. 
Results 
RFLP analysis of Tn1546-like elements 
In order to identify polymorphic regions in the vancomycin-resistant 
transposon Tn1546, 97 different vanA gene-carrying VRE (Table 1) isolated from 
different sources were analyzed by means of RFLP analysis. 
Seven different RFLP patterns, types A to G, were detected (Fig. 1). The 
banding pattern of type A was identical to the predicted pattern for the published 
sequence of Tn1546 [5]. For types B, D, E, and G, an additional fragment of 
approximately 1,800 bp was present, suggesting an insertion. The lack of 
fragment 1 or 6 in types C to G suggests that these transposons had deletions 
from the left end. Furthermore, the lack of fragment 2 in types D and G suggests 
polymorphism at the right end of the transposon. No polymorphism was found 
among the restriction fragments from the central regions of Tn1546, vanR, vanS, 
vanH, and vanA. The high molecular-mass bands present in types A to E and G 
represent DNA fragments flanking the VanA transposon. The absence of flanking 
fragments in type F is partially explained by deletions from the left end of the 
transposon (see above). In addition, the flanking fragment at the right end 
appeared to migrate at the position of fragment 4, while the original fragment 4 
in lane F was absent, probably due to a rearrangement in this region. 
Sequence analysis of the VanA transposons of representatives of the seven RFLP 
types 
Thirteen representatives of the seven different Tn1546 RFLP types (strains 3, 
17, 22, 23, 24, 26, 42, 48, 51, 70, 74, 79, and 88 [Table 1]) were analyzed in 
more detail by determining the nucleotide sequence of the entire transposon. 
Overlapping internal fragments of Tn1546 were amplified and were subsequently 
sequenced by using combinations of 35 Tn1546-specific primers (Table 2). The 
sequences that were obtained were compared with the published sequence of 
Tn1546. Consistent with the RFLP analysis, RFLP types C, D, E, F, and G lacked 
sequences at the left end of the transposon. In order to determine the exact left 
ends of the truncated Tn1546-related elements, DNA fragments were amplified 
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with a combination of Tn1546-derived primers and primers based on the 
insertion element I51216V.I51216V was found to be located upstream from 
Tn1546 in strains of RFLP types D, E, F, and G. In strains of RFLP type C, no 
IS1216V was present upstream of the transposon, so that the exact left end of 
the transposon could not be determined and was estimated from the RFLP data 
to be between 1,275 and 2,842 bp. 
The major rearrangements among the 13 strains investigated were the 
insertion of a IS1216V-I53-Iike element at the left end of the transposon (types 
A2 and B3), the insertion of one or two copies of IS1216V (types Band D to G), 
the insertion of one copy of IS1251 (type F), deletions associated with IS 
insertions downstream of vanX (types D to G), and at the left end of the 
transposon, deletions that affect the transposase or the resolvase gene (types C 
to G) (Fig. 2). 
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Figure 1: RFLP analysis and physical 
and genetic maps of Tn1546. The 
position and direction of transcription 
of genes and open reading frames 
(orfs) are indicated with open 
arrows. Black horizontal bars indicate 
the position of internal Tn1546 
fragments used as probes (probes 1 
to 4). The numbers 1 to 9 represent 
the restriction fragments visualized 
after hybridization with the Tn1546-
specific probes 1 to 4 and are 
indicated on the right side of the blot. 
The positions of the molecular size 
markers are indicated on the left side 
of the blot. Letters above the fanes 
represent the Tn1546 RFLP types. 
Only the restriction enzyme 
recognition sites relevant for this 
study are shown. H, Haeiii; X, Xbai. 
The positions of some restriction sites 
are indicated in parentheses. 
Insertion of the IS1216V-IS3-Iike element at the left end of the transposon and 
insertion of IS1216V ·,n the vanXY intergenic region have been described 
previously [36, 49]. It is interesting that copies of IS1216V inserted in the vanXY 
intergenic region in strains 24, 42, 48, 70, and 74, which were completely 
sequenced, contained a synonymous T-to-C point mutation at position 826 
120 
Molecular diversity of Tn1546 elements 
relative to the published sequence of IS1216V (GenBank accession no. L40841). 
In all strains with I51216V insertions except strains in which the IS insertions 
were accompanied by small adjacent deletions, an 8-bp duplication of the target 
sequence (CCCATTGT) was found. Insertion of I51216V in the vanXY intergenic 
region also explained the presence of the additional 1.8-kbp fragment in types B, 
D, E, and G (Fig. 1). Insertion of 151251 in the van5H intergenic region resulted 
in an 8-bp duplication of the target sequence, ATAATTTT. Furthermore, insertion 
of I51251 in this region explained the absence of fragment 4 in lane F (Fig. 1). 
Insertion of 151251 at this site has also been described previously (27). 
Furthermore, DNA polymorphism due to point mutations in orf1 (1226), vanS 
(4847), vanA (7658), vanX (8234), and vanY (9692) were found (Fig. 2). 
Altogether 11 different Tn1546 types were distinguished among the 13 strains 
whose transposons were sequenced: type A1 (which is Tn1546), A2, A3, A4, B1, 
C, D1, E1, E2, F2, and G (Fig. 2). 
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Figure 2: Genetic maps of 22 Tnl546 
types. The thick horizontal lines 
represent the Tnl546 types Al to A4, 81 
to 83, c, Dl to 04, El to £7, Fl, F2, and 
G. The positions of genes and open 
reading frames (orrs) and the direction 
of transcription are depicted with open 
arrows. Dotted boxes represent IS 
elements. The positions of the first 
nucleotide upstream and the first 
nucleotide down-stream from the IS 
insertion sites are depicted. Filled arrows 
indicate the transcriptional orientations 
of the inserted IS elements. Deletions 
(del) are indicated by dotted lines. The 
positions of base pair mutations are 
indicated above the different Tn1546 
types: 1226, T?A (K?stop); 4847, 
T?C; 7658, T?C (V?A); 8234, G?T 
(K?N); 9692, C?T (P?L). 
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Analysis of the polymorphic regions in Tn1546 in other isolates of VRE. 
We analyzed the polymorphic regions of Tn1546 of 87 additional VRE which 
were initially examined by RFLP analysis. The presence of the point mutations in 
the vanX, vanS, and orf1 genes, the exact integration sites and the orientations 
of lS1216V and !51251, the deletions surrounding the lS1216V insertion site, 
and the size of the left-end deletion were assessed by means of DNA sequencing. 
Furthermore, isolates of VRE carrying the type F transposon were analyzed for 
the point mutation in the vanA and the vanY genes. DNA sequencing finally 
distinguished 22 different transposon types. RFLP type A could be subdivided into 
four subtypes (subtypes A1 to A4), type B could be subdivided into three 
subtypes (subtypes B1 to B3), type D could be subdivided into four subtypes 
(subtypes D1 to D4), type E could be subdivided into seven subtypes (subtypes 
E1 to E7), and type F could be subdivided into two subtypes (subtypes F1 and 
F2). Types c and G could not be subdivided. On the basis of RFLP analysis, types 
D3 and D4 were initially designated E subtypes since they both lacked fragments 
6, 1, and 3 at the left ends of their transposons. However, since these two types 
also lacked the vanY gene, which is indicative of type D, they were renamed D3 
and D4. The identification of lS1216V in the vanity intergenic region in types D1, 
D2, and D4 in strains 46 to 69 contradicts the results published previously by 
Jensen et al. [39] since in that study the same strains were partly analyzed, but 
no sequence or size variation was observed in the amplicons of the vanity 
intergenic region. 
Glycopeptide susceptibility patterns of isolates 
The M!Cs of vancomycin, teicoplanin, and avoparcin for the 97 different 
isolates were determined by the agar dilution method. Generally, no association 
was found between the resistant phenotype and the transposon genotype. All 
isolates were resistant to vancomycin (M!Cs at which 50% [MICSO] and 90% 
[MIC90] of isolates are inhibited, 512 and 1,024 mg/ml, respectively) and 
avoparcin (MICSO and MIC90, 256 and 1,024 mg/ml, respectively). Exceptions 
were strains with deletions of the vanY gene (types D1, D2, D3, D4, and G). 
These strains were less resistant to teicoplanin (MICSO and MlC90, 16 and 64 
mg/ml, respectively) than strains belonging to the other types (MICSO and 
MIC90, 128 and 256 mgjml, respectively). It is conceivable that the deletion of 
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vanY affects the transcription of vanZ, resulting in a lower MIC of teicoplanin, 
because vanZ has been shown to be involved in teicoplanin resistance [10, SO]. 
Table 3: Ribotypes/ PFGE types/ and Tn1546 types of VRE isolated from the John Radcliffe 
Hospital/ Oxford/ and the Cook County Hospital/ Chicago 
Strain Source City Rfbotype PFGE Tn1546 
No. Type Type 
48 Human stool Oxford 2 G' 01 
49 Human stool Oxford 4 u 01 
50 Human stool Oxford 11 Q 01 
53 Human stool Oxford 1 H' 01 
54 Human stool Oxford 1 H 01 
55 Human urine Oxford 1 I 01 
56 Human urine Oxford 4 G 02 
57 Human urine Oxford 5 p 01 
58 Human wound Oxford 2 F 01 
59 Human blood Oxford 6 P' Dl 
60 Human urine Oxford 6 H Dl 
61 Human urine Oxford 1 H Dl 
62 Human blood Oxford 1 H 01 
63 Human urine Oxford 1 H Dl 
64 Human urine Oxford 1 H 01 
65 Human urine Oxford 1 H Dl 
66 Human urine Oxford 1 H Dl 
67 Human pus Oxford 1 H" 04 
58 Human urine Oxford 1 H 04 
69 Human pus Oxford 1 H Dl 
51 Human stool Oxford 8 A c 
52 Human stool Oxford 9 R Al 
88 Human c Chicago NOd uu F2 
89 Human c Chicago NO w F2 
90 Human c Chicago NO ww F2 
91 Human c Chicago NO XX Fl 
92 Human c Chicago NO yy F2 
93 Human c Chicago NO zz F2 
94 Human c Ch'tcago NO AAA F2 
95 Human c Chicago NO BBB F2 
96 Human c Chicago NO CCC F2 
97 Human c Chicago NO DOD F2 
a Ribotypes have been described previously [34]. 
b Interpretation of banding patterns is according to Tenover et al. [47]. 
c The strains were from multiple body sites. 
d ND, not determined. 
Tn1546 types among VRE isolated from hospitalized patients 
Our collection of VRE comprised two sets of strains isolated from hospitalized 
patients. One set of 22 VRE originated from an outbreak at the John Radcliffe 
Hospital in Oxford, United Kingdom [34]. These 22 isolates represented eight 
different ribotypes and 13 different PFGE types (Table 3), which suggests that at 
least 13 different enterococcal strains were involved in this outbreak. In contrast, 
17 of the 22 isolates contained the same 01 type of Tn1546 (Table 3). Further-
more, an additional three strains harbored either Tn1546 type 02 or Tn1546 type 
123 
Chapter 9 
D4, which could be derived from D1 by a single DNA rearrangement (Fig. 3). 
Tn1546 type D1 was found among nine different strain types. A second set of 10 
strains originated from a 7-week survey for VRE contamination at Cook County 
Hospital, Chicago, Ill. [45, 46]. All 10 E. faecium strains had different PFGE types 
(Table 3). Interestingly, all isolates except one contained the same Tn1546 
derivative, Tn1546 type F2. One isolate, isolate VS4, contained the type Fl 
transposon, which differed from type F2 by a single base pair. The data on the 
prevalence of transposon types in the Oxford and Chicago hospitals suggest the 
possibility of horizontal transmission of vancomycin resistance transposon types 
D1 and F, respectively, among different enterococcal hosts. 
Table 4: Distribution of 22 different Tn1546 derivatives among 97 isolates of VRE from human and 
animal sources 
No. of isolates from the following sources a : 
Tn1546 
Type Human Animal Human Animal Human Total 
(NL) (NL) (UK) (UK) (USA) 
(n=21) (n=24) (n=24) (n=18) n=10) 
A1 7 5 2 6 20 
A2 13 12 4 29 
A3 1 1 
A4 1 1 
B1 1 1 2 
B2 1 1 
63 1 1 
c 1 1 
D1 17 17 
D2 1 1 
D3 1 1 
D4 2 2 
E1 1 1 
E2 1 1 2 
E3 1 1 2 
E4 1 1 
ES 1 1 
E6 1 1 
E7 1 1 
F1 1 1 
F2 9 9 
G 1 1 
Total 21 24 24 18 10 97 
a NL, The Netherlands; UK, United Kingdom; USA, United States; n, total number of isolates from 
that source 
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Discussion 
To facilitate understanding of the molecular epidemiology of vancomycin 
resistance, we undertook a detailed study of the molecular diversity and the 
evolutionary relationships of Tn1546-like elements in enterococci from humans 
and animals. Knowledge of the diversity of Tn1546 is important for distinguishing 
between the dissemination of a single VRE clone and the transmission of a 
particular Tn1546 type through a genetically divergent population of enterococci. 
Typing of VRE by methods such as PFGE and ribotyping has shown the clonal 
dissemination of VRE in hospitals [30, 32, 51, 52]. However, transmission of 
particular Tn1546 types has not been documented before. Nevertheless, various 
studies suggest that this occur since genetic divergence in VRE genomes was 
found among strains isolated from epidemics caused by VRE [27-31]. 
In this study we have identified and characterized polymorphic regions in 
Tn1546-like elements from 97 VRE originating from animal and human sources. 
By means of a combination of RFLP analysis and DNA sequencing, 22 different 
Tn1546-like elements were distinguished. Three types of polymorphisms were 
found: point mutations, insertions of IS elements, and deletions generally 
associated with the insertion of IS elements. The point mutations were located in 
the orfl, vanS, vanA, van X, and vanY genes. The only point mutation described 
previously is in the vanX gene at position 8234 [10, 39]. Jensen et al. [39] also 
found this mutation in the vanX gene in three strains that we have also analyzed, 
strains 77 to 79. 
The vast majority (74 of 97) of strains contained one to three copies of the 
insertion sequence IS1216V inserted in the vancomycin resistance transposon. 
Insertion of this IS element in the vanXY intergenic region and its presence on 
either side of Tn1546 have been described previously [36, 49, 53]. The presence 
of IS element insertions was often associated with deletions, a phenomenon 
which has been described previously [54, 55]. Thirty isolates containing the type 
A2 and 83 VanA transposons had similar genetic organizations at the left end of 
the VanA transposon, as in strain GUC described by Handwerger and Skoble 
[49]. In these types as well as in strain GUC, a copy of an I51216V-I53 like 
element is present at the left end of the VanA transposon, resulting in a deletion 
of the first 120 bp. In strain GUC the Tn1546-like element is located on a large 
chromosomal mobile element designated Tn5482. Preliminary analysis of two 
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representative isolates carrying type A2 transposons indicated a chromosomal 
location of the VanA element (data not shown), which is similar to the case for 
strain GUC, which may suggest that type A2 and 83 VanA transposons are part 
of a larger chromosomal mobile element. In strains 77 to 79 the presence of the 
I51216V-I53 element at the left end of the Tn1546-like element is consistent 
with the finding of Jensen et al. [39]. In addition to I51216V, insertions of 
I51251 in the van5H intergenic region were found. Although the insertion of 
I51251 at this site was published previously, the transposon in E. faecium GUC 
described by Handwerger and colleagues [38, 49] was clearly distinct from the 
Tn1546 type F transposon, since no insertion of an I51216V-I53 like element 
was present directly upstream from Tn1546 in the type F transposons. 
Remarkable was the finding that 72 (74%) of the analyzed strains (types A2, 
83, C, Dl to D4, El to E7, Fl, F2, and G) carried small or large deletions in the 
transposase and resolvase regions of the Tn1546-like transposon. A similar 
finding has recently been reported by others [ 43]. Although it is expected that 
deletions in the transposase and resolvase regions which abolish transposition 
may affect the dissemination of truncated Tn1546-like elements, other studies 
have shown that Tn1546-like elements are often part of chromosomal mobile 
elements [ 49] or plasm ids that can be mobilized (28). 
In this study we investigated in detail the polymorphism in Tn1546 with the 
aim of exploiting differences in this genetic element for future studies on the 
epidemiology of vancomycin resistance. Because we examined a large number of 
strains from a variety of sources, some preliminary conclusions may be drawn. 
Tn1546 types Al and A2 were the most prevalent in The Netherlands both 
among isolates from humans and among isolates from farm animals (Table 4), 
suggesting an epidemiological link between animal and human reservoirs. The 
presence of identical VanA transposons in VRE isolated from humans and animals 
has also been described recently in Denmark and the United Kingdom [39, 43]. 
In VRE from hospitalized patients in the United States we found transposons 
which contain insertions of I51251. So far this IS element was been found only 
by Handwerger et al. [39], Jensen et al., and MacKinnon et al. [40] in isolates 
from U.S. patients. 
It is intriguing that the majority of the transposon types found in hospitals in 
the United Kingdom and the United States (types Dl and F2) have no 
counterpart in animals. For the U.S. isolates, this is explained by the fact that so 
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far no VRE have been isolated from animals in the United States. The fact that no 
D types were found among the isolates from animals in the United Kingdom may 
suggest that once it was introduced in the Oxford hospital the VanA transposon 
has evolved independently from the transposons from counterpart strains from 
animals. This is consistent with the scheme presented in Fig. 3. Figure 3 depicts 
a hypothetical evolutionary scheme in an attempt to explain the relationships 
between the 22 transposon types. In Fig. 3 transposon types D (types Dl, 02, 
and 04) and F (types Fl and F2) are located separately from the majority of the 
subtypes found outside hospitals. In the scheme presented in Fig. 3 we assume 
that the various Tn1546 variants evolved by base pair substitutions, 
transpositions, and deletions. We did not include homologous recombination 
events, although they could lead to a more parsimonious phylogeny. The 
preliminary data on region specificity suggest that geographic isolation 
contributed to differences in the prevalence of particular Tn1546 subtypes at 
different geographic sites. 
The combination of the polymorphism in Tn1546 and the epidemiological data 
indicate that the DNA polymorphism among Tn1546 variants can be exploited 
successfully for the tracing of the routes of transmission of vancomycin 
resistance genes. Indicative of this is the finding of identical or closely related 
VanA transposon types among genetically different enterococci in the Oxford 
hospital as well as in the hospital in Chicago. Studies are in progress to use the 
tools developed in this study to investigate in detail the prevalence of subtypes 
of Tn1546 among humans and animals. This may resolve the controversial issue 
of the spillover of vancomycin resistance to humans from the animal reservoir 
due to the use in animal husbandry of glycopeptide antibiotics, such as 
avoparcin, for growth promotion. Avoparcin has been used in Europe for more 
than 20 years, but it is anticipated that the current ban on the veterinary use of 
this antibiotic will also lead to an overall decrease in the frequency of vancomycin 
resistance among enterococci colonizing the human digestive tract. 
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Figure 3: Hypothetical evolutionary scheme for the various Tnl546 derivatives characterized in 
this study from the archetypal transposon Tnl546 (type Al) as described by Arthur eta!. in 1993 
(5}. Boxes represent the different Tnl546 types. Filled arrows indicate the transition of Tnl546 
type Al to the other Tn1546 types. The different DNA rearrangements, insertions, deletions, and 
point mutations are indicated. Strain GUC has been described by Handwerger eta/. (27) 
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Abstract 
Amplified-fragment length polymorphism (AFLP) analysis was used to 
investigate the genetic relationships among 255 vancomycin-resistant 
Enterococcus faecium (VREF) strains isolated from hospitalized patients, 
non-hospitalized persons, and various animal sources. Four major AFLP 
genogroups (A-D) were discriminated. The strains of each taxon shared >65% of 
the restriction fragments. Most isolates recovered from non-hospitalized persons 
(75%) were grouped together with all pig isolates in genogroup A. Most isolates 
from hospitalized patients (84%), a subset of veal calf isolates (25%), and all 
isolates from cats and dogs clustered in genogroup C. Most isolates from 
chickens (97%) and turkeys (86%) were grouped in genogroup B, whereas most 
veal calf isolates (70%) clustered in genogroup D. Therefore, VREF strains are 
predominantly host-specific, and strains isolated from hospitalized patients are 
genetically different from the prevailing VREF strains present in the fecal flora of 
non-hospitalized persons. 
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Introduction 
During the last 20 years, an increase in antimicrobial resistance among 
enterococci has been observed. In particular, vancomycin-resistant Enterococcus 
faecium (VREF) strains are often multidrug-resistant [1] and pose a serious 
threat in hospital infections, because infections with VREF strains are difficult to 
treat. In the United States, many hospitals reported a high prevalence of 
vancomycin resistance, but vancomycin-resistant enterococci seemed to be 
virtually absent in the community. This is in contrast to Europe, where VREF 
strains can easily be detected outside hospitals, in non-hospitalized persons and 
in farm animals [2-14]. The high prevalence of VREF strains in farm animals in 
Europe is thought to be the result of the use of the glycopeptide antibiotic 
avoparcin as an antimicrobial growth promoter [15]. Consequently, VREF strains 
from animal husbandry may enter the food chain and subsequently spread to 
humans. The most prevalent and best-studied vancomycin resistance transposon 
is Tn1546, which confers high-level resistance to vancomycin and teicoplanin 
[16]. Detailed molecular analysis of Tn1546 isolated from different animal and 
human strains has shown considerable DNA polymorphism in Tn1546 and has 
revealed the presence of common Tn1546 types among animal- and 
human-derived VREF strains, irrespective of the host strain [9, 12, 14, 17-25]. 
In addition, VREF strains from pigs predominantly carried a particular Tn1546 
type with a specific point mutation at position 8234, whereas enterococci isolated 
from poultry predominantly contained Tn1546 sub-types harboring an IS1216V 
insertion in the vanX-vanY intergenic region [9, 12, 14, 17, 18, 23]. Whether an 
animal reservoir of VREF actually poses a threat to humans depends on the 
ability of animal strains to colonize the human gut. In several studies, genetically 
indistinguishable enterococci have been found in animals and humans, 
suggesting that animal-derived enterococci may colonize the human gut [4, 9, 
17, 22, 23, 26-28]. Recently, Berchieri [29] showed that ingestion of a VREF 
strain isolated from a chicken resulted in colonization of his own gut for 20 days. 
Both molecular and non-molecular typing schemes have been used to study the 
epidemiology of VREF [30-40]. Because of the high degree of strain 
differentiation, pulsed-field gel electrophoresis (PFGE) has been considered to be 
the reference standard for tracing the transmission of strains in hospital 
out-breaks [32-34]. However, by PFGE it is difficult to establish the degree of 
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genetic relatedness between epidemiologically nonrelated strains, because the 
banding patterns of such strains are often completely different. Therefore, it is 
unlikely that PFGE allows the disclosure of strain-characteristic differences in the 
host specificity of enterococci. Devriese and colleagues [41, 42] have shown that 
raffinose-positive E. faecium are typically associated with poultry, and 
sorbitol-positive E. faecium strains are associated with dogs, which suggests that 
certain enterococci are host-specific. 
Amplified-fragment length polymorphism analysis (AFLP) is a novel technique 
that allows for the analysis of polymorphism among small restriction fragments 
[43]. An advantage of AFLP typing is that these small fragments originate from 
both variable and conserved DNA sequences, thus establishing a degree of 
genetic relatedness between strains that, by PFGE, would show no similarity at 
all. AFLP combines restriction enzyme analysis with polymerase chain reaction 
(PCR) and has been proven successful in studying the molecular epidemiology of 
various microorganisms [44-52]. In this study, we used AFLP to obtain insight in 
the genetic relationships among VREF strains isolated from infected patients, 
non-hospitalized persons, pets, and various farm animals. 
Materials and Methods 
Bacterial strains 
Two hundred fifty-five vanA-containing E. faecium isolates were analyzed. 
Eighty-seven were from hospitalized patients from 9 countries (United States: 
38, two hospitals; United Kingdom: 24, two hospitals; The Netherlands: 11, two 
hospitals; France: 6, three hospitals; Israel: 3, two hospitals; Italy: 2, two 
hospitals; Czech Republic: 1; Germany: 1; Slovak Republic: 1) [7, 53-57], 24 
were from non-hospitalized persons from 3 countries (United Kingdom: 3; 
Germany: 1; the Netherlands: 20) and 11 different cities [4, 9, 14], 12 were 
from pigs from 2 countries (United Kingdom: 3; The Netherlands: 9) and 12 
different farms [4, 11, 58], 10 were from poultry farmers (10 different farms; 
provided by A. E. J. M. van den Bogaard, University of Maastricht, The 
Netherlands) and poultry slaughterers (The Netherlands, 1 processing plant, 
provided by A. E. J. M. van den Bogaard), 31 were from chickens from 2 
countries (United Kingdom: 4; The Netherlands: 27) and 29 different farms (22 
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isolates were provided by A.E. J. M. van den Bogaard) [4, 12], 10 were from 
turkey farmers (the Netherlands: 10 different farms) and turkey slaughterers 
(the Netherlands: 1 processing plant) [9], 7 were from turkeys (The Neth-
erlands: 7 different farms) [9], 9 were from veal calf farmers (the Netherlands: 4 
different farms), 60 were from veal calves (The Netherlands: 56 different farms), 
5 were from dogs, and 2 were from cats (The Netherlands) [28]. 
PFGE analysis of VREF strains 
PFGE typing was done, as described elsewhere [12]. The DNA banding 
patterns were analyzed with BioNumerics, version 1.5 (Applied Maths, Kortrijk, 
Belgium). The Dice coefficient of similarity was calculated, and the unweighted 
pair group method with arithmetic averages was used for cluster analysis. 
Molecular characterization of Tn1546 derivatives 
Characterization of the vanA gene-containing transposons was done by a 
combination of restriction fragment length polymorphism and DNA sequencing, 
as described elsewhere [14]. The Tn1546 types and subtypes-A1, A2, A3, B, C, 
D, E, and F-mentioned in this study have been described elsewhere [9, 14]. In 
short, type A1 is identical to the first-described VanA-containing transposon, 
Tn1546 [16]. Types A2 and A3 are characterized by the G~T point mutation at 
position 8234 and the T~C point mutation at position 4847, respectively. Type B 
transposons are characterized by an I51216V insertion in the vanX-vanY 
intergenic region, and type C is characterized by a left-end deletion. Types D and 
E combine the features of type B and C-that is, a left-end deletion and the 
I51216V insertion. In addition, type D contains a deletion of the vanY gene. 
Some of the E subtypes contain a deletion of the vanZ gene. The F types are 
characterized by an I51251 insertion in the vanS-vanH intergenic region and the 
G~T point mutation at position 8234. Furthermore, in some, but not all, F types, 
point mutations at the positions 7658 (T~C) and 9692 (C~T) are found. In this 
study, the B, D, E, and F types were not subdivided into the different subtypes 
that have been described elsewhere. 
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AFLP analysis of VREF strains 
AFLP, as originally described by Vos et al. [ 43], is based on the ligation of 2 
adapters to genomic restriction fragments, followed by a PCR-based amplification 
with adapter-specific primers. In this study, we used a single adapter instead of 
2, resulting in self-ligation of the digested DNA, because the adapter will ligate to 
the cohesive ends generated by the 2 restriction enzymes. The main advantages 
of using a single adapter are less variation in peak intensities and improved 
reproducibility [44]. DNA was isolated, as described elsewhere [14], with the 
addition of a final ethanol precipitation step to further purify the DNA. The 
EcoRI-Cfol adapter used in this study was prepared by mixing 2 oligonucleotide 
solutions (2 mM each), heating for 5 min at 957C, and allowing the mixture to 
cool for >10 min at room temperature. The structure of the EcoRI-Cfol adapter 
was as follows: 5' -AATTGTAAAACGACGGCCAGTAACG and CATTTTGCTGCC-
GGTCATT-5' (complementary sequence is underlined). For restriction ligation, a 
5-mL mixture consisting of 23 One-Phor-AII buffer (Amersham-Pharmacia 
Biotech, Uppsala, Sweden), 2 mM ATP, 5 U of EcoRI, 1 U of Cfol, 1 U of T4 DNA 
ligase, and 0.8 mM adapter was prepared. After addition of 5 ~L (10 ng) of 
genomic E. faecium DNA, the mixture was incubated for 2 h at 37° C, to allow 
simultaneous restriction and ligation. This resulted in the formation of 
circularized DNA molecules. For amplification, 90 ~L of TE (20 mM Tris, 0.1 mM 
EDTA, pH 8.0) was added to the restriction ligation mixture, and, subsequently, 
2 ~L of this mixture was mixed with 0.25 ~L (10 mM) of each AFLP primer 
(primer 1 [Cfoi-G]: 5' -CGACGGCCAGTAACGC-G; primer 2 [EcoRI-A]: 
5' -GGCCGTCGTTTTACAATTC-A) and 7.5 ~L of AFLP amplification core mix (PE 
Biosystems, Foster City, CA). Primer 1 contained an extra selective base, G, and 
was labeled with the blue fluorescent dye 5-carboxyfluorescein. Primer 2 
contained an extra selective base, A. PCR was done on a thermal cycler (model 
9600; PE Biosystems). After the PCR mixture had been heated for 2 minutes 
72° C, it was used for amplification by means of a "touchdown" PCR program as 
follows: 30 cycles of a 20-s denaturing step at 94° c, a 30-s annealing step (see 
below), and a 2-min extension step at 72° C, followed by incubation at 60 ° C for 
30 min. The annealing temperature during the first cycle was 66° C and 
decreased 1° C at each cycle during the next 9 cycles. During the remaining 20 
cycles, an annealing temperature of 56° C was used. The amplification products 
were separated on a 36-cm, 5% denaturing sequencing polyacrylamide gel (Long 
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Ranger Singe! Pack; FMC Bioproducts, Rockland, ME) on a DNA sequencer (ABI 
PRISM 377; PE Biosystems). For this, 1 mL of reaction mixture was mixed with 
1.25 ~L of formamide, 0.5 ~L of loading buffer (PE Biosystems), and 0.25 ~L of 
the internal size marker (GeneScan-500 labeled with the red fluorescent dye 6-
carboxy-x-rhodamine; PE Biosystems). The gel was run in 13 TBE (89 mM Tris, 
89 mM boric acid, 2 mM EDTA, pH 8.2) for 3 h at 200 W (GeneScan run module 
36D-2400). 
Computer analysis of AFLP-generated patterns 
The GeneScan collection software (PE Biosystems) was used to collect data 
during electrophoresis. After tracking and extraction of lanes, data were exported 
to BioNumerics (version 1.5; Applied Maths) for further analysis. Normalization 
was done by use of the reference positions of the internal DNA size marker 
GS-500. Fragments ranging in size from 50 to 500 nucleotides were used for 
comparison. The Pearson coefficient of similarity of AFLP curves was calculated 
with BioNumerics software (Applied Maths). Cluster analysis was done by the 
unweighted pair group method with arithmetic averages. 
Results 
Comparison of AFLP analysis with PFGE 
In a pilot experiment, 25 VREF strains isolated from human patients, 
non-hospitalized persons, pigs, and chickens were subjected to AFLP analysis and 
PFGE. The number of AFLP bands with sizes of 50-500 bp was 13-37, with an 
average of 27 bands (figure 1). AFLP typing was found to be highly reproducible. 
The degree of similarity between quadruplicates was 95%-99% (data not 
shown). The strains clustered into 3 distinct AFLP groups (figure 1). Group A 
contained strains from non-hospitalized persons and pigs, group B from chickens, 
and group C from hospitalized patients. This apparent host-specific grouping was 
less distinct by PFGE typing (figure 1). Furthermore, the strains originating from 
a given host were more dissimilar by PFGE than by AFLP analysis, with the 
exception of strains HP3-HP12, which were recovered from a hospital outbreak 
[55]. These strains showed highly similar or identical PFGE patterns (similarity 
>82%) and have been considered to belong to a single clone [55]. As with PFGE 
typing, the strains from the hospital outbreak also showed identical AFLP 
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patterns (similarity >97%). In addition, 2 strains from non-hospitalized persons 
(NHP2 and NHP3) were indistinguishable by both PFGE and AFLP. The number of 
bands in PFGE patterns was 11-16, which is considerably less than in the AFLP 
patterns. Therefore/ genomic changes in only a few restriction fragments may 
result in disproportionate differences in the PFGE banding patterns. 
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Figure 1: Amplified-fragment length polymorphism (AFLP) patterns and dendrogram of 25 
vancomycin-resistant Enterococcus faecium strains, typed by AFLP and pulsed-field gel 
electrophoresis (PFGE). Numbers on horizontal axes indicate % similarity, as determined by 
Pearson product-moment correlation coefficient and unweighted pair group method, with arithmetic 
averages for AFLP typing, and by Dice and unweighted pair group method, with arithmetic 
averages for PFGE typing. HPl-12, hospitalized patients; NHPl-5, non-hospitalized persons; Pl-3, 
pigs; Cl-5, chickens. A, B, and C in left dendrogram represent 3 genogroups. Dotted line depicts 
95% similarity coefficient, above which strains were considered to be of identical AFLP type. 
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Genogrouping and association with source of isolation 
Two hundred fifty-five VREF strains recovered from different human and 
animal sources were subjected to AFLP typing. The strains from hospitalized 
patients were isolated from different sites, such as stool, blood, pus1 urine, and 
ascites (table 1). 
Table 1: Isolation sites and genogrouping of vancomycin-resistant Enterococcus faecium strains 
recovered from hospitalized patients. 
No. of strains isolated, by isolation site 
Genogroup Ascites Bile Blood Catheter Pus Skin Urine Stool Unknown 
A 1 1 2 
B 2 1 1 5 1 
c 3 3 10 2 3 1 27 24 
Total 5 3 10 2 4 2 29 31 1 
The result of the grouping by AFLP of these VREF strains is shown in figure 2. 
Four main groups (groups A-D) were discernible, and the strains within each 
group shared >65% of their restriction fragments. As described above, in the 
pilot experiment, grouping of the strains by AFLP was clearly associated with the 
source of the strains. Most of the 87 strains from hospitalized patients (84%) 
clustered in genogroup C (figures 2, 3A). Within this genogroup, 2 subgroups, Cl 
and C2, were discerned, each containing strains with indistinguishable AFLP 
banding patterns (similarity >95%). Group Cl strains were isolated during a 
32-month period at 6 Detroit metropolitan area hospitals [54], and group C2 
strains were isolated during a 3-month period at the John Radcliffe Hospital in 
Oxford, United Kingdom [55]. Strains in subgroups Cl and C2 are most likely 
repetitive isolates of a single strain. The same is probably true for 2 sets of 2 
strains in genogroup B and for 3 other sets of 2 strains in genogroup C, which 
have indistinguishable AFLP patterns (similarity >95%) and originated from the 
same hospital. When these repetitive isolates were counted only once, 74°/o of 
the strains from hospitalized patients clustered in genogroup C. 
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Figure 2: Abridged dendrogram of all vancomycin-resistant Enterococcus faecium (VREF) strains 
and separate dendrograms of strains belonging to each of 4 genogroups. Symbols depict VREF 
strains from various sources. A1, A2, Cl, and C2 depict subgroups of genogroups A and C. 
Numbers on horizontal axis indicate % similarities, as determined by Pearson product-moment 
correlation coefficient. Vertical dashed lines indicate 95% similarity coefficient, above which strains 
were considered to be of identical amplified-fragment length polymorphism type. 
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Group C strains also comprised some isolates from veal calves and all 5 isolates 
from cats and dogs. No association was found between the body site of the 
hospitalized patients from which the strains were recovered from and the 
grouping of the strains (table 1). Unexpectedly, most isolates recovered from the 
feces of non-hospitalized persons (75%) were grouped in a different genogroup, 
group A. Furthermore, half the isolates from poultry farmers or slaughterers and 
70% of the isolates from turkey farmers or slaughterers were in this group 
(figures 2, 3A). All isolates from pigs were also grouped in genogroup A. Two 
subgroups/ Al and A21 were distinguished, and either subgroup comprised both 
pig and human isolates indistinguishable by AFLP (similarity >95%). Genogroup 
B comprised mainly strains originating from poultry: 97% of the chicken and 
86% of the turkey isolates. Interestingly, a large percentage of isolates from 
poultry farmers or slaughterers were found in taxon B, as well (figures 2, 3A). 
Finally, genogroup D comprised exclusively strains from veal calves (70% of the 
calf strains) and veal calf farmers (figures 2, 3A). About half the genogroup D 
strains were similar, and the human isolates were identical to >1 of. the calf 
strains. 
Association between AFLP types and Tn1546 types 
The Tn1546 types of all 255 VREF strains were determined (figure 3B). The 
Tn1546 (sub)types A1, A2, and B have been found elsewhere in strains from 
humans, pigs, and poultry [9, 12, 14, 17, 18, 20, 21, 25]. Strains with these 
Tn1546 types were found among 3 or among all 4 E. faecium genogroups, 
suggesting horizontal spread of the VanA transposon among genetically different 
enterococci (figure 3B). Strains with transposon types C and E were found in half 
the genogroups. In contrast, 3 transposon types, A3, D, and F, were confined 
mainly to a single AFLP genogroup, and these strains were also closely 
associated with specific hosts. Transposon types D and F were found mainly in 
genogroup C VREF strains from hospitalized patients, suggesting clonal 
expansion (figure 3B). Type A3 was restricted to isolates of genogroup D, and 
these originated from veal calves and veal calf farmers. Remarkably, no A3 
transposon types were found in veal calves present in genogroup C. This 
suggests the existence of 2 separate VREF subtypes in veal calves. 
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Figure 3: Distribution of all 255 vancomycin-resistant Enterococcus faecium from various sources 
among 4 genogroups (A) and distribution of VanA transposon types among 4 genogroups (8}. 
AFLP, amplified-fragment length polymorphism. 
Discussion 
This study shows that particular E. faecium genogroups are associated with 
particular hosts and environments, such as farms and hospitals. We limited this 
study to vancomycin-resistant isolates. Therefore, the results may differ for 
drug-susceptible isolates. Although many studies of the epidemiology of 
vancomycin-resistant enterococci have made use of molecular typing, only a few 
studies have suggested the existence of host-specific ecovars. On the basis of 
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slight differences in E. faecium isolates, Devriese and colleagues [ 41, 42] have 
suggested that species-specific variants occur among dogs and poultry. To our 
knowledge, the study presented here is the first systematic study showing an 
association between host species and VREF strain genogroup. The disclosure of 
such ecovars has probably been hampered by the use of typing methods that 
were too limited in the degree of strain differentiation, such as ribotyping [32, 
34], or by the use of methods, such as PFGE, that discriminate well but do not 
adequately establish the degree of genetic relatedness between dissimilar strains 
[34, 35, 38]. The AFLP method used in this study permits a high degree of strain 
differentiation, because of the large number of restriction fragments analyzed 
and the establishment of genetic relatedness among dissimilar, 
non-epidemiologically related strains made possible by the presence of shared 
restriction fragments of evolutionarily more-conserved DNA stretches. 
Comparison of AFLP with PFGE for 25 VREF isolates, including VREF strains 
isolated during a hospital outbreak of VREF infections, revealed that the degree 
of strain differentiation and the identification of outbreak strains by AFLP typing 
is com-parable with that of PFGE typing. Four distinct genogroups among 255 
VREF isolates were disclosed in this study, and strains within each group shared 
two-thirds or more of their restriction fragments. The use of restriction enzyme 
combinations other than EcoRI-Cfol led to a similar grouping (R.J.L.Willems, 
unpublished data). The strongest association between host and genogroup was 
found among strains of genogroup D: virtually all genogroup D strains were from 
calves and a few were from veal calf farmers. Therefore, the host range of 
strains of this type is restricted mainly to calves. Although the host range of 
strains from the remaining 3 genogroups seems broader, these also exhibited a 
strong association with the source. Strains from chickens and turkeys were found 
almost exclusively in genogroup 6, all pig strains were found in genogroup A, 
and all 5 strains from cats and dogs were found in genogroup C. Recently, Van 
den Braak et al. [12] distinguished poultry-specific PFGE types that were not 
found in humans. The most unexpected finding in this study is the apparent 
dichotomy between VREF strains isolated from non-hospitalized persons and 
those isolated from hospitalized patients. The tight genetic clustering of strains 
from hospitalized patients is even more surprising because these strains were 
collected from geographically diverse locations (Europe, Israel, and the United 
States). The strains isolated from hospitalized patients were clustered mainly in 
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genogroup C, whereas those isolated from non-hospitalized persons without 
VREF infection were mainly of genogroup A. This difference cannot easily be 
explained byonly a difference in the habitat in the human body, because we 
found no significant difference in the distribution among the genogroups of 
hospital strains from fecal origin or from other infected body sites, such as blood 
or urine (table 1). A possible explanation for the observed dichotomy is that, in 
the hospital environment, a subset of VREF strains is being selected that is 
normally present in low numbers in the human gut. Although the nature of this 
selective force is not known, it may involve the selection of strains that are more 
resistant to antibiotics or the selection of strains with specific virulence traits. 
Various studies suggest that bacteriocins, cytolysins, and hemolysins are more 
prevalent among enterococci from infected hospitalized patients than among 
fecal isolates from healthy persons [59-61]. Furthermore, most of the E. faeca/is 
strains harboring the putative virulence gene esp, which encodes a surface 
antigen, are infection-derived [62]. It is unknown, however, whether esp-
positive strains belong to a genetically well-defined taxon, such as the E. faecium 
genogroup C disclosed in this study. Interestingly, all isolates from cats and dogs 
and 25% of the veal calf isolates grouped in genogroup C, which may suggest 
that pet animals and veal calves are a potential source of VREF strains for 
hospitalized patients. 
Molecular typing of Tn1546 in the VREF strains analyzed in this study shows 
that the various VanA transposon variants are not randomly distributed among 
the 4 main VREF genogroups identified. The transposon types A3, D, E, and Fare 
predominantly found in only 1 genogroup, thus exhibiting a high degree of host 
specificity. Transposon types A1, A2, and B seem to be more promiscuous, 
because these are found in most VREF genotypes. This finding confirms our 
previous findings. In previous studies, types D and F transposons have been 
found only in hospitalized patients in the United Kingdom and United States, 
respectively [14], and the E type transposons were found predominantly in 
poultry [9, 14]. In contrast, types A1, A2, and B transposons were found in 
various animals, humans, and other sources, including non-hospitalized persons, 
hospitalized patients, pigs, veal calves, chickens, sewage, turkeys, turkey 
farmers or slaughterers, a duck, and a pony. One of the aims of the present 
study and our previous studies [9, 14] was the assessment of the contribution of 
animal husbandry to the occurrence of vancomycin resistance in humans. In the 
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fecal flora of poultry farmers and slaughterers and veal calf farmers, we found 
VREF genotypes that were specific for the animal hosts-poultry and veal calves, 
respectively. This suggests that VREF strains from animals are transmitted to 
humans. Because strains of genotypes B and D were not or only rarely found 
among the general population, these animal-specific strains may colonize 
humans only transiently. This is in contrast to strains of genotype A. All pig 
strains were of this genogroup, and most strains from non-hospitalized persons 
were also of genogroup A. Furthermore, various pig strains were 
indistinguishable by AFLP from human strains. These data strongly suggest that, 
in the community, VREF strains in hu-mans mainly originate from pigs in which a 
high level of glycopeptide resistance has been observed [2, 11, 15]. This idea is 
consistent with observations by others that humans and pigs may harbor VREF 
strains with identical PFGE types [17, 26]. The predominance of piglike VREF 
strains among humans in the community is the result of exposure and survival in 
the gut. It is presently unclear which of these factors is critical in the ecology of 
VREF. Thus far, molecular comparison of human- and pig-derived enterococci has 
been done only on VREF strains. Therefore, further studies also including drug-
susceptible enterococci are needed to analyze more extensively the populations 
of the pre-dominant flora in humans, pigs, and other animals. 
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Chapter 11 
Enterococci harboring the vanA gene are high-level vancomycin and 
teicoplanin resistant and can cause serious infections that are hard to treat. The 
resistance is transferable to other bacteria and treatment of the infection is only 
effective when combining antimicrobials or using experimental antimicrobial 
agents that have as yet unproven efficacy. Lack of detection and control can 
result in endemic occurrence of the organisms. The prevalence of vancomycin-
resistant enterococci (VRE) has risen alarmingly over the last decades, especially 
in hospitals. Consequently, researchers all over the world have started to 
investigate its dissemination, risk factors for acquisition and virulence. In the 
USA, the lack of a balanced antibiotic policy is thought to be one of the reasons 
for this increase of VRE-related clinical problems. In 1995, the Hospital Infection 
Control Practices Advisory Committee (HICPAC) presented recommendations for 
preventing and controlling the spread of vancomycin resistance [1]. The HICPAC 
advised prudent use of vancomycin and related antimicrobials by clinicians, 
education of hospital personal, thereby preventing person-to-person transmission 
and, last but not least, early detection and rapid reporting of vancomycin 
resistance in enterococci and other Gram- positive bacteria. Consequently, the 
microbiology laboratory became part of the first line of defense against the 
spread of VRE. 
Tentative Dutch guidelines for VRE control have been written recently, as the 
VRE epidemiology in Europe differs significantly from that in the United States [2, 
3]. In Europe the prevalence of VRE is low and VRE outbreaks are usually not 
part of an endemic problem. The "search and destroy" policy which is used for 
MRSA control in The Netherlands is not effective in VRE since, in contrast to 
MRSA colonization, VRE colonization is not restricted to the hospital setting in 
Europe. Both Bonten and Schouten have suggested that extensive measures 
should only be implemented when dissemination of one single genotype of VRE is 
demonstrated to prevent further spread of the VRE strain in the hospital [2, 3]. 
Since timely and accurate detection of VRE is mandatory to prevent strain 
dissemination, the work described in this thesis was focussed in molecular and 
microbiological approaches of the identification and typing of VRE and their 
resistance determinant Tn1546. 
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Detection of VRE 
Accurate and rapid detection of vancomycin resistance is essential in any 
strategy that aims to prevent nosocomial transmission of these resistant 
organisms. Although new automated technology for the detection of antimicrobial 
resistance in bacteria has been developed, it is known that some vancomycin 
resistance phenotypes are difficult to detect accurately. 
In order to evaluate test efficacy, comparative analyses of VRE identification 
assays are warranted. When several of these tests, such as agar dilution, disc 
diffusion, E-test, vancomycin screen agar plate, Microscan® (conventional and 
rapid panel), VITEK®1 (GPS-TA and GPS-101 cards), and VITEK®2, were 
compared, no major failures in detecting vanA enterococci were demonstrated 
(Chapter 2 and 3). For identification and susceptibility testing, most conventional 
methods require a full 24 h of incubation, whereas automated methods 
significantly reduce the time to VRE detection. Earlier detection of resistant 
bacteria allows for faster alerting of the hospital staff, who can then take 
precautionary measures. It has been demonstrated that this type of rapid 
reporting of identification and susceptibility results may have important benefits 
in terms of patient outcome and cost effectiveness [4]. In contrast to vanA 
mediated resistance, we found that automated detection of vanB and vane 
enterococci remains difficult. These results are in concordance with other recent 
studies that have evaluated commercial methods for susceptibility testing of 
vancomycin resistant enterococci (5,6]. Howeverr improvement of the 
performance of the automated tests, as shown for the Vitek1 GPS-101 card and 
the new VITEK®2 system, have led to increased detection rates of vanB and 
vane enterococci. 
The prevalence and clinical implications of E. ga/linarum (vanel) and 
E. casse/if/avus (vane2) is still unknown. However, recently some reports of 
clinically significant infections with vane enterococci have been published [9]. 
These latter VRE species are often misidentified by current diagnostic systems 
and their intermediate level of resistance may go unrecognized. It is thus likely 
that infections by these two vane VRE species are underreported in the 
literature. Recently, several studies have compared different methods for the 
identification of enterococci harboring the vane gene. They conclude that 
methyl-a-D-glycopyranoside fermentation and a few other biochemical assays 
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are simple, accurate and less costly tests for the identification of these species 
[7, 8]. 
With respect to rapid and fully automated methods, we found the agar screen 
the most reliable and easy-to-perform method for routine screening, especially 
when detection of vanA-, vanB-, and vanC1/C2-mediated resistance in 
enterococci is required. In another recent study we reported the lack of 
commercial susceptibility testing methods to differentiate hetero-glycopeptide 
intermediate Staphylococcus species from glycopeptide susceptible strains [10]. 
It is clear that further improvement of test speed without compromising the 
accuracy to detect all forms of vancomycin resistance in enterococci and other 
Gram-positive cocci is still needed. 
Prevalence of VRE in (non-)hospitalized patients in The 
Netherlands 
Several studies have described fundamental differences in the epidemiology of 
vancomycin resistance in the United States and Europe [11, 12]. In Europe there 
is ample evidence suggesting that VRE were introduced into hospitals by patients 
already colonized in the community. In contrast in the USA it is unclear how VRE 
were nosocomially introduced and distributed. It is quite likely that the dramatic 
increase of vancomycin use in the USA over the past decade has played a crucial 
role. In chapter 4 and 5 we described the VRE prevalence in (non-) hospitalized 
patients in The Netherlands. In Dutch hospitals, VRE carriage in adult and 
pediatric patients on intensive care units and hemato-oncology wards remains 
low. Using selective enrichment broth for isolation of VRE, in four yearly point 
prevalence studies between 1995 and 1998, low incidences of VRE present in 
fecal swabs were observed. It was determined that 55% of all individuals were 
intestinal carriers of vancomycin susceptible enterococci. Only 1.4% of all ICU 
and hematology patients included in the study carried VRE. It must be 
emphasized that in stool samples submitted from out-patients similar VRE 
carriage rates were found. From 1995-1998, no increase in the VRE colonization 
rate was observed. Eleven VRE strains were detected and identified as 
Enterococcus faecium and four as Enterococcus faecalis. All E. faecium and one 
E. faeca/is carried the vanA gene; the other E. faeca/is strains harbored the vanB 
gene. PFGE revealed that 3 vanB VRE isolated from patients hospitalized in one 
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single ICU, were genetically related, suggesting nosocomial transmission. In 
contrast, when analyzing the 11 E. faecium isolates we found 4 that were 
genetically related without any geographical clustering. 
The Dutch situation differs from the situation in the USA, where hospitalized 
patients have been reported to be more frequently colonized, whereas outside of 
the hospital VRE are thought not to be present in the environment at all. It is 
interesting to note that the Dutch data are corroborated by other European 
studies, where a low prevalence has been documented within healthcare settings 
in the same period. In a study by Schouten et al. the prevalence of VRE carriage 
in hospitalized patients all over Europe ranged from 0% to 3% [13]. Suprisingly, 
no vanA or vanB related VRE were isolated in these hospitalized patients in the 
Netherlands. However, community-drived data sets from neighboring geographic 
locales may be significantly different. In Belgian, British and other Dutch studies 
for instance, higher VRE carriage rates of 11%, 12°/o and 17°/o, respectively/ 
have been documented [14-16]. In contrast, an extremely high prevalence rate 
was found among turkey farmers (39%) and slaughterers (20%) in the 
Netherlands [17]. Overall, we may conclude that various scenarios describing the 
prevalence of VRE in the community versus that in hospitalized patients are 
encountered. Levels of colonization can vary and local prevalence can differ 
greatly. The outcomes of VRE prevalence studies in various countries are difficult 
to compare as different methodologies for culturing are often used [18]. Thus, 
the prevalence of VRE in The Netherlands and other European countries remains 
low. However, a universal standardized protocol for the (laboratory) detection of 
VRE carriers and/or infection rate in (non-) hospitalized persons is needed to 
determine the exact prevalence of VRE in each country. 
VRE colonization and risk factors 
In recent years, various risk-factors for acquisition of VRE colonization and 
infection have been described. Known risk factors are prolonged hospital stay, 
severity of illness, renal failure, immunosuppression, recent surgery and prior 
exposure to antimicrobial agents [19-21]. However, diarrhea, age and location 
have also been documented as risk for VRE colonization [22, 23]. In contrast to 
several other studies [20, 21] we reported in chapter 5 that VRE carriage is not 
associated with prolonged hospital stay in The Netherlands. Other studies 
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showed results similair to our findings and also did not find prolonged hospital 
stay to be a risk factor of VRE colonization [24, 25]. It is important to mention 
that the number of risk factors analyzed in our study was limited, and did not 
include, for example, analysis of factors such as previous antimicrobial therapy or 
proximity to known patients with VRE. Therefore, more studies in The Netherlands 
are needed to further clarify the epidemiology of VRE in order to design of future 
interventions. 
VRE and the environment including zoonoses 
Of major European concern is the apparent relationship between the 
presence of vancomycin resistance in enterococci and the use of avoparcin, a 
glycopeptide homologue, as a growth-promoting additive in animal food [26]. 
The addition of antibiotics to animal food has been documented as being 
economically valid: animals grow faster and reach higher weights [27, 28], 
consequently, a significant quantity of antibiotics has been used for this purpose. 
Evidence is accumulating that antibiotics thus introduced into environments 
where enterococci thrive may have led to the high incidences of VRE in animal 
husbandry [29]. 
The influence of avoparcin antibiotics on the selection of intestinal vanA-VRE 
in chickens has recently been studied [30]. The results of this study indicate that 
avoparcin supplementation increases the selection of VRE. Furthermore, the 
study we describe in chapter 7 demonstrated the high prevalence of VRE in 
chicken products at the retail level in The Netherlands. The rate of contamination 
with VanA VRE in chicken meat was 100% in certain areas, with an overall 
prevalence of 79% nationwide, 59% of these were high level vancomycin-resistant 
Enterococcus faecium (VREF). PFGE revealed extensive VREF heterogeneity. 
However, two genotypes were found nationwide on multiple occasions. No PFGE-
deduced genetic overlap was found, when VREF from humans were compared with 
the VREF poultry strains. Two vanA transposon types were identified among poultry 
strains. In 59/142 (42%) of the poultry VREF, the size of the intergenic region 
between vanX and vanY was ± 1300 bp. This transposon type was not found in 
human VREF. In contrast, all human strains and 83/142 (58%) of the poultry VREF 
contained an intergenic region with the size of 543 bp. Sequencing this 543 bp 
intergenic vanX-vanY region demonstrated full sequence conservation. Though 
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preliminary, these data suggest that dissemination of the resistance genes encoded 
on transposable elements may be of greater importance than clonal dissemination 
of resistant strains. 
Subsequently, many similar studies in Europe [31] and USA [32] reported the 
existence and importance of non-human VRE reservoirs. Frequent strain sharing 
was documented among turkey farmers and their flocks for instance [17]. This 
proves that rich environmental and zoonotic VRE sources in the vicinity may well 
lead to cross-colonization of humans. Even domestic cats and dogs (Chapter 6b) 
may provide reservoirs. It goes without saying that these sources are 
"intimately" linked to humans and may thus be important for colonization of the 
human intestine. A similar and equally worrisome association can be seen in the 
case of avilamycin, an oligosaccharide antibiotic that is also used as a food 
additive [33]. Again, resistance traits can be detected in a significant proportion 
of enterococca! strains isolated from farm animals. Use of the new "human 
homologue" of avilamycin, everninomycin, may well lead to the selection of 
similar mutants in the clinical setting, particularly in the hospital where such new 
generations of antibiotics are initially evaluated. 
In contrast, in countries were avoparcin has not been used in animal 
husbandry, hardly any VRE were detected in healthy humans, animals or animal 
related food products [34]. Due to this observation the European Commission 
decided in April 1997 to ban the use of avorpacin as growth promoter all over 
Europe. Van den Bogaard et al. described the effect of banning avoparcin in The 
Netherlands in 2000. The prevalence of VRE in humans, broilers and pigs 
decreased significantly within two years after the ban. In other European 
countries such as Denmark, Germany and Italy the same effect was observed. 
Apparently, banning veterinary uses of glycopetide analogue results in 
elimination of important sources of VRE and, consequently, may lead to a lesser 
burden in human medicine as well. However, the presence of VRE is not only 
restricted to the bio-industry, since VRE has been detected in various other 
animals and in the environment. The question arises whether dissemination of 
VRE is now so extensive that elimination of all VRE is impossible. 
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VRE and dietary habits 
One way of examining the relationship between contamination of the 
environmental with VRE to human VRE carriership is to measure the effect of 
VRE contamination of meat products by the individual meat consumer. The 
prevalence of VRE in vegetarians versus that in non-vegetarians could be 
illustrative in this respect. The results of such studies have been published 
recently and suggested a close relationship between dietary habits and the 
presence of VRE in the gut flora. Microbiological studies performed on faecal 
specimens obtained from people living in an old people's home for vegetarians 
and from non-vegetarian controls from the same age group, showed statistically 
significant differences in carriage rates of vanA containing VRE [35]. Among the 
vegetarians, the VRE colonization rate tended to be lower although statistical 
significance was not reached. Our study described in chapter 6a provided 
evidence for another colonization scenario. We did not observe differences in 
colonization with vanA or vanB VRE between vegetarians and non-vegetarian 
controls. However, vegetarians were more often colonized with Vane enterococci. 
One possible explanation would be that Vane VRE in particular, are known to 
colonize plants rather than animals. Both studies suggest a relationship between 
dietary habits and intestinal colonization by enterococci with reduced 
susceptibility to glycopeptide antibiotics. Recently, Blom et al. [36] described a 
randomized double-blind study on ingestion of VRE strains of poultry origin by 
human healthy volunteers and subsequent follow-up on VRE carriage in these 
individuals. Two weeks after ingestion (107 CFU VRE) no VRE were found in the 
faeces of these persons, suggesting that VRE from poultry origin do not easily 
colonize the human intestinal tract. This raises the question whether or not 
dietary habits influence the colonization rate with respect to enterococci in 
general. 
Molecular typing of VRE 
The last decennia several molecular typing techniques, such as DNA restriction 
fragment analysis, total plasmid profile analysis, Random Amplified Polymorhic 
DNA (RAPD), pulsed-field gel electrophoresis (PFGE), and ribotyping, have been 
used for epidemiological investigations of enterococcal outbreaks and for 
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subtyping of enterococcal strains [37]. Use of these techniques leads to 
enhanced insight in the spread of bacteria. Every single technique is more or less 
suitable for genotyping of bacterial strains. In chapter 4 and 8 we compared 
PFGE and RAPD for epidemiological typing of VRE of vancomycin resistant 
enterococci. PFGE is the current gold standard for molecular analysis for several 
bacterial species. The advantage of this technique is its high discriminatory 
power and reproducibility. However, a minimum of 4 days is required before 
results are available. Moreover, expensive enzymes and special instruments are 
needed. Recently an improved, rapid and potentially cost-effective PFGE typing 
method for VRE has been reported [37]. RAPD is known as a fast and simple 
technique with somewhat less discriminating power and reproducibility. In our 
studies it appeared that the results of both typing techniques were concordant. 
Discrepancies between both techniques occur, but overall fingerprint clustering 
leads to comparable results. In conclusion, to reduce time and costs, RAPD is an 
appropriate technique to use for elucidating local spread of VRE. However, in 
cases of large clonal outbreaks of VRE we recommend PFGE, because of the high 
degree of strain differentiation with this technique and the possibility to 
exchange data between laboratories. Due to its high discriminatory power, 
however, PFGE is less suitable in verifying the degree of genetic relatedness 
between epidemiologically un-related strains, because the banding patterns of 
such strains are generally completely distinct. Amplified Fragment Length 
Polymorphism (AFLP) is a high-resolution genotyping method [38]. This method 
has been applied for typing of several other micro-organisms and has the 
advantage of high levels of discriminatory power, reproducibility, and 
standardization [39-42]. For AFLP analysis, restriction fragments of chromosomal 
DNA are selectively amplified by PCR. By using primers containing one or more 
selective nucleotides extending at the 3' ends, only a subset of fragments is 
amplified under stringent PCR conditions. AFLP is capable of establishing a 
degree of genetic relatedness between strains that by PFGE show no such 
relatedness. In chapter 10 we used AFLP to determine the genetic relationship 
among 255 VRE strains derived from diverse sources. E. faecium strains from 
hospitalized patients, healthy human and strains from various animal sources 
isolated from England, USA and The Netherlands were analyzed to investigate 
host-specificity of VRE. Among these strains we could discriminate four major 
AFLP genogroups. Strains of each group shared more than 65% of the amplified 
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restriction fragments. Genogroup A contained 75% of the strains isolated from 
non-hospitalized patients and all pig derived isolates. Ninety seven percent of the 
chicken isolates and 86% of turkey VRE were clustered in group B, whereas 25% 
of strains derived from veal calves, 84% of hospitalized patients isolates and all 
dog- and cat- derived VRE gathered in group C. The last group (Genogroup D) 
mostly contained veal calve isolates (70%). We discovered that vancomycin 
resistant E. faecium strains are mainly host-restricted and that isolates from 
hospitalized patients do not mix genetically with strains from non-hospitalized 
patients. However, VRE isolates from pig origin clustered with strains derived 
from non-hospitalized patients. Species-restricted variants of VRE have been 
described earlier by Devriese et al.; they described species that occur among 
dogs and poultry [43-44] and in chapter 7 we distinguished poultry VRE with 
specific PFGE types that were not found in humans. 
In conclusion, this study provides evidence that some animals more than 
others may play an important role in dissemination of VRE to humans in The 
Netherlands. Further investigations are necessary to clarify the exact 
dissemination and the epidemiology of VRE. 
Heterogeneity in the resistance mediating genetic element 
We analyzed the Tn1546 transposon present in a large collection of VRE 
isolates to gain more insight in the evolution of this specific resistant element. In 
chapter 9 we genetically characterized Tn1546 and found twenty-two structural 
variants of this transposon. Furthermore, a hypothetical evolutionary scheme 
was made for the various Tn1546 derivatives and we suggested that horizontal 
transmission of Tn1546 transposon might be an alternative determinant factor 
driving the spread of vancomycin resistance. Transposon polymorphism has been 
demonstrated for the first time by Handwerger et al. [45]. More recently, two 
studies on the determination of genetic polymorphism in Tn1546 have been 
published [46, 47]. A common finding of these latter studies was that although 
coding potentials remain generally unaffected, transposon polymorphism could 
be detected quite easily. The presence of additional insertion elements in 
intergenic positions or deletions at the transposon termini is encountered 
frequently. This allows adequate tracking of transposon types, which has already 
demonstrated that certain types can be encountered among VRE from both 
162 
General discussion 
human and nonhuman sources. On the other hand, "source-specific" transposons 
were identified as well. In view of these data research on horizontal gene 
transfer and detection of common reservoirs for glycopeptide resistance should 
be initiated. Furthermore, the structure-function relationship of transposons can 
be assessed: preliminary data suggest that mutations in the transposon may 
correlate with lowered conjugative potential. An important conclusion that can be 
drawn from the genome and transposon scanning data is that several 
epidemiologic scenarios can be envisaged. Epidemic VRE can be identified; in the 
UK, for instance, various examples of strains that seem to have traveled large 
distances are acknowledged [ 48]. Certain VRE are capable of highly efficient 
bacterial transfer from patient to patient in the hospital environment [49], 
whereas long-term colonization with a single type of VRE in a single individual 
has been observed as well [50]. In contrast, in certain hospital settings highly 
promiscuous transposon types have been described. Instead of epidemic spread 
of a strain, a specific Tn1546 type is encountered in various VRE genomes. In 
conclusion, the spread of vancomycin resistance is facilitated by the epidemic 
capacity of both strains and transposons. In combination with the large number 
of environmental and animal reservoirs, at least in Europe, that have already 
been identified to date, this means that the clinical threat posed by VRE may not 
be easily overcome in the near future. 
Concluding remarks 
The prevalence of VRE in hospitalized patients on Intensive-Care-, 
hematology-oncology- and hemodialysis wards in Dutch hospitals remains low in 
the period between 1995 and 1998. In 1999 and 2000, however, three outbreaks 
of VRE were discovered in hospital settings in Amsterdam, Utrecht and 
Amersfoort [51-53]. Although in each of these outbreaks the number of patients 
with infections was low, the spread of the colonization rate was high. In each of 
these events it was possible to stop the spread of VRE and finally eliminate the 
resistant bacteria from the hospital. The high incidence of VRE in animal 
husbandry and meat products in The Netherlands may lead to transmission of 
VRE to humans in and outside the hospital. However, the ban of avoparcin has 
been followed by a decrease of colonization of VRE in farm animals and non-
hospitalized persons [34]. Discussions on the best way to prevent the spread of 
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VRE in hospital settings are still ongoing [2, 3]. We suggested that horizontal 
transmission of Tn1546 transposon might be an alternative determinant factor 
driving the spread of vancomycin resistance. This scenario rents on an epidemic 
transposon rather than on patient-to-patient transfer of a given VRE strain. Even 
at the time of an ongoing outbreak, VRE can change its genotype, since in 
individual patients the transfer of Tn1546 to previously vancomycin-susceptible 
Enterococcus strains has been observed to occur in vivo. Spread of vancomycin 
resistance , therefore, may not be confined to the spread of resistant strains. 
Clearly, further investigations are needed to gain more detailed insight and to 
prevent spread of infections caused by vancomycin resistant enterococci. For 
instance it was recently shown that in all non epidemic and animal VRE isolates a 
variant of the esp gene was absent, interestingly all investigated epidemic VRE 
strains contained the gene [54]. 
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Summary and Samenvatting 
Enterococci are part of the normal human and animal gut-flora and hardly 
cause infections in healthy individuals. The last decade several enterococcal 
species have emerged as common causes of hospital-acquired infections. One of 
the major reasons why these microorganisms easily survive in the hospital 
environment is their intrinsic resistance to several commonly used antibiotics, 
and more importantly, their ability to acquire resistance to many currently used 
antibiotics, including the glycopeptides. Resistance development of enterocci to 
the glycopeptide vancomycin presents a major and worldwide noticed problem. 
Infections with vancomycin resistant enterococci are not only difficult to treat but 
the organisms show a strong propensity to disseminate and spread from patient 
to patient in the hospital setting. Glycopeptide-resistant enterococci can be 
divided in different classes depending on the presence of van-resistance genes. 
Resistance types can either be intrinsic (low-level resistance to vancomycin and 
teicoplanin; e.g. VanCl, VanC2 and VanC3) or acquired (high-level resistance to 
both vancomycin and teicoplanin [VanAL intermediate- level resistance to both 
glycopeptides [VanD, VanE] or variable level of resistance to vancomycin only 
[VanB]). The VanA(VanB resistances are encoded by homologous transposons 
named Tn1546 and Tn1547, respectively. These transposons are located on self-
transferable plasmids and can be transferred by conjugation to other bacteria. 
This thesis describes the detection, prevalence and molecular analysis of 
glycopeptide resistant enterococci in The Netherlands. 
Detection of vancomycin resistance 
Accurate and rapid detection of vancomycin resistance is essential in any 
strategy that aims to prevent nosocomial transmission of resistant organisms. In 
chapter 2, we tested the accuracy of eight different susceptibility test methods 
for the detection of glycopeptide resistance in enterococci. VanA VRE strains 
were adequately detected by all methods. Despite the techn·,cal improvement of 
all new automated susceptibility test methods, E-test and the agar screen 
appeared to be the most reliable and easy-to-perform methods for routine 
screening of detection of vanB- and vanC1/C2-mediated resistance in 
enterococci. In chapter 3, we tested a new fully automated susceptibility test 
method. The VITEK®2 approach presents an improvement over conventional 
methods for the detection of vancomycin resistance in enterococci. However, the 
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detection of teicoplanin resistance in enterococci containing the vanA gene needs 
to be reassessed. VITEK®2 is the first automated susceptibility method that tests 
for vancomycin- as well as teicoplanin- resistance, which is important for the 
description of the resistance phenotype. Although the detection time was 
reduced, further improvement of the algorithm and further reduction of the 
detection time may considerably increase the impact of rapid testing on patient 
care. 
Prevalence of VRE in- and outside the hospital 
Differences in epidemiology of VRE in the USA and Europe have been outlined 
before. In the USA the prevalence of VRE in the hospital setting increased 
enormously nationwide; many nosocomial VRE outbreaks have been described, and 
VRE were seldom found outside the hospital environment. In contrast, in Europe 
the VRE prevalence in hospitals remains low, VRE related outbreaks are rare 
although the isolation of VRE outside the hospital is common. It has been 
suggested that the frequent use of glycopeptides in hospitals in the USA and 
veterinary consumption of large amounts of glycopeptide-containing animal feeds 
in some countries of Europe have contributed to this scenario. Further gathering 
of epidemiological data will be useful to prevent the further spread of VRE. 
Therefore, an important aim of this thesis was to survey the prevalence of VRE 
colonization in and outside the hospital setting in The Netherlands and to gain more 
insight in the genetic relationship between these resistant bacteria. 
In chapters 4 and 5, the prevalence and determinants of VRE carriage in 
intensive-care units (ICU) and Hematology Oncology wards in nine Dutch 
hospitals and a non-hospitalized population (1995-1998) was determined. The 
prevalence of VRE colonization in The Netherlands remains low, as was 
determined for the rest of Europe by others. We have shown in a multicenter 
study that VRE can be isolated in hospitalized and in community-based patients 
in The Netherlands, at a frequency of 1.4% and 2%, respectively (chapter 4 and 
5). Molecular analysis showed that all E. faecalis strains, harboring the vanS 
gene, were identical; these strains were isolated in a single !CU. After the end of 
the study period two additional patients from the same ICU were colonized with 
this VRE clone. This appeared to be the first nosocomial, clonal outbreak of 
colonization caused by VRE in The Netherlands. In contrast, when analyzing E. 
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faecium we found 4/11 genetically related strains but no geographical 
relationship. We reported that VRE carriage is not associated with prolonged 
hospital stay in a low endemicity country such as The Netherlands. 
In a separate case-control study (chapter 6a) where the prevalence of VRE 
carriership between vegetarians versus meat eaters was analyzed, no significant 
association was found between the consumption of meat and high-level 
glycopeptide resistant bacteria in the gastro-intestinal flora. Remarkably, 
vegetarians are often carriers of vane enterococci. We hypothesize that the 
consumption of plant products that are contaminated with mobile E. casseliflavus 
bacteria may be the source of the high prevalence of vane-enterococci in 
vegetarians. 
Chapter 6b described the prevalence of VRE in cats and dogs in Rotterdam, 
The Netherlands (chapter 6b). Although our data are representative of a single 
region only, we propose that domestic pets may be a significant reservoir for VRE. 
One of the VRE genotypes shared among dogs and cats was also found in a human 
carrier. 
In chapter 7, we reported an extremely high prevalence (79%) of VRE in 
poultry products. Total genome and transposon analysis show that transmission 
of the resistance genes, rather than clonal dissemination of resistant micro-
organisms, may be the factor driving the spread of vancomycin resistance from 
poultry to humans. 
Genome analysis of VRE 
In the last three chapters several molecular techniques are described that can 
be applied to gain more insight into the spread of vancomycin resistant 
enterococci. The techniques we used were Pulsed Field Gel Electrophoresis 
(PFGE), Random Amplification of Polymorphic DNA (RAPD) analysis, transposon 
analysis using PCR, Restriction Fragment Length Polymorphism (RFLP) analysis 
and sequencing, and Amplified Fragment Length Polymorphism (AFLP) analysis. 
Chapter 8 showed that PFGE and RAPD analysis performed on diverse strains 
of VRE are largely concordant in outcome. This indicates that both methods can 
be used for adequate molecular typing. However, in case of clonal outbreaks we 
suggest to confirm the strain relatedness with the PFGE method, due to the 
higher discriminatory power of PFGE technique. 
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Chapter 9 reported seven different Tn1546 types using RFLP analysis of the 
VanA transposon of 97 VRE strains isolated from human and animal sources. 
Subsequent sequencing of a subset of these RFLP types resulted in the 
identification of 22 different Tn1546 derivatives. Identical Tn1546 types were 
found among isolates from humans and farm animals in The Netherlands, 
suggesting the sharing of common vancomycin resistance gene pools. Application 
of the genetic analysis of Tn1546 to VRE isolates causing infections in hospitals in 
the United Kingdom and the USA suggested that horizontal transmission of the 
vancomycin resistance transposon might occur in a clinical setting. 
Finally, chapter 10 displayed that VREF strains are predominantly 
host-specific, and strains isolated from hospitalized patients are genetically 
different from the prevailing VREF strains present in the fecal flora of 
nonhospitalized persons. AFLP and PFGE analysis were used to investigate the 
genetic relationships among 255 vancomycin-resistant Enterococcus faecium 
(VREF) strains isolated from hospitalized patients, nonhospitalized persons, and 
various animal sources. Four major AFLP genogroups were discriminated; group 
A: non-hospital isolates and pig isolates, group B: poultry and turkey isolates, 
group C: hospital isolates, calve isolates and dog/cat isolates, and group D: calve 
isolates. Molecular typing of Tn1546 in the VREF strains analyzed in this study 
shows the various VanA transposon variants are not randomly distributed among 
the four main VREF genogroups identified. Some transposon types are 
predominantly found in only one genogroup, thus exhibiting a high degree of 
host specificity. Other transposon types seem to be more promiscuous, as these 
are found in most VREF genotypes. 
In conclusion, the main findings presented in this thesis are that VRE are still 
rare among hospitalized patients in The Netherlands. However, high carriage 
rates of VRE can be documented in the open population and in chicken meat 
products. Population genetics of VRE revealed restricted host specificity, which 
may in part explain the low prevalence in hospitals in a typical clinical setting 
where antibiotic use is restricted. 
173 
Enterococcen zijn bacterien die behoren tot de normale darmflora van mens 
en dier en veroorzaken zelden infecties bij gezonde individuen. Echter, de laatste 
tientallen jaren ontwikkelden deze bacterien zich tot een belangrijke groep van 
veroorzakers van ziekenhuisinfecties. EE§n van de redenen waarom deze micro-
organismen kunnen overleven in het ziekenhuis is hun aangeboren resistentie 
tegen een aantal vee! gebruikte antibiotica en, nog belangrijker, hun vermogen 
om additionele resistenties te verwerven tegen de meeste antibiotica, inclusief de 
glycopeptiden. Resistentie ontwikkeling van enterococcen tegen het glycopeptide 
vancomycine is een groat en wereldwijd probleem. Infecties met vancomycine 
resistente enterococcen zijn moeilijk te behandelen en deze organismen vertonen 
de neiging om zich te verspreiden in een ziekenhuis setting, bijvoorbeeld van 
patient tot patient. Glycopeptide resistente enterococcen kunnen verdeeld 
worden in verschillende klassen afhankelijk van het van-resistentie gen dat in de 
bacterie aanwezig is. Resistentie typen kunnen "aangeboren" zijn (!age 
resistentie tegen de glycopeptiden vancomycine en teicoplanine; VanCl, VanC2 
en VanC3) of verkregen (hoge resistentie tegen vancomycine en teicoplanine 
[VanA], intermediaire resistentie tegen beide glycopeptide [VanD, VanE] of 
variabele resistentie tegen vancomycine aileen [VanS]). De VanA en VanS 
resistenties worden gecodeerd door transposons (kleine mobiele stukjes DNA die 
in het genoom van plaats kunnen wisselen en mede verantwoordelijk zijn voor de 
regeling van de resistentie gen-activiteit) zeals Tn1546 en Tn1547. Deze 
transposons liggen vaak op plasmiden ( circulair DNA) die kunnen worden 
overgedragen naar andere bacterien. 
Dit proefschrift beschrijft de detectie, prevalentie en moleculaire analyse van 
glycopeptide-resistente enterococcen in Nederland. 
Detectie vancomycine resistentie 
Accurate en sne!le detectie van vancomycine resistentie is essentieel in elke 
strategie die als doe! heeft om te voorkomen dat verspreiding van deze 
resistente micro-organismen binnen het ziekenhuis plaats vindt. In hoofdstuk 2, 
wordt de nauwkeurigheid van 8 verschillende methodes voor de detectie van 
glycopeptide-resistentie in enterococcen getest. We Iaten zien dat VanA 
gemedieerde vancomycine resistentie goed wordt gedetecteerd door aile 
methodes. Ondanks de beschikbaarheid en de verbetering van (nieuwe) 
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automatische resistentie test methodes, blijken E-test en vancomycine screen 
agar de meest betrouwbare en makkelijk uit te voeren methodes te zijn voor het 
routinematig screenen van vanB en vanC1/C2 resistentie in enterococcen. In 
hoofdstuk 3 wordt een nieuw volautomatisch resistentie test systeem getest. 
Vitek®2 Ievert een duidelijke verbetering ten opzichte van andere automatische 
methodes. Echter, de detectie van teicoplanine resfstentie in enterococcen die 
het vanA gen bevatten vergt echter nog enige optimalisering. VITEK®2 is het 
eerste val automatische test systeem dat zowel vancomycine als teicoplanine 
resistentie test, wat belangrijk is voor de benaming van het resistentie fenotype 
bij glycopeptide resistentie. Verdere reductie van de detectie tijd zal een grate 
impact hebben op de patientenzorg. 
Prevalentie van VRE binnen en buiten het ziekenhuis 
Er is bekend dat er verschillen bestaan tussen Amerikaans en Europese 
epidemiologie van VRE. In de VS is de VRE prevalentie in ziekenhuizen enorm 
toegenomen, vele VRE uitbraken op afdelingen zijn beschreven, maar een VRE 
wordt zelden buiten de ziekenhuissetting ge·isoleerd. In Europa daarentegen is de 
VRE prevalentie binnen de ziekenhuizen laag, zijn er nauwelijks uitbraken 
beschreven, maar er is wei bekend dat er buiten de ziekenhuisomgeving ook VRE 
ge"isoleerd worden. Gesuggereerd wordt dat het hoge gebruik van glycopeptiden 
in Amerikaanse ziekenhuizen en van glycopeptide-bevattend dierenvoedsel in 
sommige Ianden in Europa heeft bijgedragen aan deze sterk verschillende 
scenario's. Verdere uitbreiding van epidemiologische surveillances zijn van belang 
om verdere verspreiding van VRE te voorkomen. Een belangrijk doel van dit 
proefschrift is het bepalen van de prevalentie van VRE in en buiten het ziekenhuis 
in Nederland en meer inzicht te verkrijgen in de genetische relatie tussen deze 
resistente bacterien. 
In hoofdstukken 4 en 5, worden de prevalentie en enkele risicofactoren van 
VRE dragerschap op intensive-care-(IC) en hematologie-oncologie afdelingen in 
negen Nederlandse ziekenhuizen en een niet ziekenhuis populatie tussen 1995 
en 1998 onderzocht. De prevalentie van VRE kolonisatie in Nederland blijft laag, 
net als in de rest van Europa, in tegenstelling tot de situatie in Amerika. We 
hebben aangetoond dat VRE dragerschap voorkomt in ziekenhuis- en in de 
gewone populatie met een frequentie van 1.4°/o en 2%. Molecu!aire analyse van 
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ziekenhuis-VRE laat zien dat aile gedetecteerde Enterococcus faeca/is isolaten 
(n=3) het vanB gen hebben en genetisch identiek zijn. Deze stammen werden 
geTsoleerd op een IC afdeling. Na afloop van de studieperiode zijn twee 
additionele patienten van dezelfde IC afdeling gekoloniseerd met deze VRE kloon. 
Dit is de eerste ziekenhuis gerelateerde VRE-"uitbraak" in Nederland. Analyse 
van Enterococcus faecium (vanA) isolaten laat zien dat 4 van de 11 isolaten 
genetisch maar niet geografisch gerelateerd zijn. Na het onderzoeken van 
verschillende risicofactoren zien we, in tegenstelling tot een aantal andere 
studies, dat VRE dragerschap in Nederland niet geassocieerd is met Jangdurig 
verblijf in het ziekenhuis. 
In een case-control studie (hoofdstuk 6a) waarin prevalentie van VRE 
dragerschap in vegetariers versus vleeseters wordt geanalyseerd, wordt geen 
significante associatie gevonden tussen de consumptie van vlees en VRE 
dragerschap bij mensen. Opvallend is wei dat vegetariers beduidend vaker 
drager zijn van vane enterococcen. We suggereren dat de consumptie van 
plantaardige producten, wat weer geassocieerd kan worden met het eten van 
plantaardige producten die gecontamineerd kunnen zijn met de beweeglijke E. 
casseliflavus bacterie, de bron zou kunnen zijn van de hoge prevalentie vane 
enterococcen in vegetariers. 
Hoofdstuk 6b beschrijft de VRE prevalentie bij katten en honden in 
Rotterdam, Nederland. Onze data zijn representatief voor slechts een regie, 
maar toch is het duidelijk dat huisdieren een significant VRE reservoir kunnen 
vormen. Een van de VRE genotypen gevonden bij zowel honden als katten is ook 
gevonden bij een menselijke drager. 
In hoofdstuk 7 rapporteren we een extreem hoge VRE prevalentie (79%) in 
kipproducten. Totaal genoom- en transposon- analyse Iaten zien dat transmissie 
van de resistentie genen, eerder dan klonale verbreiding van resistente micro-
organismen, een factor kan zijn voor de verspreiding van vancomycine 
resistentie van kip naar mens. 
Genoom analyse van VRE 
In de laatste drie hoofdstukken worden verscheidene moleculaire technieken 
beschreven die gebruikt kunnen worden om meer inzicht te krijgen in de 
verspreiding van vancomycine resistente enterococcen. De technieken die 
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gebruikt worden zijn Pulsed Field gel Electroforese (PFGE), Random Amplificatie 
van Polymorf DNA (RAPD), transposon analyse door gebruik van Polymerase 
Chain Reactie gevold door Restrictie Fragment Lengte Polymorfisme (RFLP) en 
sequencen, en Amplified Fragment Lengte Polymorfisme (AFLP). 
Hoofdstuk 8 laat zien dat de PFGE en RAPD analyses uitgevoerd op 
verschillende type VRE stammen overeenkomstige uitslagen genereren. Dit duidt 
erop dat beide technieken bruikbaar zijn voor moleculair typeren van deze 
bacterien. Echter, als er sprake is van een klonale VRE uitbraak aan de hand van 
RAPD analyse wordt geadviseerd dit te bevestigen met PFGE analyse omdat de 
PFGE techniek een hager discriminerend vermogen heeft. 
Hoofdstuk 9 beschrijft 7 verschillende Tn1546 transposon types, die 
ge.identificeerd werden na RFLP analyse van 97 VRE isolaten afkomstig van mens 
en dier. Sequencen van deze verschillende RFLP types resulteerde in 22 
verschillende Tn1546-derivaten. ldentieke Tn1546 types werden gevonden bij 
isolaten afkomstig van mens en boerderij dieren, dit suggereerde disseminatie 
van gelijke vancomycine resistentie genen. Het toepassen van deze genetische 
analyse van de Tn1546 transposon op infectie veroorzakende VRE isolaten in een 
ziekenhuis in Engeland en Amerika laat horizontale transmissie zien van het 
vancomycine resistentie transposon. 
Tenslotte, hoofdstuk 10 laat zien dat vancomycine resistente 
Enterococcus faecium (VREF) isolaten overwegend gastheerspecifiek zijn, en 
isolaten van ziekenhuis patienten genetisch verschillen van VREF isolaten die 
aanwezig zijn in de fecale flora van niet-gehospitaliseerde personen. AFLP 
analyse is gebruikt om de genetische relatie tussen 255 VREF stammen 
gersoleerd van ziekenhuis patienten1 niet-gehospitaliseerde personen en 
verschillende dieren vast te stellen. Vier grate AFLP groepen worden 
onderscheiden; groep A: niet ziekenhuis isolaten en varkens isolaten, groep B: 
kip-en kalkoen isolaten, groep C ziekenhuis isolaten, kalf isolaten en hond/kat 
isolaten, en groep D: kalf isolaten. Moleculaire analyse van het Tn1546 
transposon in de VREF isolaten laat zien dat het aantal VanA transposon 
varianten niet random verdeeld is onder de 4 AFLP groepen. Sommige 
transposon types komen voornamelijk voor in 1 van de groepen en suggereren 
hiermee een hoge gastheer specificiteit te hebben. Andere transposon types zijn 
meer verspreid en zijn te vinden in de meeste geno-groepen. 
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In conclusie, de belangrijkste bevindingen in dit proefschrift zijn dat VRE 
zeldzaam voorkomen bij ziekenhuis patienten in Nederland. Echter, significant 
dragerschap van VRE wordt wei gerapporteerd in de open populatie en in de 
meeste kippenvlees producten. Populatie genetica van VRE laat een beperkte 
mate van gastheer specificiteit zien, wat voor een deel een verklaring kan zijn 
voor de lage prevalentie in ziekenhuizen in een klinische situatie waar het 
antibiotica gebruik beperkt is. 
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